Compositions and methods for promoting brain health
By using β-hydroxybutyrate to activate HCA2 receptors and ketogenic diets, the problem of brain health promotion in the prior art was solved, effective treatment and prevention of acquired brain injury and neurodegenerative diseases were achieved, and the brain was significantly improved Repair and metabolic status of tissue.
Patent Information
- Application Number
- CN202380025543.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-04
- Filing Date
- 2023-03-02
- Publication Date
- 2024-11-08
AI Technical Summary
The prior art is difficult to effectively promote brain health, especially in acquired brain injury and neurodegenerative diseases, and there is a lack of effective treatments and preventive measures.
A composition and method has been developed to improve neuroprotection and repair by activating HCA2 receptors, regulating inflammation and immune responses, and combining with a ketogenic diet, Energy metabolism and inflammation state of brain tissue.
It significantly improves the inflammatory response and repair process after brain injury, improves the activity of neuroprotective cells, enhances the energy supply and metabolic efficiency of brain tissue, and provides a potential treatment plan for traumatic brain injury and neurodegenerative diseases.
Smart Images

Figure BDA0005027586220000141 
Figure BDA0005027586220000981 
Figure BDA0005027586220001001
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims the benefit of priority to U.S. Provisional Application No. 63 / 316,845 (filed on March 4, 2022) entitled “COMPOSITIONS AND METHODS TO PROMOTE BRAIN HEATH,” the entire contents of which are incorporated herein by reference in their entirety. Background Art
[0003] The biology of wound healing
[0004] Wounds are caused by damage or disruption to normal anatomical structure and function (Robson MC et al., Curr Probl Surg 2001; 38: 72-140; Velnar T et al., The Journal of International Medical Research 2009; 37: 1528-1542). Wounds can range from simple disruption of the integrity of the skin epithelium to deeper subcutaneous tissues with damage to other structures such as tendons, muscles, blood vessels, nerves, parenchymal organs, and even bones (Alonso JE et al., Surg Clin North Am 1996; 76: 879-903). Regardless of cause and form, trauma damages and disrupts the local tissue environment.
[0005] Wound healing is a dynamic, interactive process involving soluble mediators, blood cells, extracellular matrix, and parenchymal cells. The wound repair process can be divided into four (4) temporally and spatially overlapping phases: (1) the coagulation phase; (2) the inflammatory phase, (3) the proliferation phase, and (4) the remodeling phase. The immune system is generally an active participant in wound healing. Many known wound healing is based on human skin.
[0006] Condensation stage
[0007] After injury, platelets immediately adhere to the damaged blood vessels, initiate a release reaction, and initiate a hemostatic reaction, thereby producing a coagulation cascade that prevents excessive bleeding and provides temporary protection for the injured area. Platelets release more than a dozen growth factors, cytokines, and other agents that induce survival or apoptosis (Weyrich AS and Zimmerman GA, Trends Immunol September 2004; 25(9): 489-495). The key components of the platelet release reaction include platelet-derived growth factor (PDGF) and transforming growth factor A1 and 2 (TGF-A1 and TGF-2), which attract inflammatory cells such as leukocytes, neutrophils, and macrophages (Singer AF and Clark RA, N Engl J Med September 2, 1999; 341(10): 738-746).
[0008] Inflammatory stage
[0009] The inflammatory phase is triggered by capillary damage, which results in the formation of a blood clot / provisional matrix composed of fibrin and fibronectin. This provisional matrix fills the tissue defect and enables the influx of effector cells. Platelets present in the clot release a variety of cytokines that participate in the recruitment of inflammatory cells (such as neutrophils, monocytes, and macrophages, etc.), fibroblasts, and endothelial cells (ECs).
[0010] Proliferation stage
[0011] The inflammatory phase is followed by a proliferative phase, in which active angiogenesis produces new capillaries, allowing nutrients to be delivered to the wound site, particularly supporting fibroblast proliferation. Fibroblasts present in granulation tissue are activated and acquire a smooth muscle cell-like phenotype, and are then referred to as myofibroblasts. Myofibroblasts synthesize and deposit extracellular matrix (ECM) components that replace the temporary matrix. The myofibroblasts also have contractile properties mediated by α-smooth muscle actin organized into microfilament bundles or stress fibers. Myofibroblast differentiation of fibroblasts begins with the appearance of protofibroblasts, whose stress fibers contain only β-cytoplasmic actin and γ-cytoplasmic actin. Protofibroblasts can evolve into differentiated myofibroblasts, whose stress fibers contain α-smooth muscle actin.
[0012] Remodeling phase
[0013] The fourth healing phase involves the gradual remodeling of granulation tissue and re-epithelialization. This remodeling process is mainly mediated by proteolytic enzymes, especially matrix metalloproteinases (MMPs) and their inhibitors (TIMPs, tissue inhibitors of metalloproteinases). During re-epithelialization, type III collagen (the main component of granulation tissue) is gradually replaced by type I collagen (the main structural component of the dermis). Elastin, which contributes to skin elasticity and is not present in granulation tissue, also reappears. Cell density is normalized by apoptosis (resolution) of vascular cells and myofibroblasts.
[0014] Inflammation
[0015] Tissue damage causes rupture of blood vessels and spillage of blood components. Blood clots reconstruct hemostasis and provide temporary extracellular matrix for cell migration. Platelets not only promote the formation of hemostatic plugs, but also secrete several wound healing mediators, such as platelet-derived growth factor, which attract and activate macrophages and fibroblasts (Heldin, C. and Westermark B., in the following document: Clark R. ed. "The molecular and cellular biology of wound repair", 2nd edition New York, Plenum Press, pp. 249-273, (1996)). However, it is suggested that in the absence of bleeding, platelets are not necessary for wound healing; many vasoactive mediators and chemokines are produced by coagulation and activated complement pathways and by damaged or activated parenchymal cells, which show that inflammatory leukocytes are recruited to the site of injury (ibid).
[0016] Cell entry into the wound and activation of local cells is initiated by mediators that are released de novo by resident cells or from reserves held in platelet and basophil granules. Sephel, GC and Woodward, SC, 3. "Repair, Regeneration and Fibrosis" in Rubin's Pathology, Rubin, R. and Strayer, DS, eds.; 5th ed., Wolters Kluwyer Health, / Lippincott Williams & Wilkins, Philadelphia, PA (2008), at 71. Cell migration uses the response of cells to cytokines and insoluble substrates of the extracellular matrix. Ibid. at 72.
[0017] Infiltrating neutrophils clear foreign particles and bacteria from the injured area and are then squeezed out along with eschar (dead tissue that falls off (falls off) from healthy skin or is engulfed by macrophages). In response to specific chemoattractants, such as fragments of extracellular matrix proteins, transforming growth factor β (TGF-β) and monocyte chemoattractant protein-1 (MCP-1), monocytes also infiltrate the wound site and become activated macrophages that release growth factors (such as platelet-derived growth factor and vascular endothelial growth factor), which trigger the formation of granulation tissue. Macrophages bind to specific proteins of the extracellular matrix through their integrin receptors, which is a function that stimulates macrophages to engulf microorganisms and extracellular matrix fragments (Brown, E. Phagocytosis, Bioessays, 17: 109-117 (1995)). Studies have reported that adhesion to the extracellular matrix also stimulates monocytes to undergo metamorphosis into inflammatory or reparative macrophages. These macrophages play an important role in the transition between inflammation and repair (Riches, D., Clark R. eds. Molecular and Cellular Biology of Wound Repair, 2nd ed., New York, Plumb Press, pp. 95-141). For example, adhesion-inducing monocytes and macrophages express colony-stimulating factor-1 (CSF-1), a cytokine essential for monocyte and macrophage survival; tumor necrosis factor-α (TNF-α), a potent inflammatory cytokine; and platelet-derived growth factor (PDGF), a potent chemoattractant and mitogen for fibroblasts. Other cytokines shown to be expressed by monocytes and macrophages include transforming growth factor (TGF-α), interleukin-1 (IL-1), transforming growth factor β (TGF-β), and insulin-like growth factor-I (IGF-I) (Rappolee, D. et al., Science, 241, pp. 708-712 (1988)). Monocyte-derived growth factor and macrophage-derived growth factor are thought to be necessary for the initiation and propagation of new tissue formation in wounds, as animals depleted of macrophages have defective wound repair (Leibovich, S and Ross, R., Am J Pathol, 78, pp. 1-100 (1975)).
[0018] Epithelialization
[0019] The re-epithelialization of the wound begins within a few hours after the injury. Epidermal cells from skin appendages (such as hair follicles) quickly remove coagulated blood and damaged matrix from the wound space. At the same time, the cells undergo phenotypic changes, which include the retraction of intracellular tension filaments (Paladini, R. et al., "Journal of Cell Biology (J.Cell Biol)", 132, pp. 381-397 (1996)); the dissolution of most intercellular desmosomes, which provide physical connections between cells; and the formation of peripheral cytoplasmic actin filaments, which allow cells to move and migrate (Goliger, J. and Paul, D. "Molecular Biology of Cells (MolBiol Cell)", 6, pp. 1491-1501 (1995); Gabbiani, G. et al., "Journal of Cell Biology", 76, pp. 561-568 (1978)). In addition, epidermal and dermal cells no longer adhere to each other because of the dissolution of the hemidesmosome junctions between the epidermis and the basement membrane, which allows epidermal cells to move laterally. The expression of integrin receptors on epidermal cells allows them to interact with a variety of extracellular matrix proteins (e.g., fibronectin and vitronectin), which are interspersed with matrix type I collagen at the wound edge and intertwined with the fibrin clot in the wound space (Clark, R., J Invest Dermatol, 94, Supplement, pp. 128S-134S (1990)). The migrating epidermal cells dissect the wound, separating the dry eschar (dead tissue that falls off (sheds) from healthy skin) from the living tissue. The dissection path seems to be determined by the integrin array expressed by the migrating epidermal cells on their cell membranes.
[0020] The degradation of the extracellular matrix required if epidermal cells migrate between the collagen dermis and the fibrin eschar depends on the production of collagenase by epidermal cells (Pilcher, B. et al., Journal of Cell Biology, 137, pp. 1445-1457 (1997)) and the activation of plasmin by plasminogen activators produced by epidermal cells (Bugge, T. et al., Cell, 87, 709-719 (1996)). Plasminogen activators also activate collagenase (matrix metalloproteinase-1) (Mignatti, P. et al., Proteinases and Tissue Remodeling. Clark, R., ed., Molecular and Cellular Biology of Wound Repair, 2nd ed., New York, Plumb Press, 427-474 (1996)) and promote the degradation of collagen and extracellular matrix proteins.
[0021] One to two days after injury, epidermal cells at the wound edge begin to proliferate after the actively migrating cells. The stimulus for epidermal cell migration and proliferation during epithelial re-formation has not yet been determined, but several possibilities have been proposed. The absence of adjacent cells at the wound edge (the "free edge" effect) can signal both migration and proliferation of epidermal cells. Local release of growth factors and increased expression of growth factor receptors can also stimulate these processes. Major competitors include epidermal growth factor (EGF), transforming growth factor-α (TGF-α), and keratinocyte growth factor (KGF) (Nanney, L. and King, L. Epidermal Growth Factor and Transforming Growth Factor-α. Clark, R., ed., Molecular and Cellular Biology of Wound Repair, 2nd ed., New York, Plumb Press, pp. 171-194 (1996); Werner, S. et al., Science, 266, pp. 819-822 (1994); Abraham, J. and Klagsburn, M. Modulation of Wound Repair by Members of the Fibroblast Growth Factor family. Clark, R., ed., Molecular and Cellular Biology of Wound Repair, 2nd ed., New York, Plumb Press, pp. 195-248 (1996)). As re-epithelialization occurs, basement membrane proteins reappear in a very orderly sequence from the wound edge inward in a zipper-like manner (Clark R. et al., Journal of Investigative Dermatology, 79, pp. 264-269 (1982)). Epidermal cells return to their normal phenotype, once again firmly attached to the reconstructed basement membrane and the underlying dermis.
[0022] Granulation tissue formation
[0023] About four days after injury, new matrix (commonly referred to as granulation tissue) begins to invade the wound space. Many new capillaries give the new matrix its granular appearance. Macrophages, fibroblasts and blood vessels move into the wound space simultaneously (Hunt, T. edited "Wound Healing and Wound Infection: Theory and Surgical Practice". New York, Appleton Century Croft Press (Appleton-Century-Crofts) (1980)). Macrophages provide a continuous source of growth factors necessary for stimulating fibrosis and angiogenesis; Fibroblasts produce new extracellular matrix necessary for supporting cell ingrowth; and blood vessels carry oxygen and nutrients necessary for maintaining cell metabolism.
[0024] Growth factors, particularly platelet-derived growth factor-4 (PDGF-4) and transforming growth factor β-1 (TGF-β1) (Roberts, A. and Sporn, M, Transforming Growth Factor-1, Clark, R., eds., Molecular and Cell Biology of Wound Repair, 2nd ed., New York, Plumb Press, pp. 275-308 (1996)) along with extracellular matrix molecules (Gray, A. et al., J Cell Sci, 104, pp. 409-413 (1993); Xu, J. and Clark, R., J Cell Biology, 132, pp. 239-149 (1996)) have been shown to stimulate fibroblasts of periwound tissue to proliferate, express appropriate integrin receptors, and migrate into the wound space. Platelet-derived growth factor has been reported to accelerate the healing of chronic pressure sores (Robson, M. et al., Lancet, 339, pp. 23-25 (1992) and diabetic ulcers (Steed, D., J Vasc Surg, 21, pp. 71-78 (1995)). In some other cases, basic fibroblast growth factor (bFGF) is effective for the treatment of chronic pressure sores (Robson, M. et al., Ann Surg, 216, pp. 401-406 (1992)).
[0025] The structural molecules of the newly formed extracellular matrix (called the provisional matrix) (Clark, R. et al., Journal of Investigative Dermatology, 79, pp. 264-269, 1982) contribute to the formation of granulation tissue by providing a scaffold or conduit for cell migration. These molecules include fibrin, fibronectin, and hyaluronic acid (Greiling, D. and Clark R., Journal of Cell Science, 110, pp. 861-870 (1997)). The appearance of fibronectin and appropriate integrin receptors that bind to fibronectin, fibrin, or both on fibroblasts is considered to be the rate-limiting step in the formation of granulation tissue. While fibroblasts are responsible for the synthesis, deposition, and remodeling of the extracellular matrix, the extracellular matrix itself can have positive or negative effects on the ability of fibroblasts to perform these tasks and generally interact with their environment (Xu, J. and Clark, R., Journal of Cell Science, 132, pp. 239-249 (1996); Clark, R. et al., Journal of Cell Science, 108, pp. 1251-1261).
[0026] Cells move into cross-linked fibrin blood clots or tightly woven extracellular matrix and need active proteolytic systems that can cut the path for cell migration. In addition to serum-derived plasmin, a variety of fibroblast-derived enzymes are considered to be potential candidates for this task, including plasminogen activators, collagenase, gelatinase A and matrix lysin (Mignatti, P. et al., protease and tissue remodeling. Clark, R. ed. "Molecular and Cell Biology of Wound Repair" 2nd edition New York, Plum Press, 427-474 (1996); Vaalamo, M. et al., "Journal of Dermatology Research", 109, pp. 96-101 (1997)). After migrating into the wound, fibroblasts begin to synthesize extracellular matrix. The provisional extracellular matrix is gradually replaced by a collagen matrix, possibly in response to transforming growth factor-β1 (TGF-β1) signaling (Clark, R. et al., Journal of Cell Science, 108, pp. 1251-1261 (1995); Welch, M. et al., Journal of Cell Biology, 110, pp. 133-145 (1990)).
[0027] Once a large amount of collagen matrix is deposited in the wound, fibroblasts cease to produce collagen, and the fibroblast-rich granulation tissue is replaced by a relatively cell-free scar. Cells in the wound undergo apoptosis triggered by unknown signals. Dysregulation of these processes has been reported to occur in fibrotic conditions such as keloid formation, hypertrophic scars, morphea, and scleroderma.
[0028] Neovascularization
[0029] The formation of new blood vessels (neovascularization) is necessary to maintain the newly formed granulation tissue. Angiogenesis is a complex process that depends on the extracellular matrix in the wound bed and the migration and mitogenic stimulation of endothelial cells (Madri, J. et al., Angiogenesis Clark, R. ed. "Molecular and Cell Biology of Wound Repair" 2nd Edition New York, Plum Press, pp. 355-371 (1996)). The induction of angiogenesis was initially attributed to acidic or basic fibroblast growth factor. Subsequently, many other molecules were also found to have angiogenic activity, including vascular endothelial growth factor (VEGF), transforming growth factor-β (TGF-β), angiogenin, angiotrophin, angiopoietin-1 and thrombospondin (Folkman, J. and D'Amore, P, "Cell", 87, pp. 1153-1155 (1996)).
[0030] These molecules induce angiogenesis by stimulating macrophages and endothelial cells to produce basic fibroblast growth factor (FGF) and vascular endothelial growth factor (VEGF). For example, it is reported that activated epidermal cells of wounds secrete a large amount of vascular endothelial growth factor (VEGF) (Brown, L. et al., Journal of Experimental Medicine (J Exp Med), 176, 1375-1379 (1992)).
[0031] It is postulated that basic fibroblast growth factor sets the stage for angiogenesis during the first three days of wound repair, whereas vascular endothelial growth factor is critical for angiogenesis during granulation tissue formation from day 4 to day 7 (Nissen, N. et al., Am. J. Pathol., 152, 1445-1552 (1998)).
[0032] In addition to angiogenic factors, it is also shown that the appropriate extracellular matrix and endothelial receptors of the temporary matrix are necessary for angiogenesis. Proliferating microvascular endothelial cells adjacent to wounds and in wounds deposit an increased amount of fibronectin in the vascular wall (Clark, R. et al., Journal of Experimental Medicine, 156, 646-651 (1982)). Since angiogenesis requires endothelial cells to express functional fibronectin receptors (Brooks, P. et al., Science, 264, 569-571 (1994)), it is shown that perivascular fibronectin acts as a conduit for moving endothelial cells into wounds. In addition, it is shown that protease expression and activity are also necessary for angiogenesis (Pintucci, G. et al., Seminar on Thrombosis and Hemostasis, 22, 517-524 (1996)).
[0033] A series of events leading to angiogenesis have been proposed as follows. Injury leads to tissue destruction and hypoxia. Angiogenic factors (such as acidic and basic fibroblast growth factors (FGF)) are released from macrophages immediately after cell rupture, and stimulate epidermal cells to produce vascular endothelial growth factor by hypoxia. Proteolytic enzymes released into connective tissue degrade extracellular matrix proteins. These protein fragments recruit peripheral blood mononuclear cells to the injury site, where they become activated macrophages and release angiogenic factors. Some macrophage angiogenic factors (such as basic fibroblast growth factor (bFGF)) stimulate endothelial cells to release plasminogen activators and procollagenase. Plasminogen activators convert plasminogen into plasmin and convert procollagenase into active collagenase, and in unison, these two proteases digest basement membranes. The fragmentation of basement membranes allows endothelial cells stimulated by angiogenic factors to migrate and form new blood vessels at the injury site. Once the wound is filled with new granulation tissue, angiogenesis ceases and many new blood vessels disintegrate due to apoptosis (Ilan, N. et al., Journal of Cell Science, 111, 3621-3631 (1998)). This programmed cell death is believed to be regulated by various matrix molecules (such as thrombospondins 1 and 2) and anti-angiogenic factors (such as angiostatin, endostatin and angiopoietin 2) (Folkman, J., Angiogenesis and angiogenesis inhibition: an overview, EXS, 79, 1-8, (1997)).
[0034] Wound contraction and extracellular matrix reorganization
[0035] Wound contraction involves a complex and coordinated interaction of cells, extracellular matrix and cytokines. During the second week of healing, fibroblasts assume a myofibroblast phenotype, characterized by large bundles of actin-containing microfilaments arranged along the cytoplasmic face of the cell's plasma membrane and cell-cell and cell-matrix connections (Welch, M. et al., Journal of Cell Biology, 110, 133-145 (1990); Desmouliere, A. and Gabbiani, G. The role of the myofibroblast in wound healing and fibrocontractive diseases. Clark, R. ed. Molecular and Cellular Biology of Wound Repair, 2nd edition, New York, Plumb Press, pp. 391-423 (1996)). The appearance of myofibroblasts corresponds to the onset of connective tissue compaction and wound contraction. This contraction is thought to require stimulation by transforming growth factor (TGF)-β1 or β2 and platelet-derived growth factor (PDGF), attachment of fibroblasts to the collagen matrix via integrin receptors, and cross-linking between individual collagen bundles (Montesano, R. and Orci, Proc Natl Acad Sci USA, 85, 4894-4897 (1988); Clark, R. et al., J Clin Invest, 84, 1036-1040 (1989); Schiro, J. et al., Cell, 67, 403-410 (1991); Woodley, D. et al., J Investig Dermatol, 97, 580-585 (1991)).
[0036] Collagen remodeling during the transition from granulation tissue to scar depends on the continued synthesis and catabolism of collagen at a low rate. The degradation of collagen in the wound is controlled by several proteolytic enzymes (called matrix metalloproteinases (MMPs)), which are secreted by macrophages, epidermal cells and endothelial cells and fibroblasts (Mignatti, P. et al., Protease and Tissue Remodeling Clark, R. Editor "Molecular and Cell Biology of Wound Repair" 2nd Edition New York, Plum Press, 427-474 (1996)). The different stages of wound repair are considered to depend on different combinations of matrix metalloproteinases and tissue inhibitors of metalloproteinases (Madlener, M. et al., "Exp Cell Res", 242, 201-210 (1998)).
[0037] The wound acquires only about 20% of its final strength during the first three weeks, during which time fibrillar collagen has accumulated relatively rapidly and has been remodeled by wound contraction. Thereafter, the rate at which the wound acquires tensile strength is slow, reflecting a much slower rate of collagen accumulation and collagen remodeling, accompanied by the formation of larger collagen bundles and an increase in the number of intermolecular cross-links.
[0038] Acquired brain damage
[0039] Acquired brain injury is brain damage caused by events after birth, rather than as part of a genetic or congenital condition. Examples of acquired brain injury include, but are not limited to, traumatic brain injury (TBI), stroke, brain tumors, poisoning, infection and disease, drowning or other hypoxic events, and alcohol and drug abuse. Examples of situations that lead to acquired brain injury may include, but are not limited to, domestic violence, falls, car accidents, etc. Acquired brain injury is different from degenerative brain conditions, such as Alzheimer's disease or Parkinson's disease.
[0040] Neurodegenerative diseases
[0041] Neurodegenerative diseases occur when nerve cells in the brain or peripheral nervous system lose function over time and eventually die. Although certain treatments can help alleviate some of the physical or mental symptoms associated with neurodegenerative diseases, it is currently impossible to slow their progression, and there is no cure. Examples include, but are not limited to, Parkinson's disease, Alzheimer's disease and other memory disorders, Huntington's disease, motor neuron disease or amyotrophic lateral sclerosis (ALS), ataxia, multiple system atrophy, and progressive supranuclear palsy. As these disorders progress, they may affect every aspect of a person's life, including mobility and balance, abnormal movements; swallowing; bladder and bowel function, blood pressure fluctuations; sleep; breathing; heart function; memory and cognitive abilities; emotions and speech. It has been hypothesized that exposure to environmental pollutants such as pesticides, fungicides, insecticides, metals (e.g., arsenic, lead, manganese), chemicals (e.g., polychlorinated biphenyls), air pollution, biological factors (e.g., bacterial endotoxins), dietary and lifestyle factors (e.g., caffeine, tobacco smoke, dietary antioxidants) may influence neurodegeneration alone or in combination with specific genes.
[0042] For example, Parkinson's disease progresses slowly as small clusters of brain neurons die. The gradual loss of these neurons reduces levels of the neurotransmitter dopamine, which sends messages to the part of the brain that coordinates muscle movement. Common symptoms of Parkinson's disease include tremors or shaking of the hands, arms, legs, jaw, and face; rigidity or stiffness of the limbs and trunk; bradykinesia, or slow movement; and difficulties with balance, speech, and coordination. Symptoms begin gradually and usually worsen over time. Although scientists do not know the cause of Parkinson's disease, most agree that the interaction between a person's genes and the environment plays a role in the onset and progression of the disease.
[0043] Alzheimer's disease (AD) is a progressive neurodegenerative disorder most commonly characterized by initial memory impairment and progressive, irreversible cognitive decline that may ultimately affect behavior, speech, visuospatial orientation, and motor systems. Pathologically, AD is defined by two lesions evident on microscopic examination of postmortem tissue: extracellular plaques composed primarily of aggregated amyloid-β (Aβ) 1–42 amino acid polypeptides and intracellular neurofibrillary tangles (NFTs) formed by hyperphosphorylated aggregated forms of the microtubule-associated protein tau [Montine, TJ et al. Acta Neuropathol. (2012) 123(1):1-11]. These proteins aggregate into highly toxic soluble oligomeric structures and ultimately into microscopically detectable fibrillar macrostructures such as plaques and tangles. This is associated with synaptic dysfunction and synapse loss in areas where one or both protein aggregates are found, disruption of neurotransmitter systems, and neuronal death (Selkoe, DJ, Science (2002) 298(5594):789-91; Spires-Jones, TL and Hyman, BT. Neuron (2014) 82(4):756-71). Ultimately, neurodegeneration leads to cognitive decline and dementia [Hardy, J. and Selkoe, DJ. Science (2002) 297(5580):353-6].
[0044] Huntington's disease (HD) is a rare, progressive neurodegenerative disorder with autosomal dominant inheritance. It is caused by a mutation in the huntingtin gene that results in an expansion of a CAG trinucleotide (cytosine, adenine, and guanine) repeat sequence located in the first exon of the HD gene, which encodes huntingtin, a 350 kDa protein of unknown function. Expansion of the CAG trinucleotide repeat sequence (CAG repeat sequence) in the coding region of the human gene causes a neurodegenerative disorder by producing a protein with an extended polyglutamine (polyQ) stretch. This group of disorders includes Huntington's disease (HD), dentatorubral pallidoluysianatrophy, spinal bulbar muscular atrophy, and spinocerebellar ataxia (SCA) types 1, 2, 3, 6, and 7 [Moncke-Buchner, E. et al. Nucleic Acids Res. (2002) 30(16):e83].
[0045] The term "motor neuron disease" describes a heterogeneous group of conditions, all of which are progressive and ultimately fatal (including amyotrophic lateral sclerosis or ALS), which cause progressive muscle weakness through the loss of upper and lower motor neurons. Non-motor pathways are also affected, and up to 50% of patients have detectable cognitive and behavioral changes. [Verber, NS et al. Frontiers in Neurology (Front. Neurol.) (2019) 10: 291, citing Wooley, SC and Jonathan, SK. Phys. Med. Rehabil. Clin. N. Am. (2008) 19: 607-17].
[0046] Ataxia, or lack of coordination, is a common manifestation of different neurological conditions, including stroke, brain tumors, multiple sclerosis, traumatic brain injury, toxicity, infection (including chickenpox described below), and congenital cerebellar defects. Its development can be acute, subacute, sporadic, or chronic. Ataxia can be broadly divided into hereditary ataxias (with or without family history) and acquired / degenerative ataxias. 'Sporadic' ataxia means no family history. Acquired progressive ataxias can be immune-mediated (e.g., paraneoplastic spinocerebellar degeneration, gluten ataxia); degenerative (e.g., cerebellar variant of multiple system atrophy (type C)); caused by deficiency states (e.g., vitamin B12, vitamin E, etc.), toxicity (e.g., alcohol-related ataxia, phenytoin); or associated with infection (HIV, sporadic Creutzfeldt-Jakob disease, progressive multifocal leukoencephalopathy, etc.). Inherited ataxias can have autosomal dominant, autosomal recessive, X-linked, or mitochondrial (maternal) inheritance. Metabolic disorders (e.g., Niemann-Pick type C, Tay-Sachs disease), even if 'inherited', may present as late-onset ataxias with no family history. [Nilantha de Silva, R. et al. Pract. Neurol. (2019) 19(3):196-207].
[0047] Progressive cognitive disorders associated with the accumulation of neurofibrillary tangles ("NFTs") include, but are not limited to, progressive supranuclear palsy; dementia; dementia pugilistica; Creutzfeldt-Jakob disease; frontotemporal dementia; Pick's disease; other tau-positive pathologies corticobasal degeneration; frontotemporal lobar degeneration (FTLD); and dementias lacking distinctive histology.
[0048] Chronic Traumatic Encephalopathy (CTE)
[0049] Chronic traumatic encephalopathy is considered to be a rare progressive degenerative brain disease found in people with a history of repetitive head trauma. Because the chronic traumatic encephalopathy can only be clearly diagnosed by autopsy after death, it is not yet fully understood. The chronic traumatic encephalopathy was originally called pugilistic dementia, but has been expanded to include brain damage from other sources. Severe impacts suffered in the case of traumatic brain injury (TBI) may lead to CTE, especially when they are repeatedly suffered. Repetitive head impacts (RHI), defined as cumulative exposure to recurrent concussive events and subconcussive events, have long been associated with CTE. [Nowinski, CJ et al. Frontiers in Neurology (2022) 13: 938163]. Even relatively small impacts in mild traumatic brain injury (MTBI) or concussion may also cause or lead to the condition.
[0050] CTE is characterized by a progressive degeneration of brain tissue, along with an accumulation of tau protein. The symptoms may appear within a few months of the injury, or they may begin years or even decades after the last impact. Symptoms of CTE include behavioral changes, memory loss, depression, aggression, impulsive behavior, and impaired judgment, and the individual will gradually develop dementia. [www.protectthebrain.org, accessed February 6, 2023].
[0051] epilepsy
[0052] Seizures are paroxysmal rhythmic changes in cortical electrical activity, which are almost always accompanied by behavioral changes. This change may be purely subjective (i.e., sensory symptoms that are not obvious to an outside observer), and sometimes this electrical activity does not produce symptoms at all - so-called subclinical or electrographic seizures. Focal or partial seizures are seizures that originate in one cerebral hemisphere; the generator may be a small area or a large multilobed network within the cerebral hemisphere, and the discharge may then spread to widely involve both cerebral hemispheres. Generalized seizures originate from both cerebral hemispheres at the same time. There are several different types of generalized seizures, the most common of which is the tonic-clonic ("grand mal") type, in which there is first a loss of consciousness with tonic rigidity, followed by gradually increasing clonic (forward and backward) muscle activity, all lasting about one minute. There are also isolated clonic seizures and isolated tonic seizures, each of which is characterized by the absence of corresponding forms of motor activity of other types, as well as terrible atonic seizures, in which the patient suddenly loses all muscle tone and collapses to the ground, often producing self-mutilation. Common in children are absence ("petit mal") seizures, episodes of loss of consciousness and a few seconds of behavioral stasis, sometimes accompanied by eye twitches, with the patient immediately resuming his or her previous activities as if nothing had happened (and usually without knowing it). Finally, myoclonic seizures—sudden, momentary, lightning-like contractions of a muscle or muscle group accompanied by diffuse changes in the electroencephalogram (EEG)—are not usually mentioned by the patient and usually have little effect on the patient's well-being in themselves, but can provide very important clues to the correct classification of the patient's epilepsy syndrome. [Mintzer, S. Pharmacology and Therapeutics, Principles to Practice (2009), pp. 663-83, Elsevier, Inc.]
[0053] Generalized epilepsy is further subdivided into idiopathic (primary), in which patients have normal intelligence and brain function, and symptomatic (secondary), in which patients have generalized seizures secondary to some diffuse brain disease that also produces mental retardation (eg, congenital anemia, tuberous sclerosis complex).
[0054] It is generally believed that primary generalized epilepsy is hereditary in nature, and there are many specific genes associated with various generalized epilepsy syndromes, of which only some genes have clearly identified functions. However, inheritance and penetrance patterns appear to be complex, and the genes found so far account for only a small part of patients with primary generalized epilepsy. [Same, citing Berkovic, SF. Genetics of epilepsy syndromes. In Engel, J. Pedley, T. (ed.) Epilepsy: A comprehensive Textbook. Philadelphia: Lippincott-Raven (1997).
[0055] At the "macro" level, focal epilepsy can be caused by many focal lesions occurring anywhere in the cerebral cortex, including cortical dysplasia, tumors, ectopy and hamartomas, congenital malformations, infarctions, hemorrhages, vascular malformations, traumatic injuries, and different kinds of central nervous system infections. The most well-studied cause of focal epilepsy is hippocampal sclerosis, a condition with a very specific pattern of neuronal cell loss and gliosis that is different from that observed under hypoxic injury, Alzheimer's disease, or other hippocampal pathologies. 8 Hippocampal sclerosis is often associated with neurological "hits" in childhood (e.g., prolonged febrile seizures, meningitis), and is probably the most common cause of drug-resistant focal epilepsy, which often requires resection surgery (discussed later in this section). Despite extensive research and the astonishing success of hippocampal resection for this condition, it is still completely unclear why this condition produces attacks at a systemic level.
[0056] At the "microscopic" level, seizures have been conceptualized as being due to excessive neuronal excitation, inadequate inhibition, or both. Focal seizures are the product of electrically overexcited groups of neurons that fire synchronously, producing rhythmic, ever-changing discharges. Between seizures, most of these neuronal groups produce much shorter synchronized depolarizations; in electric field recordings such as EEG, the synchronized depolarizations appear as sharp waves (interictal epileptiform activity, also called spikes or sharp waves). These waves—and seizures that may be caused by the same neurons—result from the sum of many paroxysmal depolarization shifts in the postsynaptic neuron, which are presumed to be due to excitatory postsynaptic potentials generated by the release of neurotransmitters from the presynaptic neuron. [Ibid., citing Prince, DA and Futamachi, KT. Intracellular recordings in chronic focal epilepsy. Brain Res. (1968) 11: 681-4; Dichter, M. and Spencer, WA. Penicillin-induced interictal discharges from the cat hippocampus. I. Characteristics and topographical features. J. Neurophysiol. (1969) 32: 649-62]. Although recent evidence suggests that many excitatory neurotransmitters under paroxysmal depolarization shifts may come from astrocytes rather than neurons [ibid., citing Tian, GF et al. An astrocytic basis of epilepsy. Nature Med. (2005) 11: 973-81], it is clear that, in any case, glutamate and its ionotropic receptors play a role in the generation of epileptiform activity. Some anticonvulsants can act at least in part through glutamate (e.g., N-methyl-d-aspartate [NMDA] receptor antagonism), while other anticonvulsants can act by reducing the rapid frequency of neuronal discharges, so that less glutamate is released at the synapse. In a similar manner, GABA (the main inhibitory neurotransmitter in the central nervous system) can clearly hinder the development of epileptiform activity and reduce seizures, and several anticonvulsants (e.g., barbiturates, benzodiazepines, tiagabine) appear to exert their anticonvulsant properties by increasing synaptic GABA or enhancing its effects.Notably, in some cases (e.g., in absence seizures, as described previously), neuronal hypersynchrony may result from excessive rather than insufficient inhibition, depending on the epileptogenic circuitry.
[0057] A nearly universal feature of seizures is that individual events terminate within minutes or even seconds. If the pathophysiological basis of seizure initiation is largely unknown, those potential seizure terminations remain even more obscure. Occasionally, seizures fail to terminate, resulting in sustained rhythmic cortical discharges, which are often of profound clinical relevance and are known as status epilepticus. It is speculated that the onset of seizures involves seizure termination mechanisms inherent in the brain, and that the status epilepticus is caused by the failure of these termination mechanisms. Status epilepticus is a medical emergency in most cases, so that although the pharmacological mechanisms involved in combating the status epilepticus are similar to those used for recurrent single seizures, the delivery mode is usually more invasive (e.g., intravenous [IV], rectal, etc.).
[0058] Seizures can occur early (within the first week of brain injury) or late (more than a week after brain injury). Seizures that occur early after traumatic brain injury are considered symptoms of recent injury. Seizures that occur late after TBI are more likely to recur and cause epilepsy.
[0059] According to the Epilepsy Foundation (www.epilepsy.com, accessed February 6, 2023), approximately 1 in 10 people (10%) will experience an early seizure after a TBI. 50% of early seizures occur during the first 24 hours after a TBI, and 25% of early seizures occur during the first hour after a TBI. Most very early seizures (within 24 hours of injury) are generalized tonic-clonic seizures.
[0060] In the early days after TBI, approximately 1 in 10 people will develop status epilepticus. Younger children are at the highest risk for early post-traumatic seizures and status epilepticus.
[0061] People who have more severe head injuries (examples: car crashes, falls from height, military blast injuries) that cause brain swelling or bleeding outside the brain (subdural hemorrhage) or involve penetration of the brain by a foreign object (examples: bullets, combat injuries) or are accompanied by a prolonged period of loss of consciousness (>30 minutes) are more likely to have an early attack. One in four people who have bleeding in the brain that requires surgery (intracerebrovascular hematoma) or skull fractures that compress or damage brain tissue experience an early attack.
[0062] In some cases, even if the head injury is "mild" and there is no evidence of human brain damage on brain imaging with CT or MRI, a seizure may still occur.
[0063] There may or may not be EEG changes in the period immediately following a head injury. If markers of seizures appear on the early EEG after a TBI, this may mean that the person is more likely to develop epilepsy. People who have early seizures after a brain trauma are at a higher risk of developing post-traumatic epilepsy.
[0064] Seizures that occur more than a week after a traumatic brain injury are considered late onset. Most often, when this happens, it's because brain cells have been more severely damaged and the chemical environment around the cells has changed. Late onset seizures are more likely to lead to complications of post-traumatic epilepsy.
[0065] People with post-traumatic epilepsy (PTE) are at risk for recurrent seizures as a result of a brain injury. About 1 in 50 people with a traumatic brain injury will go on to develop PTE. There is a spectrum in the severity of PTE, from well-controlled seizures to disabling seizures that are resistant to treatment. Most seizures in post-traumatic epilepsy (8 in 10 people) are focal and can spread to become bilateral tonic-clonic seizures.
[0066] In 1 in 2 people, post-traumatic epilepsy develops within a year of their brain injury. The more severe the head injury, the greater the person's risk of developing epilepsy. The risk of developing PTE decreases significantly over time, but for people with the most severe brain injuries, it can extend up to 15 years after the original traumatic injury. People are at higher risk of developing PTE if:
[0067] People experience early onset after TBI;
[0068] When a person is injured, there is bleeding in the brain tissue or contusion (bruise);
[0069] A person has a skull fracture and a piece of the skull moves into the brain, damaging brain tissue or compressing the brain (depressed skull fracture);
[0070] Penetrating brain trauma occurs (example bullet, combat injury);
[0071] The person has a head injury related to alcohol consumption;
[0072] Needing surgery to remove bleeding from the brain (hematoma), to remove a foreign object from the brain, or to drain fluid from the brain if there is swelling in the brain related to trauma (ventriculostomy);
[0073] The EEG has abnormalities that appear early after injury;
[0074] The person is over 65 years old; and / or
[0075] The person has a family history of epilepsy.
[0076] Traumatic brain injury
[0077] Traumatic brain injury (TBI) is a non-degenerative, non-congenital injury to the brain caused by external mechanical forces, which may lead to permanent or temporary impairment of cognitive, physical and psychosocial functions, with associated diminished or altered states of consciousness. Clinically, it can manifest from concussion to coma and death. TBI has received increasing attention due to head injuries caused by sports and recreation.
[0078] As in Figure 1 As schematically depicted in , TBI is divided into two subcategories: (1) primary injury, which occurs at the moment of trauma, and (2) secondary injury, which occurs immediately after the trauma and produces effects that can last for a long time. Secondary injuries may develop hours or days after the initial traumatic attack.
[0079] The primary injury may be focal (e.g., skull fracture, intracranial hematoma, laceration, contusion, penetrating injury), or it may be diffuse (as in diffuse axonal injury). Diffuse injuries are microscopic changes that do not appear on CT scans and are dispersed throughout the brain.
[0080] Concussion is considered a mild form of diffuse axonal injury. Concussion is caused by deformation of the deep structures of the brain, resulting in widespread neurological dysfunction that may lead to impaired consciousness or coma.
[0081] One of the most widely used systems for classifying head injury outcomes is the Glasgow Outcome Scale (GOS).
[0082] Glasgow Outcome Scale 1
[0083]
[0084] 1 Teasdale, G. and Jennett, B. Lancet (1974) 81-84; Teasdale, G. and Jennett, B. Acta Neurochir. (1976) 34:45-55.
[0085] For patients with closed head injuries, patients with mild head injuries (usually defined as GCS scores of 13-15 on admission) tend to do well. These patients may experience headaches, dizziness, irritability, or similar symptoms, but these symptoms gradually improve in most cases. Patients with moderate head injuries do not fare as well. About 60% of patients will recover actively, and an estimated 25% of patients will be left with a moderate degree of disability. Death or a persistent vegetative state is the result in about 7-10% of cases. The remaining patients will have a severe degree of disability.
[0086] Although the GOS is useful, it is not a good tool for measuring subtle mood or cognitive issues.
[0087] Other tools are available to assess athletes for concussion.
[0088] For example, the Sports Concussion Assessment Tool (SCAT5) is a standard tool for evaluating concussions in athletes aged 13 years and older for use by physicians and licensed healthcare professionals. For children aged 12 years and younger, the Child SCAT5 is recommended.
[0089] The BESS test (Balance Error Scoring System) is a balance assessment protocol developed specifically for the assessment of sports concussions. It is part of the Sports Concussion Assessment Tool (SCAT) developed by the Sports Concussion Group as a standard protocol for concussion testing. It contains an interpretation of the Romberg test, which consists of a balance test originally introduced in 1853. Although the BESS test is generally accepted by the clinical research community, some concerns have been raised regarding the inter- and intra-rater reliability of manual scoring. Pressure measurement mat systems (such as Tekscan's MobileMat TM ) and SportsAT TM The combination of software is designed to minimize the chance of human error by automating the scoring of the BESS test. The MobileMat acts as a solid surface for the test subject to stand on for the test, and a foam pad can be placed on the pad for the portion of the test. The pad is 0.3 inches thick and contains a high-resolution pressure sensor, adding objective data to the BESS test.
[0090] ImPACT Applications, Inc. offers a concussion assessment tool that contains a set of computerized cognitive tests to help manage concussions. For example, ImPACT version 4 is suitable for people aged 12-80 years.
[0091] The King-Devick test is a two-minute rapid digit naming assessment in which individuals rapidly read aloud single digits and assess impairments in eye movements, attention, and language function.
[0092] Changes in brain glucose metabolism after TBI
[0093] Figure 2A and Figure 2B Demonstrated normal glucose metabolism in the glycolytic pathway and oxidative metabolism of glucose after TBI ( Figure 2A ) and damage point ( Figure 2B ).
[0094] During an impact, the rapid movement of the brain within the skull triggers a series of neurochemical disruptions that alter brain metabolism. Within minutes of injury, ionic balance across neuronal membranes is disrupted, with extracellular potassium and glutamate concentrations and intracellular calcium accumulation increasing with the severity of injury [Prins, ML and Matsumoto, JH. The collective therapeutic potential of cerebral ketone metabolism in traumatic brain injury. J. Lipid Res. (2014) 55(12):2450-7, citing Fineman I. et al. Concussive brain injury is associated with a prolonged accumulation of calcium: a 45Ca autoradiographic study. Brain Res. (1993) 624:94–102; Katayama Y. et al. Massive increases in extracellular potassium and the indiscriminate release of glutamate following concussive brain injury. injury). Journal of Neurosurgery (J. Neurosurg.) (1999) 73: 889–900].Disruption of this ion balance requires cellular energy to reestablish homeostasis, as reflected by the increase in brain glucose uptake observed within 30 minutes after fluid percussion (FP) injury in adult rodents [ibid., citing Yoshino A. et al. Dynamic changes in local cerebral glucose utilization following cerebral conclusion in rats: evidence of a hyper- and subsequent hypometabolic state. Brain Res. (1991) 561: 106–119] and within 8 days after human TBI [ibid., citing Bergsneider M. et al. 1997. Cerebral hyperglycolysis following severe traumatic brain injury in humans: a positron emission tomography study. J Neurosurgery (1997) 86: 241–251]. This transient increase in glucose uptake is also referred to as "hyperglycolysis" and is followed by a prolonged period of suppression of glucose metabolism. These brain metabolic changes are hallmark responses described in both experimental and clinical brain trauma.Experimental studies have shown that the magnitude and duration of glucose metabolism suppression increase with injury severity and age [ibid., citing Prins, M. et al. Mapping cerebral glucose metabolism during spatial learning: interactions of development and traumatic brain injury. J. Neurotrauma. (2001) 18:31–46; Thomas, S. et al. Cerebral metabolic response to traumatic brain injury sustained early in development: a 2-deoxy-D-glucose autoradiographic study. J. Neurotrauma. (2000) 17:649–665; Hovda, D. A. et al. Long-term changes in metabolic rates for glucose following mild, moderate, and severe concussive head injuries in adult rats. rats). Abstracts of Social Neuroscience (Soc. Neurosci.) (1994). 20:845].
[0095] Other biochemical changes that occur after TBI further disrupt glucose uptake and metabolism. For example, [1,2- 13Proton NMR spectroscopy of [C]-labeled glucose indicated that glucose processing via the pentose phosphate pathway increased by 9-12% 3 to 24 hours after controlled cortical impact (CCI) injury, thereby reducing the available glucose supply for energy production [ibid., citing Bitnik, BL et al. Upregulation of pentose phosphate pathway and preservation of tricarboxylic acid cycle flux after experimental brain injury. Journal of Neurotrauma (2005). 22: 1052–1065]. It has also been shown that TBI causes an early increase in reactive oxygen species (ROS) that damage lipids, proteins, and DNA [ibid., citing Hall, ED et al. Brain hydroxyl radical generation in acute experimental head injury. J. Neurochem. (1993) 60:588–594; Althaus, JS et al. The use of salicylate hydroxylation to detect hydroxyl radical generation in ischemic and traumatic brain injury. Reversal by tirilazad mesylate. mesylate)(U-74006F). Mol. Chem. Neuropathol. (1993) 20:147–162; Marklund, N. et al. Effects of the nitrone radical scavengers PBN and S-PBN on in vivo trapping of reactive oxygen species after traumatic brain injury in rats. J. Cereb. Blood Flow Metab. (2001) 21:1259–1267; Sen, S.et al. Oxypurinol inhibits free radical release from the cerebral cortex of closed head injured rats. Neurosci. Lett. (1993) 162: 117–120; Sens, S. et al. Alpha-phenyl-tert-butyl-nitrone inhibits free radical release in brain concussion. Free Radic. Biol. Med (1994). 16: 685–691]. ROS-induced DNA damage activates DNA repair enzymes such as poly-ADP ribose polymerase (PARP). In the presence of DNA strand breaks, pathological activation of PARP depletes cytoplasmic NAD. +, which ultimately inhibits the glycolytic processing of glucose in the glyceraldehyde phosphate dehydrogenase step [ibid., citing Sheline, C. et al. Zinc-induced cortical neuronal death: contribution of energy failure attributable to loss of NAD(+) and inhibition of glycolysis. Journal of Neuroscience (J. Neurosci.) (2000) 20: 3139-3146. In general, these series of biochemical changes shift and hinder the processing of glucose through the glycolytic pathway. The resulting decrease in glucose oxidation and ATP concentration [ibid., citing Singh, IN et al. Time course of post-traumatic mitochondrial oxidative damage and dysfunction in a mouse model of focal traumatic brain injury: implications for neuroprotective therapy. Journal of Cerebral Blood Flow and Metabolism (2006) 26:1407–1418; Lee, S. et al. Evidence for energy failure following irreversible traumatic brain injury. Ann. NY Acad. Sci. (1999) 893:337–340] makes glucose an inefficient energy substrate in the brain after TBI.
[0096] TBI induces an inflammatory response in the brain
[0097] Damage to CNS also triggers inflammatory responses from resident microglia and macrophages and peripheral immune cells (such as neutrophils, monocytes and T cells). Microglia and resident macrophages will immediately respond to damage after sensing damage-associated molecular patterns (DAMPs), such as the presence of adenosine triphosphate (ATP) or intracellular proteins released from damaged cells or dying cells. Signal transduction from DAMP receptors initiates local cytokines and chemokines to produce, which affects the immediate environment and provides clues for peripheral immune infiltration (Russo, M. and McGavern, DB, "Inflammatory neuroprotection following traumatic brain injury", "Science" (2016) 353 (6301): 783-6, citing Corps, KN. et al. "JAMA Neurol. (2015) 72: 355-62).
[0098] Within the CNS, the positive aspects of immune cells mobilized in response to injury include clearing dead cells, supporting barrier systems, and setting the stage for wound healing. Microglia, monocytes, macrophages, neutrophils, and T cells may work together to coordinate a response that preserves neural tissue and promotes regeneration.
[0099] Generally, microglia are key players in the acute phase of CNS injury. Sealing the barrier and clearing debris are just two benefits that make these cells participate in the response. Due to their ubiquitous and abundant DAMP sensors, microglia are usually the first responders of brain damage. For example, microglia express several purinergic receptors, which allow them to quickly respond to extracellular purines, such as ATP. The detection of extracellular ATP allows microglia to project projections to the site of injury within minutes. Microglia are also involved in the immediate CNS barrier support after brain capillary damage (ibid., citing Lou, N. et al. "Proceedings of the National Academy of Sciences of the United States (Proc.Natl Acad.Sci.USA)" (2016) 113: 1074-9). In addition to providing barrier support, microglia and macrophages can also remove debris from damaged CNS.
[0100] Although various protective layers separate CNS from peripheral tissues, immune cells infiltrate CNS in response to trauma. In spinal cord injury models, neutrophil recruitment is necessary for proper wound healing and repair (ibid., citing Stirling, DP et al. "Journal of Neuroscience" (2009) 29: 753-64). Mice treated with neutrophil depletion antibodies showed reduced astrocyte reactivity, larger lesions and poor neurological outcomes at the site of injury. After acute brain injury, neutrophils are also recruited to the meninges in a purinergic receptor-dependent manner, and interference with this response increases the amount of meningeal cell death (ibid., citing Roth, TL et al. "Nature (Nature)" (2014) 505: 223-8). Although it is not clear how neutrophils contribute to neuroprotective responses after CNS injury, these cells do have the ability to recruit peripheral monocytes within one or two days. Spinal cord injury causes a significant recruitment of proinflammatory macrophages, followed by wound healing macrophages a few days later (ibid., citing Shechter, R. et al. Immunity (2013) 38: 555-69). When this wound healing response is blocked, mice cannot properly repair the injury and recover motor skills (ibid., citing Shechter, R. et al. Immunity (2013) 38: 555-69). Similar to peripheral tissues, innate immune cells are essential for tissue remodeling and repair in the CNS.
[0101] T cells can also play an active role in CNS injury response. CNS injury can promote the nonspecific recruitment of CD4+T cells that produce interleukin-4 (IL-4) in a major histocompatibility complex II-independent manner (ibid., citing Walsh, JT et al. "Journal of Clinical Research" (2015) 125: 699-714). The release of IL-4 enhances neurotrophin signaling that helps stimulate axonal regeneration after injury. Mice lacking T cells or IL-4 show increased neuronal loss and neurological dysfunction after CNS injury. During CNS tissue repair, effectors and regulatory CD4+T cells work together. Regulatory T cells (Treg) usually keep immune responses in check by regulating inflammatory mediators to promote wound healing and remodeling. Depleting Treg before CNS injury increases the recruitment of effector CD4+T cells and improves neural recovery (ibid., citing Raposo, C. et al. "Journal of Neuroscience" (2014) 34: 10141-55). In contrast, Treg depletion days after injury interferes with tissue repair processes. Similar to the shift from pro-inflammatory macrophages to wound-healing macrophages, these Treg data show that the neuroinflammatory response to injury changes over time.
[0102] Currently, treatments that prevent nerve damage or promote nerve healing after TBI are not available. Efforts to block neuroinflammation, while successful in treating multiple sclerosis, have failed in other pathologies because anti-inflammatory strategies block not only harmful aspects of inflammation, but also beneficial aspects.
[0103] The metabolic relationship between β-hydroxybutyrate (BHB) and cellular metabolism and energy in the ketogenic diet
[0104] Metabolism is the sum of chemical and physical changes that occur in tissues. Metabolism consists of anabolism (those reactions that convert small molecules into large molecules) and catabolism (those reactions that convert large molecules into small molecules).
[0105] Catabolism
[0106] Under normal circumstances, the proteins, lipids, and polysaccharides that make up most of the food people eat must be broken down into smaller molecules before cells can use them. The enzymatic breakdown, or catabolism, of these molecules occurs in three stages. In stage 1, large polymer molecules are broken down into their monomer subunits by digestion—proteins into amino acids, polysaccharides into sugars, and fats into fatty acids and glycerol. These processes occur outside the cell, primarily through the action of secreted enzymes. In stage 2, the resulting small molecules enter the cell and are further degraded in the cytoplasm. Most of the carbon and hydrogen atoms of the sugar are converted into pyruvate, which then enters the mitochondria, where it is converted into the acetyl group of acetyl coenzyme A (acetyl CoA). Acetyl CoA (like ATP) is a chemically reactive compound that releases large amounts of energy when hydrolyzed. Large amounts of acetyl CoA are also produced by the oxidation of fatty acids. Stage 3 occurs when the acetyl group of acetyl CoA is completely degraded into CO2 and H2O. Most of the ATP is produced in this final stage. By producing ATP, the energy originally derived from the burning of carbohydrates and fats is redistributed as a conveniently packaged form of chemical energy that is easily released. [Alberts, B. et al., Molecular Biology of the Cell (1983) Garland Publishing, NY, Chapter 2, pp. 67-75].
[0107] The most important part of phase 2 of catabolism is glycolysis, meaning a series of reactions involving the breakdown of glucose. In glycolysis, a glucose molecule with six carbon atoms is converted into two pyruvate molecules, each with three carbon atoms, through a series of nine enzyme reactions involving a series of phosphate-containing intermediates. At the end of glycolysis, the ATP balance sheet shows a net profit of two molecules of ATP per glucose molecule. For most animal cells, the pyruvate formed quickly enters the mitochondria to be completely oxidized to CO2 and water.
[0108] In addition to pyruvate, fatty acids and some amino acids also enter the mitochondria from the cytosol where they are converted to acetyl CoA or one of the other intermediates of the citric acid cycle.
[0109] Glucose homeostasis
[0110] Glucose, a fundamental source of cellular energy, is released by the breakdown of endogenous glycogen reserves located primarily in the liver. Glucose is also released indirectly in muscle through intermediate metabolites. These systemic energy reserves are replenished by dietary glucose, which is distributed to various tissues of the body after digestion and absorption through the intestinal wall. (Bryant, NJ et al., Nat. Rev. Mol. Cell Biol. 2002: 3(4): 267-77).
[0111] Typically, after glucose uptake, an increase in plasma glucose concentration triggers insulin release, which stimulates visceral (liver and gastrointestinal tissue) and peripheral glucose uptake and inhibits endogenous (mainly liver) glucose production. In healthy adults, blood glucose levels are strictly regulated within the range of 70 mg / dL to 99 mg / dL and are maintained by specific hormones (e.g., insulin, glucagon, incretin) and the central and peripheral nervous systems to meet metabolic requirements. Various cells and tissues (in the brain, muscle, gastrointestinal tract, liver, kidney, and adipose tissue) also participate in blood glucose regulation through uptake, metabolism, storage, and secretion. DeFronzo, RA., Med. Clin. N. Am. 88:787-835 (2004); Textbook of Medical Physiology; Gerich, JE, Diabetes Obes. Metab. 2000:2:345-350. Under normal physiological circumstances, glucose levels rarely rise above 140 mg / dL, even after consuming a high carbohydrate meal.
[0112] Insulin, a potent anti-lipolytic (inhibits fat breakdown) hormone, is known to lower blood glucose levels by accelerating the transport of fructose to insulin-sensitive cells and promoting its conversion to storage compounds through glucogenesis (conversion of glucose to glycogen) and lipogenesis (fat formation). Glucagon, which also plays a role in glucose homeostasis, is produced in response to low normal glucose levels or hypoglycemia and increases glucose levels by accelerating glycogenolysis and promoting gluconeogenesis. After a meal containing glucose, hyperinsulinemia suppresses glucagon secretion, which helps to suppress hepatic glucose production and maintain normal postprandial glucose tolerance.
[0113] Incretins, including glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1), are also involved in the regulation of blood glucose, in part through their effects on insulin and glucagon. (Drucker and Nauk, The Lancet 368: 1696-1705 (2006)). However, both GLP-1 and GIP are considered glucose-dependent hormones, meaning that they are secreted only when glucose levels are above normal fasting plasma glucose levels. Normally, these hormones are released in response to a meal, and by activating certain receptors on pancreatic beta cells, these hormones help stimulate insulin secretion. However, when glucose levels are low, GLP-1 and GIP levels (and their stimulating effects on insulin secretion) decrease. Drucker, Cell Metab. 3: 153-165 (2006).
[0114] Ketosis
[0115] As an alternative to glucose utilization, the body can metabolically bend into a state of ketosis. Ketosis relies on fat-derived ketones produced in the liver to provide fuel for nearly every cell in the body. Ketones—acetoacetate, beta-hydroxybutyrate, and acetone—are water-soluble molecules produced by the liver from fatty acids when blood sugar and liver glycogen reserves are at a minimum. Untreated patients with type 1 diabetes experience glycogen depletion and elevated ketone levels during periods of fasting, low carbohydrate intake, intense exercise, starvation, or due to a complete lack of insulin. [Gershuni, VM et al. Curr. Nutr. Rep. (2018) 7(3):97-106].
[0116] The hormone activation of lipolysis and ketosis is mediated by adrenaline and glucagon and is resistant to insulin. In the case of minimal dietary carbohydrates, insulin is low and glucagon increases. In addition to stimulating glycogenolysis in the liver, glucagon stimulates lipolysis to release stored fatty acids from adipose tissue. [Ibid., citing Sato, K. et al. Insulin, Ketone bodies and mitochondrial energy transduction (Insulin, Ketone bodies and mitochondrial energy transduction). "Federation of American Societies for Experimental Biology Journal (FASEB J.)" (1995) 9: 651-58]. In addition to forming ketones, fatty acids can be converted into acetyl CoA (an intermediate substrate between fatty acid oxidation and glucose metabolism), which enters the citric acid cycle and then undergoes oxidative phosphorylation to produce ATP. On the contrary, in response to hyperglycemia (i.e., after a high carbohydrate diet), insulin levels rise and ketosis stops to facilitate de novo lipogenesis (fat reserves). Therefore, ketosis represents the ability to increase from an insulin-mediated glucose-dependent state to use dietary fat and fat reserves as fuel.
[0117] Nutritional ketosis
[0118] Nutritional ketosis is the intentional restriction of dietary carbohydrate intake to accelerate ketone production and induce metabolic effects that stabilize blood glucose, minimize insulin release, and thereby mitigate the downstream anabolic and tumorigenic effects of long-standing insulin resistance. As described by Volek and Phinney, a "well-adjusted" ketogenic diet consists of 5-10% carbohydrates (<20-50 g / day), adequate protein (1-1.5 g / kg / day), and fat until satiety is achieved. Nutritional ketosis is characterized by blood ketone levels of 0.5 mg / dL to 3 mg / dL. [Ibid., citing Volek, JS and Phinney SD. The Art and Science of Low Carbohydrate Living. Beyond Obesity, LLC, Miami FL USA]. This is in stark contrast to the pathophysiological state of type 1 diabetic ketoacidosis (DKA), and should not be confused with it. Despite the similar-sounding names, they are two different metabolic processes. Endogenous insulin production is protective against the development of DKA; the range of ketones present in DKA is 5–10 times the levels achieved during nutritional ketosis. Additionally, when in nutritional ketosis, the body is able to maintain normal blood glucose levels and maintain a normal pH, rather than the extremely elevated blood glucose and acidic pH associated with DKA.
[0119] After many weeks, "keto-adaptation" occurs, which represents the body's ability to adapt and respond to using primarily ketones as fuel. One potential reason this occurs is secondary to upregulated transcription of genes encoding metabolic machinery, which leads to increased mitochondrial density in oxidative tissues such as brain and muscle. Mouse studies have shown that this can occur either through increased mitophagy or decreased mitochondrial damage. [Ibid., citing Bough, KJ et al. Mitochondrial biogenesis in the anticonvulsant mechanism of the ketogenic diet. Ann. Neurol. (2006) 60: 223–35; Ahola-Erkkila, S. et al. Ketogenic diet slows down mitochondrial myopathy progression in mice. Hum. Mol. Genet. (2010) 19: 1974-84] Additionally, ketones can induce epigenetic regulation by inhibiting histone deacetylation, indicating that they are signaling molecules in addition to energy sources. [Ibid., citing Newman, JC and Verldin E. Beta-hydroxybutyrate: much more than a metabolite. Diabetes Res. Clin. Pract. 2014] 106:173-81].
[0120] Through this process, fat-derived energy is produced in the liver and then transported to the whole body to provide energy for the brain, renal cortex, heart and skeletal muscle. [Same, citing Laffel, L. Ketone bodies: a review of physiology, pathophysiology and application of monitoring to diabetes. Diabetes Metab. Res. Rev. (1999) 15: 412-26]. Ketones can supply up to 60% of the ATP needed by the body [Same, citing Veech, RL et al. Ketone bodies, potential therapeutic uses. International Union of Biochemistry and Molecular Biology: Life (IUBMB Life) (2001) 51: 241-47]; the rest is derived from endogenous gluconeogenesis, which uses triglycerides in the form of glycerol and glycogenic amino acids from proteins for glucose production. Ketones cross the blood-brain barrier and replace glucose as the main energy source for the brain. George Cahill's pioneering work using the starvation ketosis model revealed that the brain has metabolic flexibility and can be transformed from a glucose-dependent organ (about 150 grams / day) to an organ that derives more than 2 / 3 of its energy from ketones. [Ibid., citing Veech, RL et al. Ketone bodies, potential therapeutic uses. International Union of Biochemistry and Molecular Biology: Life (2001) 51: 241-47; Westman, EC et al. Low-carbohydrate nutrition and metabolism. American Journal of Clinical Nutrition (Am. J. Clin. Nutr.) (2007) 86: 276-84].The main features of the ketogenic diet are the establishment of ketosis and the stabilization of insulin levels, which address the biomarkers of metabolic syndrome [ibid., citing Volek, JS et al. Carbohydrate restriction has a more favorable impact on the metabolic syndrome than a low-fat diet. Lipids (2009) 44: 297-309; Volek, JS and Feinman, RD. Carbohydrate restriction improves the features of Metabolic syndrome. Metabolic Syndrome may be defined by the response to carbohydrate restriction. Nutr. Metab. (London) (2005) 2: 31I]. By reducing the rise in insulin, lipids are released from reserves and oxidized. [Ibid., citing Volek JS et al. Dietary carbohydrate restriction induces a unique metabolic state positively affecting atherogenic dyslipidemia, fatty acid partitioning, and metabolic syndrome. Prog Lipid Res (2008) 47, 307–318].
[0121] However, intravenous ketone administration can be an inefficient method for inducing changes in brain energy metabolism [Prins, ML and Matsumoto, JH. Journal of Lipid Research (2014) 55:2450-55, citing Pan JW et al. (2001). Measurement of beta-hydroxybutyrate in acute hyperketonemia in human brain. Journal of Neurochemistry 79:539-544; White, H. et al. Effect of a hypertonic balanced ketone solution on plasma, CSF and brain beta-hydroxybutyrate levels and acid-base status. Intensive Care Med. (2013) 39:727–733; Pan, J. et al. Increased beta-hydroxybutyrate and lactate in fasting-induced ketosis in human brain. beta-hydroxybutyrate and lactate increase in fasting-induced ketosis). Journal of Cerebral Blood Flow and Metabolism (2000) 20: 1502-1507]. Strategies designed to primarily increase plasma ketone levels must also target the transport of increased ketones across the blood-brain barrier (BBB) via monocarboxylate transporters (MCTs), membrane proteins that serve as carriers of lactate, pyruvate, and ketone bodies. In addition, the high doses required to achieve the desired ketone levels may result in serious side effects involving insulin / glucagon balance.[Ibid., citing Clarke, K. et al. Kinetics, safety and tolerance of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate in healthy adults. Regul. Toxicol. Pharmacol. (2012) 63:401–408; van Delft, R. et al. Blood beta-hydroxybutyrate correlates better with seizure reduction due to ketogenic diet than do ketones in the urine. Seizure. (2010) 19:36–39; Madison, LL et al. The hypoglycemic action of ketones. II. Evidence for a stimulatory feedback of ketones on the pancreatic beta cells. Journal of Clinical Investigation (1964) 43:408–415].
[0122] HCA2 and its role in protecting against ischemic brain injury
[0123] HCA2 is a G protein-coupled receptor originally named GPR109A that belongs to the hydroxycarboxylic acid (HCA) receptor family. [Offermanns, S. and Schwaninger, M. Nutritional or pharmacological activation of HCA2 improves neuroinflammation 2amelioratesneuroinflammation). Trends in Molec. Med. (2015) 21(40):345-55, citing Offermanns, S. et al. (2011) Pharmacol. Rev. (2011) 63:269–90]. It couples with G proteins of the G family [ibid., citing Soga, T. et al. Molecular identification of nicotinic acid receptor. Biochem. Biophys. Res. Commun. (2003) 303: 364–69; Tunaru, S. et al. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat. Med. (2003) (9): 352-55; Wise, A. et al. Molecular identification of high and low affinity receptors for nicotinic acid. acid). Journal of Biological Chemistry (J.Biol.Chem.) (2003) 278:9869-74; Taggart, AK et al. D-β-hydroxybutyrate inhibits adipocyte lipolysis via the nicotinic aidreceptor PUMA-G. Journal of Biological Chemistry (2005) 280:26649-52; Benyo, Z. et al. GPR109A (PUMA-G / HM74A) mediates nicotinic acid-induced flushing. acid-induced flushing). Journal of Clinical Research (2005) 115:3634-40] and is activated by the ketone body BHB and, to a lesser extent, by butyrate [ibid., cited in Taggart, AK et al. D-β-hydroxybutyrate inhibits adipocyte lipolysis via the nicotinic acid receptor PUMA-G.Journal of Biological Chemistry (2005) 280: 26649-52]. HCA2 is also expressed in various immune cells, including neutrophils, macrophages, epidermal Langerhans cells, dendritic cells and microglia, but not in lymphocytes [ibid., citing Benyo, Z. et al. GPR109A (PUMA-G / HM74A) mediates niacin-induced flushing. Journal of Clinical Research (2005) 115: 3634-40; Kostylinn, G. et al. Neutrophil apoptosis mediated by nicotinic acid receptors (GPR109A). Cell Death and Differentiation (Cell Death Differ.) (2005) 15: 134-42; Kostylina, G. et al. Neutrophil apoptosis mediated by nicotinic acid receptor (GPR109A). Cell Death and Differentiation (2008) 15: 134-42; Maxiejewski-Lenoir, D. et al. Langerhans cells release prostaglandin D2 in response to nicotinic acid. Journal of Investigative Dermatology (2006) 126: 2637-46; Rahman, M. et al. The β-hydroxybutyrate receptor HCA2 activates a neuroprotective subset of macrophages. ofmacrophages). Nat. Commun. (2014) 5: 3944; Schaub, A. et al. PUMA-G, an IFN-γ-inducible gene in macrophages is a novel member of the seven transmembrane spanning receptor superfamily. Eur. J. Immunol. (2001) 31: 3714-25; Singh, N.et al. Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis. Immunity (2014) 40: 128-39]. BHB (the main endogenous ligand of HCA2) activates human HCA2 with an EC50 of about 700 μM [ibid., citing Taggart, AK et al. D-β-hydroxybutyrate inhibits adipocyte lipolysis through nicotinic acid receptor PUMA-G. Journal of Biological Chemistry (2005) 280: 26649-52], which is the concentration that this ketone body can only reach after fasting or a ketogenic diet. HCA2 can also mediate anti-inflammatory and immunomodulatory effects through its expression in immune cells, and it has been shown that this activity helps to conserve energy when induced by ketone bodies during starvation. [Same, citing Lukasova, M. et al. Nicotinic acid (niacin): new lipid-independent mechanisms of action and therapeutic potentials. Trends Pharmacol. Sci. (2011) 32: 700-7].
[0124] Recent evidence suggests that HCA2 can mediate the neuroprotective effects of BHB [ibid., citing Rahman, M. et al. β-Hydroxybutyrate receptor HCA2 activates neuroprotective subsets of macrophages. Nature Communications (2014) 5:3944]. Although the ketogenic diet is established as a treatment for childhood epilepsy [ibid., citing Levy, RG et al. Ketogenic diet and other dietary treatments for epilepsy. Cochrane Database Syt. Rev. (20120 3:CD001903), preclinical studies have provided evidence that the ketogenic diet may also be protective in experimental models of other neurological diseases, including TBI. Research on the therapeutic potential of the ketogenic diet has been driven by the idea that it improves energy balance in the diseased brain. However, BHB is not only a metabolic intermediate, but also a signaling molecule that activates HCA2 and inhibits GPR41 and histone deacetylase (HDAC) 1, 3 and 4 [ibid., citing Newman, JC and Verdin, E. Ketone bodies as signaling metabolites. Trends in Endocrinology and Metabolism Endocrinol. Metab.) (2014) 25: 42-52; Won, YJ et al. β-hydroxybutyrate modulates N type calcium channels in rat sympathetic neurons by acting as an agonist for the G protein coupled receptor FFAS FFAS). Journal of Neuroscience (2013) 33:19314-25], which led to the hypothesis that BHB induces neuroprotection through specific effects on receptors or enzymes. Recent studies on a ketogenic diet in a mouse model of stroke support a role for HCA2 in the BHB effect in this disease model [ibid., citing Rahman, M. et al. β-Hydroxybutyrate receptor HCA2 activates a neuroprotective subset of macrophages. Nature Communications (2014) 5:3944]. These researchers concluded that an additional supply of energy substrate is not sufficient to explain the protection provided by BHB; instead, activation of HCA on monocyte-derived cells, neutrophils, or microglia is required. 2Without being limited by theory, HCA2 activation may be a therapeutic principle for treating brain disorders with neuroinflammatory components. For example, it has been hypothesized that HCA2 on monocyte-derived cells may provide a mechanism for stimulating neuroprotective Ly6C in the brain. lo Target of monocyte-derived cells. Lymphocyte antigen 6 complex (Ly6C) is a marker for macrophage subsets. Ly6C hi Monocytes have pro-inflammatory and antimicrobial functions and express high levels of CC chemokine receptor 2 (CCR2) and low levels of CX3C chemokine receptor 1 (CX3CR1). [Kratofil, RM et al. "Monocyte Conversion During Inflammation and Injury". Arteriosclerosis, Thrombosis and Vascular Biology (2017) 37(1):35-42, citing Geissmann, F. et al. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity (2003) 19:71-82]. Ly6C low Monocytes (also known as patrolling monocytes) survey the vasculature by continually crawling along the lumen of the vasculature and are involved in early responses to inflammation and tissue repair.
[0125] Figure 3Schematic representation of the direct and indirect signaling effects of BHB. In addition to the direct signaling effects of BHB, indirect signaling mechanisms increase the impact of BHB through downstream effects that are at least partially removed from those observed within the molecule. In contrast to the direct signaling function that can be attributed to the BHB compound itself, the indirect signaling function requires catabolism into other molecules, abbreviations: BHB, β-hydroxybutyrate; CoA, coenzyme A; FFAR3, free fatty acid receptor 3; GABA, γ-amino-butyric acid; HDAC, histone deacetylase; HCAR2, hydroxycarboxylic acid receptor 2; NAD, nicotinamide adenine dinucleotide; VGLUT, vesicular glutamate transporter. [From Newman JC and Verdin, E. β-hydroxybutyrate: a signaling metabolite. Ann. Rev. Nutrition (2017) 37:51-76].
[0126] The molecular weight of β-hydroxybutyrate (BHB) is 104.1 g / mol. As a small polar molecule, BHB is easily soluble in water and blood. [Newman, JC and Verdin, E β-Hydroxybutyrate. Annual Review of Nutrition (2017) 37:51-76]. BHB is a chiral molecule at the 3' hydroxyl group. There are two enantiomers, R / d and S / l, usually represented as D and L, respectively. The human liver produces the D enantiomer of this molecule. [Chriett, S. et al. Prominent action of butyrate over β-hydroxybutyrate as histone deactylase inhibitor, transcriptional modulator and anti-inflammatory molecule. Sci. Reports (2019) 9(1):742]. R-BHB is a normal product of metabolism in humans and mice. S-BHB itself is not a normal product of human metabolism. Experiments involving the infusion of labeled R-BHB, S-BHB, or mixtures thereof into rats or pigs found that most of S-BHB was converted to R-BHB (Newman, JC and Verdin, Eβ-hydroxybutyrate. Annual Review of Nutrition (2017) 37:51-76, citing Lincoln, BC et al. Arch. Biochem. Biophys. (1987) 259:149-56); its molecular pathway is unclear, but it can occur by converting S-BHB to acetyl CoA and then producing R-BHB from acetyl CoA. At least some of the S-BHB in the S-BHB is ultimately converted to CO 2, presumably also after metabolism to acetyl CoA. Data have shown that at the same dose, the D enantiomer is superior at elevated D-β-hydroxybutyrate levels compared to the racemic mixture of the molecule [Cuenoud, B. et al. Metabolism of exogenous D-beta-hydroxybutyrate, an energy substrate avidly consumed by the heart and kidney. Frontiers Nutrition (2020) 7:13]. Many currently available exogenous forms of β-hydroxybutyrate are racemic mixtures, salt forms, or variants of the true molecule, such as 1,3-butanediol.
[0127] The data suggest that the effectiveness of D-β-hydroxybutyrate for neurological indications is limited by the rate at which D-β-hydroxybutyrate can be transported across the BBB to sufficiently increase D-β-hydroxybutyrate concentrations in the brain. [White, H. et al. A systematic review of intravenous β-hydroxybutyrate use in humans–a promising future therapy? Frontiers Medicine (2021) 8:740374]. Several monocarboxylate transporters, including MCT1 and MCT2, carry BHB across the blood-brain barrier (Pellerin, L. et al. J. Neurosci. Res. (2005) 79:55-64), and their expression can regulate brain BHB uptake (ibid., citing Barton, KM and Palmer, SE (2016) Curr. HIV / AIDS Rep. (2016) 13:77-84).
[0128] The present disclosure provides a targeted method for delivering synthetic D-β-hydroxybutyrate to the brain bypassing the BBB, wherein the controlled release of the β-hydroxybutyrate may result in increased levels of D-β-hydroxybutyrate in the brain both immediately after administration and over time. BRIEF DESCRIPTION OF THE DRAWINGS
[0129] Figure 1Delineates a cascade of negative effects in the brain of traumatic injury. Primary injury occurs within the first few seconds after impact and is typically mechanical in nature. Secondary injury occurs within minutes to weeks after impact and affects the brain's ability to properly regulate ion balance, metabolism, and inflammation. Tertiary injury or neuropathology occurs weeks to years after impact and is thought to be driven by energy crisis and oxidative stress from secondary injury. From Daines, SA et al. The therapeutic potential and limitations of ketones in traumatic brain injury. Frontiers Neurology (2021), 12:723148, Figure 1 .
[0130] Figure 2A and Figure 2B is normal( Figure 2A ) and after TBI ( Figure 2B ) Schematic comparison of glucose metabolism in physiology. Glucose metabolic pathways are impaired after TBI at six points in the glycolytic pathway and oxidative metabolism of glucose: (1) A transient increase in glucose uptake is followed by a prolonged decrease in glucose metabolism; (2) More glucose-6-phosphate is shunted to the pentose phosphate pathway to produce protective and reparative molecules; (3) Glyceraldehyde-3-phosphate dehydrogenase activity is slowed, thereby reducing tricarboxylic acid cycle intermediates. (4) Lactate production is increased in astrocytes to shuttle lactate to energy-deficient neurons. (5) Pyruvate dehydrogenase complexes are inhibited, thereby reducing tricarboxylic acid cycle intermediates; (6) Impairment of electron transport chain function and oxidative phosphorylation leads to reduced ATP production. From Daines, SA et al. Therapeutic potential and limitations of ketones in traumatic brain injury. Frontiers in Neurology (2021), 12:723148, Figure 2.
[0131] Figure 3 Schematic representation of the direct and indirect signaling effects of BHB. Abbreviations: BHB, β-hydroxybutyrate; CoA, coenzyme A; FFAR3, free fatty acid receptor 3; GABA, γ-amino-butyric acid; HDAC, histone deacetylase; HCAR2, hydroxycarboxylate receptor 2; NAD, nicotinamide adenine dinucleotide; VGLUT, vesicular glutamate transporter. From Newman JC and Verdin, E. β-Hydroxybutyrate: a signaling metabolite. Annual Review of Nutrition (2017) 37:51-76.
[0132] Figure 4is a diagram showing the internal nasal anatomy in cross section. [From Janfaza, P. et al. Surgical anatomy of the head and neck. Harvard University Press (June 15, 2011), Chapter 5.
[0133] Figure 5A It is a graph showing the change in plasma β-hydroxybutyrate (BHB) concentration (μg / mL, y-axis) over time (hours) (x-axis) on day 14 after intranasal administration to C57BL / 6J mice for Group 1 (vehicle), Group 2 (30 mg / kg BHB salt), and Group 3 (BHB ester (15 mg / kg)). Figure 5B It is a graph showing the change in brain β-hydroxybutyrate (BHB) concentration (μg / mL, y-axis) over time (hours) (x-axis) on day 14 after intranasal administration to C57BL / 6J mice for Group 1 (vehicle), Group 2 (30 mg / kg BHB salt), and Group 3 (BHB ester (15 mg / kg)).
[0134] Fig. 6A It is a graph showing the change in plasma β-hydroxybutyrate (BHB) concentration (ug / g, y-axis) over time (hours) (x-axis) on day 14 after intranasal administration to C57BL / 6J mice for Group 1 (vehicle), Group 2 (30 mg / kg BHB salt), and Group 3 (BHB ester (15 mg / kg)). Figure 6B It is a graph showing the change in brain β-hydroxybutyrate (BHB) concentration (ug / g, y-axis) over time (hours) (x-axis) on day 14 after intranasal administration to C57BL / 6J mice for Group 1 (vehicle), Group 2 (30 mg / kg BHB salt), and Group 3 (BHB ester (15 mg / kg)).
[0135] Figure 7 is a graph showing the endogenous baseline level of β-hydroxybutyrate (BHB) (y-axis) over time (x-axis) when BHB is administered at 15 mg / kg and 30 mg / kg. It should be noted that Figure 7 The endogenous baseline in Figure 5A The same as the vehicle line in (approximately 19 μg / mL).
[0136] Figure 8The bar graph of the result of the beam-walk behavioral assay after TBI or sham surgery injury is shown. Taking C57BL / 6J female mice as the sample study group, 20 animals in each group, the number of foot faults is drawn. From the 0th day after TBI, immediately to the 14th day, 20 μl of the standard stock solution (50 mg / kg) of the test compound R-(-)-3-hydroxybutyric acid sodium salt (Sigma (Sigma)) (BHB) prepared freshly every day is intranasally administered every day. Saline is added to the compound to an appropriate concentration. The study groups were: (1) sham-injured, treated with vehicle; (2) TBI-injured, treated with vehicle; (3) pretreated with BHB IN prior to TBI-injury, followed by saline treatment after TBI-injury; (4) pretreated with saline prior to TBI-injury, followed by BHB treatment after TBI-injury; and (5) pretreated with BHB IN prior to TBI-injury, followed by BHB treatment after TBI-injury; and pretreated with 2X dose of BHB IN prior to TBI-injury, followed by BHB treatment after TBI-injury. Sham-injured mice remained sound on their feet. TBI mice showed the highest number of foot faults on day 1; by day 3, the number of foot faults in this group had decreased by approximately 50%. The pre-, post-, pre- and post-treatment groups, and 2x pre- and post-treatment groups all showed improvements in beam walking on days 1 and 3. On day 3, all treatment groups were significantly improved, with the best results in the post- and 2x pre+post-groups. The 2x Anterior+Posterior group saw a 70% improvement in foot faults 1 day after TBI.
[0137] Figure 9A-9C Shown in the Figure 8 In each study group, the expression of IL-1β in the cortex ( Fig.9A )、IL-6( Fig. 9B ) and IL-10( Fig. 9C ) of pg / μg total protein. The results for TNF-α were not significant (data not shown). Fig.9A , Fig. 9B and Fig. 9C The data at 24 hours and 14 days showed that treatment reduced the expression of IL-1β, IL-6 and Il-10. Although IL-10 is generally considered an anti-inflammatory cytokine, it can also promote the fibrotic process [Steen, EH et al. "Adv. Wound Care" (New Rochelle) (2020) 9 (4): 184-98, citing O'Garra, A. et al. "Immunol. Rev." (20008) 223: 114-31]. The data of the front + rear group are consistent with the behavioral data. Summary of the invention
[0138] According to one aspect, the present disclosure provides a composition comprising an active ingredient encapsulated in a suspension of particles, the particles comprising a biodegradable polymer containing an effective amount of the active agent, wherein the particles are configured to bypass the blood-brain barrier, wherein the active ingredient is synthetic D-beta hydroxybutyrate, and wherein the targeted delivery is to the brain.
[0139] According to some embodiments of the composition, the size of the particles is greater than 10 nm in diameter, greater than 15 nm in diameter, greater than 20 nm in diameter, greater than 30 nm in diameter, greater than 40 nm in diameter, greater than 50 nm in diameter, greater than 60 nm in diameter, greater than 70 nm in diameter, greater than 80 nm in diameter, greater than 90 nm in diameter, greater than 100 nm in diameter, greater than 200 nm in diameter, greater than 300 nm in diameter, greater than 400 nm in diameter, greater than 500 nm in diameter, greater than 600 nm in diameter, greater than 700 nm in diameter, greater than 800 nm in diameter, greater than 900 nm in diameter, greater than 1000 nm in diameter, greater than 2000 nm in diameter, greater than 3000 nm in diameter, greater than 4000 nm in diameter, greater than 5000 nm in diameter, greater than 6000 nm in diameter, greater than 7000 nm in diameter, greater than 8000 nm in diameter, greater than 9000 nm in diameter, or greater than 10,000 nm in diameter. According to some embodiments of the composition, the synthetic D-β-hydroxybutyrate is dispersed throughout the particles; or the particles are impregnated with the D-β-hydroxybutyrate; or the particles include a matrix, and the matrix includes the D-β-hydroxybutyrate. According to some embodiments of the composition, the synthetic D-β-hydroxybutyrate is integrated into a polymer carrier to achieve controlled release, including delayed release and sustained release. According to some embodiments of the composition, the polymer includes a mucoadhesive polymer, a thermoresponsive polymer, or both. According to some embodiments of the composition, a portion of the synthetic D-β-hydroxybutyrate is adsorbed or weakly bound to the surface of the particles and contributes to a rapid initial release or burst release. According to some embodiments of the composition, the particles have any order release kinetics, including zero-order release, first-order release, second-order release, delayed release, sustained release, immediate release, long-term release, or a combination thereof. According to some embodiments of the composition, the release of the synthetic D-β-hydroxybutyrate from the particles is by diffusion, erosion, or both. According to some embodiments of the composition, the composition is formulated for intranasal delivery.
[0140] According to some embodiments of the composition, the mucoadhesive polymer comprises chitosan, alginate, and cellulose or a derivative thereof.
[0141] According to some embodiments of the composition, the thermoreversible polymer comprises gelatin, carrageenan, methylcellulose, hydroxypropyl methylcellulose (HPMC), xyloglucan, poly(N-isopropylacrylamide-c-acrylic acid), poly(N-isopropylacrylamide) (PNIPAAm) / polyethylene oxide (PEO), poloxamer (Pluronic) or PEO / polylactic-co-glycolic acid (PLGA).
[0142] According to some embodiments of the composition, the polymer is selected from cellulose derivatives, polyacrylates, starch, gelatin, phospholipids, chitosan, poly-N-alkylacrylamide / poly-N-isopropylacrylamide, cyclodextrin, poloxamer and methylcellulose.
[0143] According to some embodiments of the composition, when formulated for intranasal delivery, a maximum amount of about 25 mg / dose is administered to achieve a minimum daily dose ranging from about 85 mg / day to about 800 mg / day, inclusive.
[0144] According to another aspect, the present disclosure provides a method for promoting brain health, comprising (a) formulating a composition containing an active ingredient as a suspension of particles, the particles comprising a biodegradable polymer, the biodegradable polymer containing an effective amount of the active ingredient; (b) administering the composition including the active ingredient to a subject, wherein the active ingredient is D-β-hydroxybutyrate; and (c) targeting the composition to the brain, wherein burst release and controlled release of the D-β-hydroxybutyrate can produce effective D-β-hydroxybutyrate levels in the brain.
[0145] According to some embodiments of the method, the size of the particles is greater than 10 nm in diameter, greater than 15 nm in diameter, greater than 20 nm in diameter, greater than 30 nm in diameter, greater than 40 nm in diameter, greater than 50 nm in diameter, greater than 60 nm in diameter, greater than 70 nm in diameter, greater than 80 nm in diameter, greater than 90 nm in diameter, greater than 100 nm in diameter, greater than 200 nm in diameter, greater than 300 nm in diameter, greater than 400 nm in diameter, greater than 500 nm in diameter, greater than 600 nm in diameter, greater than 700 nm in diameter, greater than 800 nm in diameter, greater than 900 nm in diameter, greater than 1000 nm in diameter, greater than 2000 nm in diameter, greater than 3000 nm in diameter, greater than 4000 nm in diameter, greater than 5000 nm in diameter, greater than 6000 nm in diameter, greater than 7000 nm in diameter, greater than 8000 nm in diameter, greater than 9000 nm in diameter, or greater than 10,000 nm in diameter. According to some embodiments of the method, the synthetic D-β-hydroxybutyrate is dispersed throughout the particles; or the particles are impregnated with the D-β-hydroxybutyrate; or the particles include a matrix and the matrix includes the D-β-hydroxybutyrate. According to some embodiments of the method, incorporating the synthetic D-β-hydroxybutyrate into a polymer carrier can achieve controlled release, including delayed release and sustained release. According to some embodiments of the method, the polymer includes a mucoadhesive polymer, a thermoresponsive polymer, or both. According to some embodiments of the method, a portion of the synthetic D-β-hydroxybutyrate is adsorbed or weakly bound to the surface of the particles and contributes to a rapid initial release or burst release. According to some embodiments of the method, the particles have any order release kinetics, including zero-order release, first-order release, second-order release, delayed release, sustained release, immediate release, long-term release, or a combination thereof. According to some embodiments of the method, the release of the synthetic D-β-hydroxybutyrate from the particles is by diffusion, erosion, or both. According to some embodiments of the method, the composition is formulated for oral delivery or intranasal delivery.
[0146] According to some embodiments of the method, the mucoadhesive polymer comprises chitosan, alginate, and cellulose or a derivative thereof.
[0147] According to some embodiments of the method, the thermoreversible polymer comprises gelatin, carrageenan, methylcellulose, hydroxypropyl methylcellulose (HPMC), xyloglucan, poly(N-isopropylacrylamide-c-acrylic acid), poly(N-isopropylacrylamide) (PNIPAAm) / polyethylene oxide (PEO), poloxamer (Pluronic) or PEO / polylactic-co-glycolic acid (PLGA).
[0148] According to some embodiments of the method, the polymer is selected from cellulose derivatives, polyacrylates, starch, gelatin, phospholipids, chitosan, poly-N-alkylacrylamide / poly-N-isopropylacrylamide, cyclodextrin, poloxamer and methylcellulose.
[0149] According to some embodiments of the method, when formulated for intranasal delivery, a maximum amount of about 25 mg / dose is administered to achieve a minimum daily dose ranging from about 85 mg / day to about 800 mg / day, inclusive.
[0150] According to another aspect, the present disclosure provides a method for reducing the risk of brain damage caused by acquired brain injury in a subject susceptible to or otherwise at risk of developing the acquired brain injury, the method comprising administering a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a formulation comprising a therapeutic amount of an API, wherein the API is synthetic D-β-hydroxybutyrate, wherein the administration is performed intranasally (IN), wherein the administration comprises targeted delivery to the olfactory region of the nasal cavity of the subject; wherein the targeted delivery achieves an effective amount of the API in the brain, and wherein the effective amount of the pharmaceutical composition: (i) eliminates or reduces the risk of the acquired brain injury, or (ii) reduces the severity of the acquired brain injury, or (iii) delays the onset of the acquired brain injury; or (iv) a combination thereof.
[0151] According to some embodiments of the method, the acquired brain injury is a traumatic brain injury. According to some embodiments of the method, the administering is neuroprotective. According to some embodiments of the method, the subject's risk of developing the acquired brain injury is increased by participation in an event for which the acquired brain injury is a known risk. According to some embodiments of the method, the administration is within 1 minute, within 5 minutes, within 10 minutes, within 15 minutes, within 30 minutes, within 45 minutes, within 1 hour, within 2 hours, within 3 hours, within 4 hours, within 5 hours, within 6 hours, within 7 hours, within 8 hours, within 9 hours, within 10 hours, within 11 hours, within 12 hours, within 13 hours, within 14 hours, within 15 hours, within 16 hours, within 17 hours, within 18 hours, within 19 hours, within 20 hours, within 21 hours, within 22 hours, within 23 hours, within 24 hours, within 1 day, within 2 days, within 3 days, within 4 days, within 5 days, within 6 days, within 7 days, within 8 days, within 9 days, within 10 days, within 11 days, within 12 days, within 13 days, within 14 days, within 15 days, within 16 days, within 17 days, within 18 days, within 19 days, within 20 days, within 21 days, etc. A maximum amount of 25 mg / dose. According to some embodiments of the method, the pharmaceutical composition comprises a liquid spray formulation or a dry powder formulation. According to some embodiments of the method, the pharmaceutical composition comprises an active substance formulated as a solution, suspension or dispersion. According to some embodiments of the method, the minimum daily dose of the pharmaceutical composition contains about 85 mg / day to about 800 mg / day, inclusive, of the API.
[0152] According to some embodiments of the method, the traumatic brain injury comprises a concussion. According to some embodiments of the method, the event is a military operation or a sporting event. According to some embodiments of the method, the sporting event is hockey, football, soccer, baseball, polo, rugby, equestrian, racing, gymnastics, mountaineering, basketball, mixed martial arts, Brazilian Jiu-Jitsu, Muay Thai, taekwondo, kickboxing, boxing, wrestling, lacrosse, softball, cheerleading, volleyball, beach volleyball, alpine skiing, water skiing, wakeboarding, snowboarding, skateboarding, kayaking, handball, cycling, mountain biking, barrel racing, bull riding, base jumping, skydiving, paragliding, tennis, squash, BMX, motocross, surfing, bobsleigh, luge, skeleton, ball game, lacrosse, camogie, cricket, diving, field hockey, figure skating, speed skating, sailing, ski jumping, ultimate Frisbee, water polo, or windsurfing.
[0153] According to some embodiments of the method, the pharmaceutical composition is delivered as a liquid spray comprising a droplet size distribution comprising droplets comprising the API. According to some embodiments of the method, the dry powder formulation upon aerosolization comprises a cloud of very fine particles comprising the API. According to some embodiments of the method, the formulation is formulated with an excipient.
[0154] According to some embodiments of the method, the droplet size distribution of the liquid spray containing a therapeutic amount of the API ranges from about 20μ to about 120μm, inclusive. According to some embodiments of the method, the particle distribution is depleted of smaller particles that would otherwise enter the lung.
[0155] According to another aspect, the present disclosure provides a method for treating symptoms of brain injury in a subject, the brain injury including neuroinflammation, the method comprising administering a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a formulation, the formulation comprising a therapeutic amount of an API, wherein the API is synthetic D-β-hydroxybutyrate, wherein the administration is performed intranasally (IN); wherein the administration comprises targeted delivery to the olfactory region of the nasal cavity of the subject, wherein the targeted delivery achieves an effective amount of the API in the brain, and wherein the effective amount of the pharmaceutical composition achieves one or more therapeutic effects, the one or more therapeutic effects comprising: (i) reducing the severity of the acquired brain injury; or (ii) limiting the development of symptoms characteristic of the acquired brain injury being treated; or (iii) limiting the worsening of symptoms characteristic of the acquired brain injury being treated; or (iv) limiting the recurrence of the acquired brain injury in a subject who has previously suffered from the acquired brain injury; or limiting the recurrence of symptoms in a subject who was previously asymptomatic for the acquired brain injury.
[0156] According to some embodiments of the method, the acquired brain injury is a traumatic brain injury. According to some embodiments of the method, the administering is neuroprotective. According to some embodiments of the method, the subject's risk of developing the acquired brain injury is increased by participation in an event for which the acquired brain injury is a known risk. According to some embodiments of the method, the administering is within 1 minute, within 5 minutes, within 10 minutes, within 15 minutes, within 30 minutes, within 45 minutes, within 1 hour, within 2 hours, within 3 hours, within 4 hours, within 5 hours, within 6 hours, within 7 hours, within 8 hours, within 9 hours, within 10 hours, within 11 hours, within 12 hours, within 13 hours, within 14 hours, within 15 hours, within 16 hours, within 17 hours, within 18 hours, within 19 hours, within 20 hours, within 21 hours, within 22 hours, within 23 hours, within 24 hours, within 1 day, within 2 days, within 3 days, within 4 days, within 5 days, within 6 days, within 7 days, within 8 days, within 9 days, within 10 days, within 11 days, within 12 days, within 13 days, within 14 days, within 15 days In some embodiments, the pharmaceutical composition comprises a liquid spray formulation or a dry powder formulation. According to some embodiments of the method, the pharmaceutical composition comprises an active substance formulated as a solution, suspension, or dispersion. According to some embodiments of the method, the minimum daily dose of the pharmaceutical composition contains about 85 mg / day to about 800 mg / day, inclusive, of the API. According to some embodiments of the method, the traumatic brain injury comprises a concussion. According to some embodiments of the method, the event is a military action or a sporting event.According to some embodiments of the method, the sporting event is hockey, football, soccer, baseball, polo, rugby, equestrian, racing, gymnastics, mountaineering, basketball, mixed martial arts, Brazilian Jiu-Jitsu, Muay Thai, taekwondo, kickboxing, boxing, wrestling, lacrosse, softball, cheerleading, volleyball, beach volleyball, alpine skiing, water skiing, wakeboarding, snowboarding, skateboarding, kayaking, handball, cycling, mountain biking, barrel racing, bull riding, base jumping, skydiving, paragliding, tennis, squash, BMX, motocross, surfing, bobsleigh, luge, skeleton, ball game, plate hockey, camochie, cricket, diving, field hockey, figure skating, speed skating, sailing, ski jumping, ultimate Frisbee, water polo, or windsurfing. According to some embodiments of the method, the pharmaceutical composition is delivered as a liquid spray, the liquid spray comprising a droplet size distribution, the droplet size distribution comprising droplets comprising the API. According to some embodiments of the method, the dry powder formulation, when aerosolized, comprises a cloud of very fine particles comprising the API. According to some embodiments of the method, the formulation is formulated with an excipient. According to some embodiments of the method, the droplet size distribution of the liquid spray containing a therapeutic amount of the API ranges from about 20μ to about 120μm, inclusive.
[0157] According to another aspect, the present disclosure provides a method for reducing the risk of acquired brain injury in a subject susceptible to or otherwise at risk of developing the acquired brain injury and for treating symptoms of the brain injury after the subject has acquired the acquired brain injury, wherein the subject's risk of developing the acquired brain injury is increased by participation in an event for which acquired brain injury is a known risk; the method comprising (a) administering a pharmaceutical composition prior to the event, the pharmaceutical composition comprising a pharmaceutically acceptable carrier and formulation, the formulation comprising a therapeutic amount of an API, wherein the API is synthetic D-beta hydroxybutyrate, wherein the administration is performed intranasally (IN) and is neuroprotective, wherein the administration comprises targeted delivery to the olfactory region of the nasal cavity of the subject; wherein the targeted delivery achieves an effective amount of the API in the brain, and wherein the effective amount The pharmaceutical composition (i) eliminates or reduces the risk of the acquired brain injury, or (ii) reduces the severity of the acquired brain injury, or (iii) delays the onset of the acquired brain injury; or (iv) a combination thereof; and (b) continues the intranasal (IN) administration after the brain injury is acquired in the event, wherein the effective amount of the pharmaceutical composition achieves one or more therapeutic effects, the one or more therapeutic effects including: (i') reducing the severity of the acquired brain injury; (ii') limiting the development of symptoms characteristic of the acquired brain injury being treated; (iii') limiting the worsening of symptoms characteristic of the acquired brain injury being treated; (iv') limiting the recurrence of the acquired brain injury in a subject who has previously suffered from the acquired brain injury; or (v') limiting the recurrence of symptoms in a subject who was previously asymptomatic for the acquired brain injury; (vi') or a combination thereof.
[0158] According to some embodiments of the method, the acquired brain injury is a traumatic brain injury. According to some embodiments of the method, the pharmaceutical composition comprises a liquid spray formulation or a dry powder formulation. According to some embodiments of the method, the pharmaceutical composition comprises the API formulated as a solution, a suspension, or a dispersion. According to some embodiments of the method, the minimum daily dose of the pharmaceutical composition contains about 85 mg / day to about 800 mg / day, inclusive of the API. According to some embodiments of the method, the traumatic brain injury comprises a concussion. According to some embodiments of the method, the event is a military operation or a sporting event. According to some embodiments of the method, the sporting event is hockey, football, soccer, baseball, polo, rugby, equestrian, racing, gymnastics, mountaineering, basketball, mixed martial arts, Brazilian Jiu-Jitsu, Muay Thai, taekwondo, kickboxing, boxing, wrestling, lacrosse, softball, cheerleading, volleyball, beach volleyball, alpine skiing, water skiing, wakeboarding, snowboarding, skateboarding, kayaking, handball, cycling, mountain biking, barrel racing, bull riding, base jumping, skydiving, paragliding, tennis, squash, BMX, motocross, surfing, bobsleigh, luge, skeleton, ball game, plate hockey, camochie, cricket, diving, field hockey, figure skating, speed skating, sailing, ski jumping, ultimate Frisbee, water polo, or windsurfing.According to some embodiments of the method, the administering is performed at a tolerated frequency, e.g., every 2 minutes, 5 minutes, 10 minutes, 20 minutes, 30 minutes, 40 minutes, 50 minutes, or 60 minutes, at a maximum amount of 25 mg / dose for at least 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, 18 hours, 19 hours, 20 hours, 21 hours, 22 hours, 23 hours prior to the event. and at least 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, 18 hours, 19 hours, 20 hours, 21 hours, 22 hours, 23 hours, or at least 24 hours, at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 7 days, at least 8 days, at least 9 days, at least 10 days, at least 11 days, at least 12 days, at least 13 days, at least 14 days, at least 15 days, at least 16 days, at least 17 days, at least 18 days, at least 19 days, at least 20 days, at least 21 days after obtaining the brain injury.
[0159] According to some embodiments of the method, the pharmaceutical composition is delivered as a liquid spray, the liquid spray comprising a droplet size distribution, the droplet size distribution comprising droplets comprising the API. According to some embodiments of the method, the dry powder formulation when aerosolized comprises a cloud comprising a distribution of fine particles comprising the API. According to some embodiments of the method, the formulation is formulated with an excipient. According to some embodiments of the method, the droplet size distribution of the liquid spray containing a therapeutic amount of the API ranges from about 20μ to about 120μm, inclusive. According to some embodiments of the method, the particle distribution is depleted of smaller particles that would otherwise enter the lungs.
[0160] According to another aspect, the present disclosure provides a pharmaceutical composition for reducing the risk of brain damage caused by acquired brain injury in a subject susceptible to or otherwise at risk of developing the acquired brain injury, the composition comprising a pharmaceutically acceptable carrier and a formulation comprising a therapeutic amount of an API, wherein the API is synthetic D-β-hydroxybutyrate, wherein treatment comprises (a) before the subject participates in an event for which acquired brain injury is a known risk; (b) after the subject participates in the event; or both, targeting delivery of 25 mg / dose to the olfactory region of the nasal cavity of the subject, which is used to treat symptoms of the acquired brain injury including neuroinflammation in the subject.
[0161] According to some embodiments of the pharmaceutical composition for use, the targeted delivery achieves an effective amount of the API in the brain of the subject. According to some embodiments, the effective amount of the pharmaceutical composition limits the development of symptoms characteristic of the acquired brain injury; and / or limits the worsening of symptoms characteristic of the acquired brain injury; and / or limits the recurrence of the acquired brain injury in a subject who has previously suffered from the acquired brain injury; and / or limits the recurrence of symptoms in a subject who was previously asymptomatic for the acquired brain injury.
[0162] According to some embodiments of the pharmaceutical composition for use, the acquired brain injury is traumatic brain injury; and / or the brain damage includes neuroinflammation; and / or the event is a sports event; and / or the event is a military operation; and / or the administration is neuroprotective; and / or the pharmaceutical composition includes the API formulated as a solution, suspension, or dispersion; and / or the administration is a minimum amount of about 85 mg / day to about 800 mg / day inclusive of the API. According to some embodiments of the pharmaceutical composition for use, the traumatic brain injury includes a concussion. According to some embodiments of the pharmaceutical composition for use, the sporting event is hockey, football, soccer, baseball, polo, rugby, equestrian, racing, motorsports, skiing, gymnastics, mountaineering, basketball, mixed martial arts, Brazilian Jiu-Jitsu, Muay Thai, taekwondo, kickboxing, boxing, wrestling, lacrosse, softball, cheerleading, volleyball, beach volleyball, alpine skiing, water skiing, wakeboarding, snowboarding, skateboarding, kayaking, handball, cycling, mountain biking, barrel racing, bull riding, base jumping, skydiving, paragliding, tennis, squash, BMX, motocross, surfing, bobsleigh, luge, skeleton, ball game, lacrosse, camochie, cricket, diving, field hockey, figure skating, speed skating, sailing, ski jumping, ultimate Frisbee, water polo, or windsurfing. DETAILED DESCRIPTION
[0163] Glossary
[0164] As used herein, the term "aerodynamic diameter" refers to the diameter of a sphere of unit density that behaves aerodynamically the same as particles of the test substance / compound. It is used to predict where particles of different sizes and densities are likely to deposit in the respiratory tract.
[0165] As used herein, the term "active ingredient" refers to a drug, molecule, composition, or other substance that provides a biological activity or effect.
[0166] The term "active pharmaceutical ingredient" ("API" or "substance active substance") is the pharmaceutically active substance in a drug.
[0167] The term "adenosine 5'-triphosphate" or "ATP" is the primary molecule used to store and transfer energy in cells.
[0168] As used herein, the term "administer" means to give or apply. As used herein, the term "administering" includes in vivo administration, as well as direct application to ex vivo tissue. Typically, the composition can be administered orally, buccally, parenterally, by inhalation or insufflation (i.e., by mouth or by nose), or by rectum in a dosage unit formulation systemically containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles (as desired), or can be administered locally by means such as, but not limited to, injection, implantation, transplantation or topical application. Administration can be performed, for example, once, multiple times and / or over one or more extended periods of time in the form of a single unit dose or in a treatment regimen of multiple drugs and / or substances including multiple unit doses.
[0169] As used herein, the term "adsorb" refers to adhering to a surface.
[0170] As used herein, the term "aerosol" refers to a substance that is enclosed under pressure and can be released in the form of a fine spray, usually with the aid of a propellant gas. For example, a colloidal dispersion of solid or liquid particles in a gas is an aerosol.
[0171] The term "aerosol generator" refers to a device that generates an aerosol.
[0172] As used herein, the term "atomized" means to disperse or discharge in the form of a colloidal dispersion of solid or liquid particles in a gas.
[0173] Anatomical terms:
[0174] When referring to an animal (one end of which usually has a head and mouth, and the other end of which usually has an anus and tail), the head end is called the cranial end, and the tail end is called the caudal end. Within the head itself, rostral refers to the direction toward the end of the nose, and caudal is used to refer to the tail direction. The surface or side of the animal's body that is generally oriented upward, away from the pull of gravity, is dorsal; the opposite side (usually the side closest to the ground when walking, swimming, or flying with all legs) is ventral. On a limb or other appendage, the point closer to the body is "proximal"; the farther point is "distal". Three basic reference planes are used in zoological anatomy. The "sagittal" plane divides the body into left and right parts. The "mid-sagittal" plane lies in the midline, that is, the plane will pass through the midline structures (such as the spine), and all other sagittal planes are parallel to the plane. The "coronal" plane divides the body into dorsal and ventral parts. The "transverse" plane divides the body into cranial and caudal parts.
[0175] When referring to humans, the body and its parts are always described using the assumption that the body is upright. The part of the body that is closer to the head is the "upper part" (corresponding to the cranium of an animal), while the part that is farther away is the "lower part" (corresponding to the tail of an animal). Objects near the front of the body are called the "front" (corresponding to the ventral side of an animal); objects near the back of the body are called the "posterior" (corresponding to the dorsal side of an animal). The transverse, axial, or horizontal plane is the XY plane parallel to the ground, which separates the upper part / head from the lower part / feet. The coronal or frontal plane is the YZ plane perpendicular to the ground, which separates the front and the posterior. The sagittal plane is the XZ plane perpendicular to the ground and the coronal plane, which separates the left side from the right side. The midsagittal plane is a specific sagittal plane exactly in the middle of the body.
[0176] Structures near the midline are called medial, while structures near the side of the animal are called lateral. Therefore, medial structures are closer to the midsagittal plane and lateral structures are farther from the midsagittal plane. Structures in the midline of the body are medially located. For example, the tip of the nose of a human subject is located on the midline.
[0177] Ipsilateral refers to the same side, contralateral refers to the other side and bilateral refers to both sides. Structures closer to the center of the body are proximal or central, while structures farther away are distal or peripheral. For example, the hand is at the distal end of the arm, while the shoulder is at the proximal end.
[0178] As used herein, the term "axon" refers to a nerve fiber that carries nerve impulses from a nerve cell to a target cell and also carries material from the nerve ending back to the nerve cell.
[0179] The term "axonal injury" refers to the impairment and gradual loss of function of axons that enable nerve cells to communicate with each other.
[0180] The terms "beta-hydroxybutyrate" and "BHB" are used interchangeably herein to refer to the major ketone body or synthetic BHB compound in the blood. In vivo, it is primarily formed in the liver from free fatty acids during fasting or in a high-fat, low-carbohydrate ketogenic diet.
[0181] The term "binding" and its other grammatical forms refer to a persistent attraction between chemical species. Binding specificity involves binding to a specific partner and not to other molecules. "Relative binding specificity" is a property whereby, in a biochemical system, a molecule interacts differentially with its target or partner, thereby differentially affecting the individual targets or partners depending on their identity.
[0182] The term "bioavailability" refers to the extent and rate at which the active moiety is absorbed from a drug product and becomes available at the site of action. 21CFR 320.1. For products that enter the systemic circulation and thus reach the site of action, the surface charge on the polymer particles affects the distribution of the particles throughout the body and the level of cellular uptake. [Vhora, I. et al., Applications of Polymers in Drug Delivery, Chapter 8, pp. 221-61, at 234; Elsevier (2021)]. Because cell membranes are negatively charged, positive charges favor higher intracellular concentrations. The exterior of the particles can be modified to attach targeting moieties, thereby limiting distribution at the target site. For example, PEG, PVP, and dextran are surface modifiers that protect particles from being captured by the reticuloendothelial system (RES), thereby increasing their blood residence time (increasing half-life) and improving their bioavailability. [Ibid.]
[0183] As used herein, the term "biocompatible" refers to a material that is generally non-toxic to the recipient and does not have any significant adverse reactions to the subject, and in addition, any metabolites or degradation products of the material are non-toxic to the subject. Typically, a "biocompatible" material does not cause clinically relevant tissue irritation, damage, toxic reactions, or immune responses to living tissue.
[0184] As used herein, the term "biodegradable" refers to a material that will corrode into soluble species or will degrade into smaller units or chemical species under physiological conditions, which material itself is non-toxic to the subject (biocompatible) and can be metabolized, eliminated or excreted by the subject. The two main types of biodegradation of the delivered biodegradable polymeric material are chemical degradation and enzymatic degradation, such as by hydrolysis and oxidation-dependent degradation. Polymers can also be degraded mechanically or thermally. [Vhora, I. et al., Applications of Polymers in Drug Delivery, Chapter 8, pp. 221-61, at 228; Elsevier (2021)]
[0185] As used herein, the term "bioequivalence" means that in appropriately designed studies, the rate and extent to which the active ingredient or active moiety in a pharmaceutical equivalent or pharmaceutical substitute becomes available at the site of drug action when administered at the same molar dose under similar conditions does not differ significantly. 21 CFR 320.21.
[0186] The terms "biological fermentation" or "microbial fermentation" are used interchangeably herein to refer to anaerobic biological processes in which the oxidation of one substrate is coupled to the reduction of another substrate or an intermediate derived from the oxidation. Although fermenting bacteria are anaerobic, they use organic molecules as their final electron acceptors to produce fermentation end products.
[0187] As used herein, the term "blood-brain barrier" ("BBB") refers to a network of blood vessels and tissues composed of closely spaced cells that helps prevent harmful substances in the blood from reaching the brain.
[0188] As used herein, the term "brain damage" refers to damage that causes destruction or deterioration of brain cells. According to some embodiments, the brain damage comprises neuroinflammation.
[0189] The term "brain health" as defined by the World Health Organization refers to a state in which the brain functions across cognitive, sensory, social-emotional, behavioral, and motor domains, allowing people to achieve their full potential throughout their lives, regardless of the presence or absence of pathology.
[0190] As used herein, the term "carrier" describes a material that does not cause significant irritation to an organism and does not eliminate the biological activity and properties of the compound of the described composition of the present invention. The carrier must have a sufficiently high purity and sufficiently low toxicity to make it suitable for application to the treated mammal. The carrier can be inert, or the carrier can have a pharmaceutical benefit. The terms "excipient", "carrier" or "vehicle" are used interchangeably to refer to a carrier material suitable for the formulation and administration of a pharmaceutically acceptable composition described herein. The carriers and vehicles that can be used herein include any such material known in the art that is non-toxic and does not interact with other components.
[0191] As used herein, the term "carryover" or "CO" refers to a type of systematic error in HPLC-based analytical methods that originates from a previous sample and is introduced into the next sample.
[0192] As used herein, the term "central nervous system" ("CNS") refers to the portion of the nervous system consisting of the brain and spinal cord.
[0193] As used herein, the term "cerebrospinal fluid" refers to the ultrafiltrate of plasma contained in the ventricles of the brain and the subarachnoid space of the skull and spine. It is primarily secreted by the choroid plexus. In an average young adult, continuous secretion contributes to 4-5 CSF turnovers per 24-hour period.
[0194] As used herein, the term "chemical bond" refers to an attractive force between atoms that is strong enough to allow the combined aggregate to function as a unit.
[0195] The term "chiral" is used to describe asymmetric molecules that are non-superimposable because they are mirror images of each other and therefore have chiral properties. Such molecules are also called enantiomers and are characterized by optical activity.
[0196] The term "chirality" refers to the geometric property of a rigid object (or a spatial arrangement of points or atoms) that is not superimposable on its mirror image. If an object is superimposable on its mirror image, the object is described as achiral.
[0197] The term "chiral axis" refers to an axis about which a set of ligands are fixed so as to produce a spatial arrangement that is non-superimposable on its mirror image.
[0198] The term "chiral center" refers to an atom that holds a set of ligands in an arrangement in space that is non-superimposable on its mirror image. A chiral center can be considered as a generalized extension of the concept of an asymmetric carbon atom to a central atom of any element.
[0199] As used herein, the term "closed head injury" refers to an impact to the head by an external force without any skull fracture or displacement. The term "open head injury" refers to brain trauma resulting in loss of consciousness due to penetration of the brain by a foreign object (such as a bullet).
[0200] As used herein, the term "compatible" means that the components of the composition are capable of being combined with one another in a manner without interaction that would significantly reduce the effectiveness of the composition under ordinary conditions of use.
[0201] As used herein, the term "composition" refers to a mixture of ingredients.
[0202] As used herein, the term "concussion" refers to a disruption of neurological function caused by a head injury or severe vibration.
[0203] As used herein, the term "condition" refers to various health states and is intended to encompass conditions or diseases caused by any underlying mechanism or disorder, injury, and promotion of healthy tissues and organs.
[0204] As used herein, the term "configuration" refers to the stereochemical arrangement of atoms that cannot be changed without breaking the chemical bonds.
[0205] The term "conformation" refers to the geometric arrangement of atoms in a polymer chain.
[0206] As used herein, the term "contacting" and its various grammatical forms refer to the state or condition of being in contact or in close proximity or local proximity and encompasses contacting a composition with a target destination.
[0207] As used herein, the term "container closure system" refers to the sum of packaging components that together contain, protect and deliver the dosage form, including pumps for nasal sprays and inhalation sprays.
[0208] The term "controlled release" refers to any formulation containing an active substance, wherein the mode and curve of the active substance released from the formulation are controlled. This includes immediate release formulations and non-immediate release formulations, wherein non-immediate release formulations include but are not limited to slow release and delayed release formulations. The term "delayed release" is used herein in its conventional sense to refer to an active formulation, wherein there is a time delay between the application of the formulation and the release of the active substance therefrom. "Delayed release" may or may not involve gradually releasing the active substance over an extended period of time, and therefore may or may not be "slow release". As used herein, the term "long-term" release refers to constructing and arranging implants to deliver therapeutic levels of active ingredients for at least 7 days, and preferably about 30 to about 60 days. The term "slow release" (also referred to as "extended release") is used herein in its conventional sense to refer to an active formulation that provides a gradual release of an active substance over an extended period of time and preferably, although not necessarily, produces a substantially constant blood level of an active substance over an extended period of time.
[0209] As used herein, the term "cytokine" refers to a small soluble protein substance secreted by a cell that has various effects on other cells. Cytokines mediate many important physiological functions, including growth, development, wound healing and immune response. The cytokine acts by binding to its cell-specific receptor located in the cell membrane, which allows different signal transduction cascades to be started in the cell, which will eventually lead to biochemical and phenotypic changes in the target cell. Cytokines can act locally or away from the release site. The cytokines include type I cytokines, which cover many interleukins and several hematopoietic growth factors; type II cytokines, including interferons and interleukin-10; tumor necrosis factor ("TNF") related molecules, including T NFα and lymphotoxin; immunoglobulin superfamily members, including interleukin 1 ("IL-1"); and chemokines, a family of molecules that play a key role in various immune and inflammatory functions. Depending on the state of the cell, the same cytokine can have different effects on the cell. Cytokines usually regulate the expression of other cytokines and trigger cascades of other cytokines. Non-limiting examples of cytokines include, for example, IL-1α, IL-β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12 / IL-23P40, IL13, IL-15, IL-17, IL-18, IL-21, IL-23, TGF-β, IFN-γ, GM-CSF, Gro.α., MCP-1 and TNF-α.
[0210] As used herein, the term "D value" or "mass divide diameter" refers to the diameter that divides the mass of a sample into specified percentages when all particles in the sample are arranged in order of increasing mass. The mass percentage below the diameter of interest is the number indicated after the "D". For example, the D10 diameter is the diameter when 10% of the sample mass is made up of smaller particles, and the D50 is the diameter when 50% of the sample mass is made up of smaller particles. The D50 is also called the "mass median diameter" because it divides the sample equally by mass. The D90 diameter is the diameter when 90% of the sample mass is made up of smaller particles. Although the D value is based on the mass of the sample divided by the diameter, the actual mass of the particles or sample does not need to be known. Relative mass is sufficient because the D value is only related to the mass ratio. This allows the use of optical measurement systems without the need for any sample weighing.
[0211] From the diameter values obtained for each particle, the relative mass can be assigned according to the following relationship:
[0212] The mass of the sphere = π / 6d3ρ
[0213] Assume ρ is constant for all particles and eliminate all constants from the following equation:
[0214] Relative mass = d3
[0215] That is, the diameter of each particle is therefore the cube of its relative mass. These values can be added together to calculate the total relative mass of the sample measured. The values can then be sorted in ascending order and added iteratively until the total reaches 10%, 50%, or 90% of the total relative mass of the sample. The corresponding D value for each of these values is the diameter of the last particle added to reach the desired mass percentage.
[0216] As used herein, the term "delivery" refers to bringing an active agent to a location in the body.
[0217] As used herein, the term "derived from" is intended to encompass any method for receiving, obtaining, or modifying something from a source.
[0218] "Diastereomers" are stereoisomers that have at least two asymmetric atoms, but which are not mirror images of each other.
[0219] As used herein, the term "diffusion" refers to the movement of individual molecules of a substance from an area of higher concentration to an area of lower concentration across a semipermeable barrier.
[0220] As used herein, the term "disease" or "disorder" refers to a condition in which health is impaired or function is abnormal.
[0221] As used herein, the term "distributed" refers to the act or process of distributing things over a wide area.
[0222] As used herein, the term "dispersion" refers to a two-phase system in which one phase is distributed as droplets in a second or continuous phase. In these systems, the dispersed phase is often referred to as the discontinuous phase or internal phase, and the continuous phase is referred to as the external phase and includes the continuous processing medium. For example, in a process dispersion, the particle size is 0.5 μm. In a colloidal dispersion, the size of the dispersed particles ranges from about 1 nm to 0.5 μm. A molecular dispersion is one in which the dispersed phase consists of single molecules; if the molecules are smaller than the colloid size, the result is a true solution.
[0223] As used herein, the term "dissolution" refers to the process by which a substance forms a solution. The "dissolution rate" is the amount of active substance that goes into solution per unit time under standard conditions of liquid / solid interface, temperature, and solvent composition.
[0224] As used herein, the term "dose" refers to a predetermined amount of an active agent administered at one time.
[0225] As used herein, the term "dose" refers to the predetermined amount and rate of administration of an active agent. The dosage level is based on various factors, including the type of injury, the patient's age, weight, sex, medical condition, severity of the condition, route of administration, and the specific active agent employed. Thus, dosage regimens can vary widely, but can be routinely determined by a physician using standard methods.
[0226] The term "dosage form" refers to a physical form containing an active agent in combination with an excipient. Examples include solid dosage forms (tablets, capsules, pellets, pills, lozenges, granules, etc.), liquid dosage forms (solutions, suspensions, emulsions, elixirs, etc.), semisolid dosage forms (ointments, creams, pastes, etc.), and gaseous dosage forms (aerosols, insufflations, etc.).
[0227] As used herein, the term "dosage regimen" refers to the frequency of administration of an active agent, and includes formulations, routes of administration, dosage, dosing intervals, and duration of administration. The total daily dose is calculated based on the dosage and the number of times the dosage is administered each day. Designing a correct dosing regimen is important for achieving the desired efficacy and for avoiding undesirable effects.
[0228] As used herein, the term "droplet" refers to a small droplet, meaning a flowable substance of very small volume. Some factors that affect droplet size are pressure, viscosity, fluid temperature, and surface tension. For example, increased pressure, increased fluid temperature, increased viscosity, and increased surface tension can reduce droplet size.
[0229] As used herein, the term "droplet size distribution" refers to a statistical indication of the percentage of droplets of a certain size (or a certain size interval). Simple distribution functions assume that all droplets have the same shape (usually a sphere), which is generally valid for fully developed sprays. Such a distribution is characterized entirely by (1) a maximum diameter; (2) a size parameter; and (3) a distribution parameter, which can be calculated based on any three independent mean diameters known. The remaining problem is to relate these parameters to the physical properties of the spray generation system (including the physical properties of the droplet phase and the continuous medium). Among these properties are density, viscosity and interfacial tension. [Mugele, RA and Evans, HD. Droplet size distribution in sprays. "Indust. And Engineering Chemistry" (1951) 43 (6): 1317-24].
[0230] The terms "drug loading (%)" and "drug loading capacity" are used interchangeably herein to refer to the ratio of the weight of the compound of the invention in the microparticles relative to the total weight of the microparticles, expressed as a percentage. It reflects the drug content of the microparticles.
[0231] As used herein, the term "drug product" refers to a finished dosage form containing the drug substance, usually but not necessarily in association with one or more other ingredients.
[0232] As used herein, the term "drug substance" refers to active ingredients intended to provide pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment or prevention of disease, or to affect the structure and function of the body, but does not include intermediates used in the synthesis of such ingredients.
[0233] The term "effective amount" refers to the amount of the described pharmaceutical composition of the present invention that is necessary or sufficient to achieve the desired biological effect. Additionally, the term "effective amount" includes the described control or prevention amount of the composition of the present invention. In the described control or prevention application of the present invention, the pharmaceutical composition or drug is administered to a patient susceptible to or otherwise at risk of a disease, disorder or condition in an amount sufficient to eliminate or reduce the risk of, reduce the severity of, or delay the onset of a disease, disorder or condition, including biochemical, histological, and / or behavioral symptoms of the disease, disorder or condition; its complications; and intermediate pathological phenotypes presented during the development of the disease, disorder or condition.
[0234] As used herein, the term "emulsion" refers to a two-phase system prepared by combining two immiscible liquid carriers, one of which is uniformly dispersed in the other. It consists of globules with a diameter equal to or greater than the diameter of the largest colloidal particle. The phase in the form of small droplets is called the dispersed phase, and the surrounding liquid is called the continuous phase. The globules must be of such size that the system achieves maximum stability. Typically, the two phases will separate unless a third substance, an emulsifier, is incorporated.
[0235] "Enantiomers" are a pair of stereoisomers that are non-superimposable mirror images of each other. A 1:1 mixture of a pair of enantiomers is a "racemic" mixture. When a compound is pure enantiomers, the stereochemistry at each chiral carbon can be designated by R or S. Resolved compounds whose absolute configuration is unknown can be designated as (+) or (-), depending on the direction (right- or left-handed) that they rotate plane polarized light at the wavelength of the sodium D line.
[0236] As used herein, the term "endogenous" means related to or developed from factors in the body.
[0237] As used herein, the term "entrapment efficiency (%)" refers to the ratio of the drug retained by the microparticles relative to the total amount available, expressed as a percentage.
[0238] As used herein, the term "corrosion" refers to the loss of material from a polymer body.
[0239] The term "excipient" is used herein to include any other agent or compound that may be included in a formulation that is not an active agent. Thus, an excipient should be pharmaceutically or biologically acceptable or relevant (e.g., an excipient should generally be non-toxic to a subject). An "excipient" includes a single such compound and is also intended to include a plurality of such compounds.
[0240] As used herein, the term "exogenous" means associated with or developed from factors outside the body.
[0241] As used herein, the term "formulation" refers to a mixture prepared according to a specific procedure or a formulation prepared according to a specific recipe or rule.
[0242] As used herein, the term "G protein" refers to a specialized protein that has the ability to bind to the nucleotides guanosine triphosphate (GTP) and guanosine diphosphate (GDP).
[0243] The term "G protein-coupled receptor" (GPCR) refers to a membrane receptor in eukaryotic organisms that allows cells to receive information from their environment. GPCRs consist of a single polypeptide folded into a small globular shape and embedded in the cell's plasma membrane. The seven segments of the molecule span the entire width of the membrane - this explains why GPCRs are sometimes called seven-transmembrane receptors - and the middle section forms a loop inside and outside the cell. The extracellular loop forms part of a pocket where signaling molecules bind to the GPCR. GPCRs interact with G proteins in the plasma membrane. When an external signaling molecule binds to a GPCR, it causes a conformational change in the GPCR. This change then triggers an interaction between the GPCR and a nearby G protein. The G protein associated with the GPCR is a heterotrimer, meaning that the G protein has three different subunits: an alpha subunit, a beta subunit, and a gamma subunit. Two of these subunits - alpha and gamma - are attached to the plasma membrane by lipid anchors. The G protein alpha subunit binds to GTP or GDP, depending on whether the protein is active (GTP) or inactive (GDP). In the absence of a signal, GDP is linked to the α subunit, and the entire G protein-GDP complex binds to a nearby GPCR. This arrangement continues until the signaling molecule binds to the GPCR. At this point, the conformational change of the GPCR activates the G protein, and GTP physically replaces the GDP bound to the α subunit. As a result, the G protein subunit breaks down into two parts: the GTP-bound α subunit and the β-γ dimer. These two parts are still anchored to the plasma membrane, but the two parts are no longer bound to the GPCR, so the two parts can now diffuse laterally to interact with other membrane proteins. As long as the α subunit of the G protein is bound to GTP, the G protein can remain active. However, when this GTP is hydrolyzed back to GDP, the subunits once again take on the form of an inactive heterotrimer, and the entire G protein re-associates with the now inactive GPCR. In this way, the G protein acts like a switch—turned on or off by signal-receptor interactions on the cell surface. Whenever a G protein is active, both its GTP-bound α subunit and its β-γ dimer can forward messages in cells by interacting with other membrane proteins involved in signal transduction. Specific targets for activated G proteins include various enzymes that produce second messengers, as well as certain ion channels that allow ions to act as second messengers. Some G proteins stimulate the activity of these targets, while other G proteins are inhibitory. [Li, J. et al. The Molecule Pages database. Nature (2002) 420: 716-17].
[0244] The term "glial cell", "neuroglial cell" or "glia" is a small cell lacking axons and / or dendrites present in the central nervous system and peripheral nervous system. Glial cells act as regulators of the CNS and PNS environment; the glial cells increase and decrease activity within synapses by regulating neurotransmitters, oxygen and ion uptake; and help recover from nerve damage. Macroglia (which include astrocytes and oligodendrocytes) isolate, protect and help neurons develop and migrate. Microglia are smaller cells derived from hematopoietic stem cells (although some may be directly derived from neural stem cells). They share many characteristics with tissue macrophages and are primarily scavenger cells that remove cell debris from the site of injury or normal cell renewal. In fact, some neurobiologists tend to classify microglia as a type of macrophage. After brain damage, the number of microglia at the site of injury increases dramatically. Some of these cells proliferate from microglia that reside in the brain, while others come from macrophages that migrate from the circulation to the area of injury. Furthermore, microglia and macroglia work together to ensure optimal neuronal function and neurotransmission across synapses. [See Purves D et al., eds. (2001). "Neuroglial Cells." Neuroscience. 2nd ed. Retrieved from: https: / / www.ncbi.nlm.nih.gov / books / NBK10869 /
[0245] As used herein, the term "glial fibrillary acidic protein" or "GFAP" refers to a marker of astrocyte injury, which is a marker for predicting TBI. Several mouse model studies have been performed to assess functional outcomes after TBI. Increased GFAP levels are associated with inhibitory spatial learning, as demonstrated by decreased performance in a maze trial [Brennan, J. et al. Biomarkers for Traumatic Brain Injury, Chapter 26 - Neuropsychological testing, eds. Alan HB Wu, W. Peacock, Academic Press (2020), pp. 397-409, citing Ferguson, S. et al. J. Neurotrauma (2016) 34(8): 1676-91; Marschner, L. et al. Behav. Brain Res. (2019) 365: 222-30; Broussard, JI et al. Brain In. (2018) 32(1): 113-22]. Human trials focusing on TBI outcomes and GFAP were conducted and found that GFAP was significantly correlated with the Glasgow Outcome Scale (GOS) [ibid., citing Nylen, K. et al., J. Neurol. Sci. (2006) 240(1):85-91].
[0246] As used herein, the term "HCA 2 ” refers to the G protein-coupled receptors of BHB and niacin.
[0247] As used herein, the term "healthy control" refers to a subject without symptoms or other clinical evidence of TBI.
[0248] As used herein, the term "immune cell" refers to cells that are part of the immune system and help the body fight infection and other diseases. Immune cells include lymphocytes (e.g., B cells, T cells, natural killer (NK) cells), neutrophils, and monocytes / macrophages.
[0249] As used herein, the term "immune system" refers to the body's defense system for disease, which includes the innate immune system and the adaptive immune system. The innate immune system provides a nonspecific first line of defense against pathogens. The innate immune system includes both physical barriers (e.g., skin) and cell (granulocytes, natural killer cells) defense mechanisms and humoral (complement system) defense mechanisms. The response of the innate immune system is immediate, but unlike the adaptive immune system, the innate immune system does not provide permanent immunity for pathogens. The adaptive immune response is the response of the vertebrate immune system to specific antigens that usually produce immune memory.
[0250]
[0043] The term "impregnate" as used herein in its various grammatical forms means to infuse or permeate throughout a substance; to fill interstices with a substance; and / or to saturate with a substance.
[0251] As used herein, the term "impurity profile" refers to a description of the identified and unidentified impurities present in an API.
[0252] As used herein, the term "intermediate" refers to a material produced during a processing step of an API that undergoes further molecular changes or purification before becoming the API. An intermediate may or may not be isolated.
[0253] As used herein, the term "inflammation" refers to the physiological process of vascularized tissue in response to damage.See, for example, "FUNDAMENTAL IMMUNOLOGY", 4th edition, William E.Paul edited Lippincott-Raven Publishers (1999) in Philadelphia at 1051-1053, the document is incorporated herein by reference. During the inflammatory process, the cells involved in detoxification and repair are mobilized to the damaged site by inflammatory mediators. The feature of inflammation is usually the strong infiltration of leukocytes at the site of inflammation, particularly neutrophils (polymorphonuclear cells). These cells promote tissue damage by releasing toxic substances at the vascular wall or in undamaged tissue. Traditionally, inflammation is divided into acute response and chronic response.
[0254] As used herein, the term "acute inflammation" refers to a rapid, short-lived (minutes to days), relatively uniform response to an acute injury characterized by the accumulation of fluid, plasma proteins, and neutrophils. Examples of noxious agents that cause acute inflammation include, but are not limited to, pathogens (e.g., bacteria, viruses, parasites); foreign bodies from exogenous (e.g., asbestos) or endogenous (e.g., urate crystals, immune complexes) sources; and physical (e.g., burns) or chemical (e.g., caustic) agents.
[0255] As used herein, the term "chronic inflammation" refers to inflammation that is of longer duration and has an ambiguous and indeterminate termination. Chronic inflammation occurs when acute inflammation persists, either through incomplete clearance of the initial inflammatory agent or due to multiple acute events occurring at the same location. Chronic inflammation involving an influx of lymphocytes and macrophages and growth of fibroblasts may result in tissue scarring at sites of prolonged or repeated inflammatory activity.
[0256] As used herein, the term "injury" refers to damage or harm to the structure or function of the body caused by an external agent or force, which may be physical or chemical.
[0257] As used herein, the term "insufflation" refers to the action of delivering air, gas, or powder under pressure to a cavity or chamber of the body. For example, nasal insufflation involves the action of delivering air, gas, or powder under pressure through the nose.
[0258] As used herein, the term "isomer" refers to one of two or more molecules with the same number and type of atoms and therefore the same molecular weight but different in chemical structure. Isomers can be different (structural isomers) in terms of the connectivity of atoms, or the isomers can have the same atomic connectivity but only in spatial arrangement or configuration of atoms (stereoisomers). Stereoisomers can include but are not limited to double bond isomers, enantiomers and diastereomers. Enantiomers are non-superimposable mirror images. The mixture of equal parts of the optical form of a compound is referred to as a racemic mixture or racemate. Diastereomers are non-mirror stereoisomers. Stereoisomers can include enantiomers, diastereomers or E or Z olefins, imines or oxime isomers. Stereoisomeric mixtures include racemic mixtures, diastereomeric mixtures or E / Z isomeric mixtures. Stereoisomers may be synthesized in pure form (Nogradi, M.; Stereoselective Synthesis, (1987) VCH Publishers (VCH), ed. Ebel, H. and Asymmetric Synthesis, Vol. 3-5, (1983) Academic Press, ed. Morrison, J.), or they may be resolved by various methods such as crystallization and chromatographic techniques (Jaques, J.; Collet, A.; Wilen, S.; Enantiomers, Racemates, and Resolutions, 1981, John Wiley and Sons and Asymmetric Synthesis, Vol. 2, 1983, Academic Press, ed. Morrison, J.). Unless otherwise indicated, the formulations disclosed herein are intended to include all such possible isomers, including racemic mixtures, optically pure forms, and intermediate mixtures. Optically active (R)- and (S)-isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. If the compound contains a double bond, the substituents may be in the E or Z configuration. If the compound contains a disubstituted cycloalkyl, the cycloalkyl substituents may have a cis or trans configuration. All tautomeric forms are also intended to be included.
[0259] As used herein, the term "interleukin" or "IL" is a general name for cytokines produced by leukocytes.
[0260] As used herein, the term "interleukin-1β" or "IL-1β" refers to a member of the IL-1 family of inflammatory cytokines. As of 2019, human sequence algorithm technology indicates that the IL-1 family includes a total of 11 members with similar or different biological effects [32,33]. IL-1α, IL-1β, IL-1Ra, IL-18, IL-33, IL-36α, IL-36β, IL-36γ, IL-36Ra, IL-37, and IL-38 have been identified and characterized [Kaneko, N. et al. Inflammation and Regeneration (2019) 39:12, citing Dinarello, C. et al. Nature Immunol. (2010) 11:973]. Among them, IL-1α, IL-1β, IL-18, IL-33 and IL-36 are receptor agonists, and IL-1Ra, IL-36Ra and IL-38 are receptor antagonists. IL-37 is the only anti-inflammatory cytokine. There are two separate forms of IL-1, IL-1α and IL-1β isolated from two different cDNAs, but they are indistinguishable in terms of biological function [ibid., citing Lachman, LB et al. Journal of Immunology (J.Immunol.) 91977] 119: 2019-23]. Although the homology between IL-1α and IL-1β is not high (27%) in terms of amino acid sequence, IL-1α and IL-1β are structurally similar and show the same function by sharing a common receptor IL-1 type 1 receptor (IL-1R1). IL-1R1 initiates inflammatory responses upon binding to the ligands IL-1α and IL-1β, and is reported to be expressed by T-lymphocytes, fibroblasts, epithelial cells, and endothelial cells.
[0261] As used herein, the term "interleukin-6" or "IL-6" refers to a pleiotropic cytokine that is involved not only in immune responses but also in inflammation, hematopoiesis, bone metabolism, embryonic development and other essential processes [Hirano, T. Intl Rev. Immunol. (1998) 16:249; Hunter, CA and Jones, SA. Nature Immunology (2015) 16:448; Van Snick, J. Annu. Rev. Immunol. (1990) 8:253; Heinrich, P.C. et al. Biochem. J. (2003) 374(Pt. 1):1; Kamimura, D. et al. Rev. Physiol. Biochem. Pharmacol. (2003) 149:1; Hasegawa, H. et al. Frontier Immunol. (2016) 7:479]. IL-6 is the prototype member of the IL-6 family of cytokines, which consists of 10 members, including IL-6, IL-11, IL-27, oncostatin M (OSM), leukemia inhibitory factor (LIF), ciliary neurotrophic factor (CNTF), cardiotrophin 1 (CT-1), cardiotrophin-like cytokine 1 (CLCF1), IL-35 and IL-39 [ibid., citing Murakami, M. et al. "Immunity" (2019) 50: 812]. IL-6 is involved in cell senescence, produced by senescent cells, and is critically involved in aging-induced inflammation and age-dependent pathology and cancer [ibid., citing Kuilman, T. et al. "Cell" (2008) 133: 1019]. IL-6 is also a key factor in inflammation, autoimmunity and cancer, and it mainly acts through the IL-6-signal transducer and activator of transcription 3 (STAT3) pathway [ibid., citing Grivennikov, S. et al. Cancer Cell (2009) 15:103; Yu;, H. et al. Nat. Rev. Cancer (2009) 9:798; Jones, SA and Jenkins, BJ. Nat. Rev. Immunol. (2018) 18:773; Hirano, T. et al. Oncogene (2000) 19:2548; Jenkins, BJ et al. Blood (2007) 109:2380].
[0262] As used herein, the term "interleukin 10" or "IL-10" refers to a pleiotropic cytokine produced by activated immune cells of nearly all species, including B cells, mast cells, granulocytes (e.g., neutrophils, basophils, eosinophils), macrophages, dendritic cells, and multiple T cell subsets. [Steen, EH et al. Advances in Wound Care (New Rochelle) (2020) 9(4):184-98, citing O'Garra, A. et al. Immunology Reviews (20008) 223:114-31]. Its primary effects are primarily thought to be anti-inflammatory, suppressive, or autoregulatory, as IL-10 appears to be a potent negative feedback regulator that affects the control and resolution of inflammation through autocrine and paracrine mechanisms. This immunosuppressive effect is extensive and occurs at both the cellular and humoral levels, but there are two main means by which IL-10 limits potentially destructive inflammatory responses: (1) inhibition of antigen presentation by dendritic cells, and (2) inhibition of macrophage activation and infiltration into sites of injury, with a secondary effect of attenuating the expression of proinflammatory cytokines. [Ibid., citing O'Garra, A. et al., Immunology Reviews (20008) 223: 114-31]. At the cellular level, IL-10 is thought to act as a post-transcriptional regulator for inhibiting the messenger RNA (mRNA) stabilizing protein HuR (human antigen R), thereby promoting specific destabilization of inflammatory cytokine mRNA. [Ibid., citing Willis-Karp, M. et al., Mucosal Immunol. (2010) 3: 104-10]. In addition, IL-10 is believed to inhibit apoptotic signaling pathways, such as the p38 MAPK (mitogen-activated protein kinase) pathway, through signal transducer and activator of transcription 3 (STAT3)-dependent signaling, thereby limiting tissue death and organ dysfunction after injury. [Ibid., cited in Rajasingh, J. et al., Journal of the Federation of American Societies for Experimental Biology (2006) 20:2112-14; Krishnamurthy, P. et al., Circ. Res. (2009) 104:e9-e18; Krishnamurthy, P. et al., Journal of the Federation of American Societies for Experimental Biology (2010) 24:2484-94]. IL-10 signals through a tetrameric receptor complex (IL-10R) composed of two identical binding subunits, IL-10Rα, and two homologous signaling subunits, IL-10Rβ. Although some studies have suggested that IL-10 inhibits fibrosis primarily by modulating inflammatory processes thought to drive fibrosis, the molecular mechanisms underlying this purported effect remain incompletely characterized.For example, long-term IL-10 exposure or IL-10 application to chronic disease processes may actually worsen tissue damage and promote fibrotic outcomes despite being largely beneficial in the context of acute inflammation and early stages of wound healing.
[0263] As used herein, the term "ketogenic diet" refers to a diet high in fat and low in carbohydrates (sugars) that causes the body to break down fat into molecules called ketones. Ketones circulate in the blood and become the main source of energy for many cells in the body.
[0264] As used herein, the term "label" refers to a traceable component incorporated into a molecule in order to locate the molecule in space or to follow the molecule through a reaction or purification scheme. As a verb, it means to add such a group or atom that can be detected or measured.
[0265] As used herein, the term "unstable" refers to those that are subject to increased degradation.
[0266] The term "LLOQ" or "lower limit of quantitation" is used interchangeably to refer to the lowest amount of an analyte in a sample that can be quantitatively determined with suitable precision and accuracy. Because bioanalytical assays are validated within a pre-specified range, results below the LLOQ are BLQ (below the limit of quantitation).
[0267] As used herein, the term "logS" is the base 10 logarithm of the solubility measured in mol / l, ie, logS = log(solubility measured in mol / l), which is a common unit for measuring solubility.
[0268] As used herein, the term "macrophage" refers to large mononuclear phagocytes present in most tissues with many functions, such as scavenger cells, pathogen recognition cells, and production of pro-inflammatory cytokines.
[0269] As used herein, the term "microglia" refers to the smallest glial cell in the glial cells that can act as phagocytes and remove CNS debris. It is considered to be the type of immune cells found in the brain. Microglia are close cousins of other phagocytes (including macrophages and dendritic cells). Like macrophages, microglia are derived from myeloid progenitor cells from bone marrow. During embryonic development, these cells migrate to the CNS, where these cells differentiate into microglia.
[0270] As used herein, the term "modulate" means to adjust, alter, adapt, or adjust to a certain degree or proportion.
[0271] The term "mutation" refers to a change in the DNA sequence within a gene or chromosome of an organism, resulting in a new characteristic or trait not found in the parental type, or the process by which such a change occurs in a chromosome by a change in the nucleotide sequence of the DNA encoding the gene or by a change in the physical arrangement of the chromosome. The three mechanisms of mutation include substitution (exchanging one base pair for another), addition (insertion of one or more bases into a sequence), and deletion (deletion of one or more base pairs).
[0272] As used herein, the term "nasal spray" refers to a drug product that contains an active ingredient dissolved or suspended in a formulation (usually water-based) that may contain other excipients and is intended for use by nasal inhalation. The container closure system for a nasal spray contains the container and all components responsible for metering, atomizing, and delivering the formulation into a subject.
[0273] As used herein, the term "neurofilament light" or "NfL" refers to a recognized biomarker for subcortical large-caliber axonal degeneration [Mielke, MM et al. Neurology (2019) 93(3):e252-260, citing Hoffman, PN et al. Proc. Natl. Acad. Sci. USA (1987) 84:3472-6; Norgren, N. et al. Brain Res. (2003) 987:25-31]. CSF and plasma NfL levels are elevated in a variety of neurodegenerative disorders, including Alzheimer's disease (AD dementia) [ibid., citing Mattsson, N. et al., JAMA Neurology (2017) 74:557-66; Kern, S. et al., JAMA Neurology (2019) 76(2):187-933], frontotemporal dementia [ibid., citing Scherling, CS et al., Annals of Neurology (2014) 75:116-26], multiple sclerosis [ibid., citing Teunissen, CE et al., Lancet Neurol. (2005) 4:32-41] and TBI.
[0274] As used herein, the term "neuroinflammation" refers to an inflammatory response in the central nervous system initiated by peripheral immune cells and glial cells, during which the permeability of the BBB is generally increased.
[0275] As used herein, the term "neuroprotection" refers to the use of agents to protect neural cells from damage, degeneration, or functional impairment.
[0276] As used herein, the term "niacin" refers to a B-complex vitamin that prevents pellagra (such as niacinamide). The daily requirement for adults is 15-20 mg. At higher doses (0.5-2 g), niacin can activate HCA 2 Receptor.
[0277] As used herein, the phrase "nutritionally acceptable carrier" refers to any substantially nontoxic carrier that can be used to formulate and administer the described compositions of the present invention, wherein the described product of the present invention will remain stable and bioavailable. A pharmaceutically acceptable carrier must have sufficiently high purity and sufficiently low toxicity to make it suitable for application to treated mammals. It should further maintain the stability and bioavailability of the health-care medicament. A pharmaceutically acceptable carrier can be a liquid or solid and is selected to provide the volume, consistency, etc. of expectation when combined with the health-care medicament and other components of a given composition in the context of a planned mode of administration.
[0278] As used herein, the term "nutraceutical" or "dietary supplement" refers to a food that provides health benefits in addition to basic nutritional value.
[0279] The terms "health-promoting amount" or "effective amount" of an active agent are used interchangeably to refer to an amount sufficient to provide the desired health benefit. The dosage level is based on various factors, including the type of injury, the patient's age, weight, sex, medical condition, severity of the condition, route of administration, and the specific active agent employed. Thus, dosage regimens can vary widely, but can be routinely determined by a physician using standard methods.
[0280] As used herein, the term "health effect" refers to the result or consequence of exposure to an active ingredient that is not intended to diagnose, treat, cure or prevent any disease.
[0281] As used herein, the term "health-care loading" refers to the ratio of the weight of the health-care product in the granules to the total weight of the granules, expressed as a percentage, which reflects the health-care content of the granules.
[0282] As used herein, the term "optically active" refers to the ability of many organic compounds to rotate the plane of plane polarized light. In describing optically active compounds, the prefixes D and L or R and S are used to indicate the absolute configuration of the molecule about its chiral center. The prefixes d and l or (+) and (-) are used to indicate the sign of the rotation of plane polarized light by the compound, where (-) or l indicates that the compound is levorotatory. Compounds prefixed with (+) or d are dextrorotatory.
[0283] As used herein, the term "parenteral" refers to a route of administration in which the active substance or agent enters the body without passing through the stomach or "guts" and therefore does not encounter the first-pass effect of the liver. Examples include, but are not limited to, otic, ocular, intranasal, inhalation, topical, suppository, buccal, sublingual, and introduction into the body by injection (i.e., administration by injection), including, for example, subcutaneous (i.e., subcutaneous injection), intramuscular (i.e., injection into a muscle), intravenous (i.e., injection into a vein), intrathecal (i.e., injection into the space surrounding the spinal cord or the subarachnoid membrane of the brain), intraventricular injection, intracisternal injection, or infusion techniques.
[0284] As used herein, the term "particle" refers to a very small component (e.g., nanoparticles or microparticles) that may contain, in whole or in part, at least one active agent as described herein. The term "microparticle" is generally used herein to refer to structures comprising microcapsules, microparticles, nanoparticles, nanocapsules, and nanospheres. The particles may contain an active agent in a core surrounded by a coating. The therapeutic agent may also be dispersed throughout the particles. The active agent may also be adsorbed into the particles. The particles may have any order release kinetics, including zero-order release, first-order release, second-order release, delayed release, sustained release, immediate release, etc. and any combination thereof. In addition to the active agent, the particles may also include any of those materials conventionally used in the field of pharmacy and medicine, including but not limited to corrodible, non-corrodible, biodegradable or non-biodegradable materials or combinations thereof. The particles may be microcapsules containing active agents in solution or semi-solid form. The particles may be in practically any shape.
[0285] As used herein, the term "particle size distribution" refers to a statistical indication of the percentage of particles of a certain size (or a certain size interval). An exemplary descriptive way to represent the particle size distribution is a histogram, in which the width of the bar corresponds to the lower or upper limit of the size category, and the height of the bar corresponds to the number in the size category. In particle measurement technology, a cumulative distribution is usually generated based on category-related values. For this purpose, starting from the smallest part, the number in each measurement category is summed. This produces a curve that continuously increases from 0% to 100%, the "cumulative curve". The cumulative particle size distribution is represented by the letter Q. Each value Q (x) represents the amount of the sample composed of particles less than size x. Many statistical parameters can be derived from the particle size distribution. The cumulative distribution is particularly suitable for this purpose. Among them, the most important parameters are percentiles. These represent in each case the size x under which a certain amount of sample is located. The percentile is represented by the letter d followed by the % value. The average value (or average particle size) can also be calculated based on the tabulated values. This is done by multiplying the number in each measurement category by the average size measurement category and summing the individual values. Cumulative curves are also useful in determining oversize and undersize particles, which are small particle fractions that are significantly larger or smaller than the bulk of the sample.
[0286] As used herein, the term "partition coefficient" (P) is the ratio of the concentration of a substance in the lipid to the concentration of the aqueous phase. Therefore, it is a measure of lipophilicity. The higher the P, the greater the amount of substance (usually octanol) in the lipid phase and the stronger the lipophilicity. For convenience, the logarithm of P ("log P") is usually used. When P < 1, log P is negative, and the solubility of the compound in the aqueous phase is greater. When P > 1, log P is positive, and the compound favors the lipid phase. As used herein, the term "Log D" is the log P (e.g., log D) of a compound at a specific pH. 5.5 ). According to some embodiments, the log P range of β-hydroxybutyrate is predicted to be -0.49 to -0.39.
[0287] As used herein, the term "peripheral nervous system" ("PNS") refers to the portion of the nervous system located outside the brain and spinal cord that connects the CNS to the sense organs, other organs of the body, muscles, blood vessels, and glands. It contains 12 cranial nerves, spinal nerves and roots, and autonomic nerves involved in the regulation of the heart muscle, muscles in the walls of blood vessels, and glands.
[0288] The term "pharmaceutical composition" is used herein to refer to a composition used to prevent, reduce the intensity, cure or otherwise treat a target condition or disease.
[0289] As used herein, the term "pharmaceutically acceptable carrier" refers to any substantially nontoxic carrier that is conventionally useful for administering a drug, wherein the synthetic compound of the present invention described will remain stable and bioavailable. A pharmaceutically acceptable carrier must have a sufficiently high purity and sufficiently low toxicity to make it suitable for administration to a treated mammal. It should further maintain the stability and bioavailability of the active agent. A pharmaceutically acceptable carrier can be a liquid or solid and is selected to provide a desired volume, consistency, etc. when combined with an active agent and other components of a given composition, taking into account the intended mode of administration.
[0290] As used herein, the term "pharmaceutically acceptable salt" refers to salts that are suitable for contact with the tissues of humans and lower animals without excessive toxicity, irritation, allergic response, etc. and that are commensurate with a reasonable benefit / risk ratio within the scope of reasonable medical judgment. When used in medicine, the salt should be pharmaceutically acceptable, but non-pharmaceutically acceptable salts can be conveniently used to prepare its pharmaceutically acceptable salts. Such salts include but are not limited to salts prepared by the following acids: hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, maleic acid, acetic acid, salicylic acid, p-toluenesulfonic acid, tartaric acid, citric acid, methanesulfonic acid, formic acid, malonic acid, succinic acid, naphthalene-2-sulfonic acid and benzenesulfonic acid. In addition, such salts can be prepared into alkali metal salts or alkaline earth metal salts, such as sodium salts, potassium salts or calcium salts of carboxylic acid groups. "Pharmaceutically acceptable salts" refers to salts that are suitable for contact with the tissues of humans and lower animals without excessive toxicity, irritation, allergic response, etc. and that are commensurate with a reasonable benefit / risk ratio within the scope of reasonable medical judgment. Pharmaceutically acceptable salts are well known in the art. For example, P. H. Stahl et al. describe pharmaceutically acceptable salts in detail in "Handbook of Pharmaceutical Salts: Properties, Selection, and Use" (Wiley VCH, Zurich, Switzerland: 2002). The salts can be prepared in situ during the final isolation and purification of the compounds described within the present invention, or separately by reacting a free base function with a suitable organic acid. Representative acid addition salts include, but are not limited to, acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate (isethionate), lactate, maleate, methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, pamoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, phosphate, glutamate, bicarbonate, p-toluenesulfonate, and undecanoate. In addition, basic nitrogen-containing groups can be quaternized with such agents as lower alkyl halides (e.g., methyl, ethyl, propyl and butyl chlorides, bromides and iodides); dialkyl sulfates (e.g., dimethyl, diethyl, dibutyl and diamyl sulfates); long chain halides (e.g., decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides); aralkyl halides (e.g., benzyl and phenethyl bromides, etc.), thereby obtaining water-soluble or oil-soluble or dispersible products.Examples of acids that can be used to form pharmaceutically acceptable acid addition salts include inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid and phosphoric acid, and organic acids such as oxalic acid, maleic acid, succinic acid and citric acid. Base addition salts can be prepared in situ by reacting the carboxylic acid-containing moiety with a suitable base (such as a pharmaceutically acceptable metal cation hydroxide, carbonate or bicarbonate) or with ammonia or an organic primary, secondary or tertiary amine during the final separation and purification of the compounds described in the present invention. Pharmaceutically acceptable salts include but are not limited to cations based on alkali metals or alkaline earth metals, such as lithium salts, sodium salts, potassium salts, calcium salts, magnesium salts and aluminum salts, and non-toxic quaternary ammonium and amine cations, including ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, diethylamine, ethylamine, etc. Other representative organic amines that can be used to form base addition salts include ethylenediamine, ethanolamine, diethanolamine, piperidine, piperazine, etc. Pharmaceutically acceptable salts can also be obtained using standard procedures well known in the art, for example by reacting a sufficiently basic compound (such as an amine) with a suitable acid providing a physiologically acceptable anion. Alkali metal (e.g., sodium, potassium or lithium) or alkaline earth metal (e.g., calcium or magnesium) salts of carboxylic acids can also be prepared.
[0291] As used herein, the term "plume width" refers to the width of the plume at a given distance from the nozzle (eg, 3 cm).
[0292] As used herein, the term "polymer" refers to a macromolecule or polymer composed of many repeating subunits having the same structure (monomers). A polymer having two different repeating units in its chain is called a copolymer.
[0293] As used herein, the term "powder" refers to fine, dry particles produced by grinding, crushing or pulverizing a solid substance.
[0294] As used herein, the term "pump" refers to all components of the container closure system responsible for metering, aerosolizing, and delivering a formulation into a subject.
[0295] As used herein, the term "receptor" refers to a protein that binds to a specific extracellular signaling molecule (ligand) and triggers a response in the cell. Cell surface receptors are located in the plasma membrane, and the ligand binding site of the cell surface receptor is exposed to the external medium. Intracellular receptors bind to ligands that diffuse into the cell across the plasma membrane.
[0296] As used herein, the terms "reduce" or "reducing" refer to a decrease, reduction, attenuation, restriction, or alleviation of the degree, intensity, extent, size, amount, density, number, or incidence.
[0297] The term "release" and its various grammatical forms refer to the dissolution of the active ingredient and the diffusion of dissolved or solubilized species by a combination of the following processes: (1) hydration of the matrix, (2) diffusion of the solution into the matrix; (3) dissolution of the active substance; and (4) diffusion of the dissolved active substance out of the matrix.
[0298] As used herein, the term "second messenger" (eg, cyclic AMP [cAMP], diacylglycerol [DAG], and inositol 1,4,5-triphosphate [IP3]) refers to small molecules that initiate and coordinate intracellular signaling pathways.
[0299] The terms "soluble" and "solubility" refer to the property of being readily soluble in a specified fluid (solvent). The term "insoluble" refers to the property of a material having minimal or limited solubility in a specified solvent.
[0300] A "solution" is generally considered to be a homogeneous mixture of two or more substances. It is usually (although not necessarily) a liquid. In a solution, the molecules of the solute (or dissolved substance) are evenly distributed among the molecules of the solvent.
[0301] As used herein, the term "spray" refers to a system of droplets in a fluid continuous phase.
[0302] As used herein, the term "spray angle" refers to the angle of the emitted plume measured from the apex of the spray cone and nozzle.
[0303] The terms "subject" or "individual" or "patient" are used interchangeably to refer to a member of an animal species of mammalian origin, including but not limited to mice, rats, cats, goats, sheep, horses, hamsters, pigs, dogs, guinea pigs, rabbits, and primates such as monkeys, apes, or humans.
[0304] As used herein, the phrase "a subject in need thereof" refers to: (i) a subject at risk for developing a traumatic brain injury that includes neuroinflammation; (ii) a subject that has suffered a traumatic brain injury that includes neuroinflammation; or (iii) a subject that has suffered a traumatic brain injury that includes neuroinflammation, unless the context and usage of the phrase indicates otherwise.
[0305] The term "support" is used herein to mean to maintain, supply, sustain, assist.
[0306] As used herein, the term "susceptible" refers to a member of a group at risk.
[0307] A "suspension" is a dispersion (mixture) of finely divided, undissolved matter in a liquid vehicle, wherein the former is so finely divided and mixed that it does not quickly settle out. In everyday life, the most common suspension is that of a solid in a liquid.
[0308] The term "slow-release" (also referred to as "extended release") is used herein with its conventional meaning to refer to an active formulation that provides a progressive release of an active substance over an extended period of time and preferably, although not necessarily, produces a substantially constant blood level of an active substance over an extended period of time. Alternatively, delayed absorption of the active substance form of parenteral administration is achieved by dissolving or suspending the active substance in an oily vehicle. Non-limiting examples of slow-release biodegradable polymers include polyesters, polyester-polyethylene glycol copolymers, polyamino-derived biopolymers, polyanhydrides, hydrogels, polyorthoesters, polyphosphazenes, SAIB, photopolymerizable biopolymers, protein polymers, collagen, polysaccharides, chitosans, and alginate.
[0309] As used herein, the term "symptom" refers to a sign or indication of a condition or disease, especially when an individual experiences a change from normal function, feeling, or appearance.
[0310] As used herein, the term "synthetic" means made by a chemical process or altered by deliberate human intervention. As used herein, "synthetic" includes products derived from biological fermentation.
[0311] As used herein, the term "T cell" or "T lymphocyte" refers to one of the two types of antigen-specific lymphocytes responsible for the adaptive immune response, the other being the B cell. T cells are responsible for cell-mediated adaptive immune responses. T cells originate in the bone marrow, but undergo most of their development in the thymus. The highly variable antigen receptors on T cells are called T cell receptors. Effector T cells play a variety of functions in the immune response, always acting by interacting with another cell in an antigen-specific manner. Some T cells activate macrophages, some T cells help B cells produce antibodies, and some T cells kill cells infected by viruses and other intracellular pathogens.
[0312] As used herein, the term "targeted delivery" refers to a system that directs the active moiety to its targeted body area (organ, cellular and subcellular levels of specific tissues) to overcome the specific toxic effects of conventional active delivery, thereby reducing the amount of active agent required to achieve efficacy.
[0313] The term "therapeutic amount" is an amount sufficient to provide the intended therapeutic benefit. In conjunction with the teachings provided herein, by weighing factors such as efficacy, relative bioavailability, subject weight, severity of adverse side effects, and preferred modes of administration, an effective prophylactic or therapeutic treatment regimen can be planned that does not cause significant toxicity and is still effective in treating a particular subject.
[0314] As used herein, the term "therapeutic component" refers to a therapeutically effective dose (i.e., dosage and frequency of administration) that eliminates, reduces, or prevents the progression of a particular disease manifestation in a certain percentage of a population. An example of a commonly used therapeutic component is the ED50, which describes a dose that is a specific dose effective for treating a particular disease manifestation in 50% of a population.
[0315] As used herein, the term "therapeutic effect" refers to the result of treatment, which is judged to be desirable and beneficial. The therapeutic effect can directly or indirectly include the containment, reduction or elimination of disease manifestations. The therapeutic effect can also directly or indirectly include the containment, reduction or elimination of the progression of disease manifestations.
[0316] As used herein, the term "therapeutic window" reflects the concentration range that provides efficacy without unacceptable toxicity. The duration of a substance's action is determined by the time period during which the concentration exceeds the minimum effective concentration (MEC). Typically, another dose may be administered to maintain the concentration within the therapeutic window over time.
[0317] The terms "treat" or "treating" include abrogating, substantially inhibiting, slowing, or reversing the progression of a disease, condition, or disorder; substantially ameliorating the clinical or aesthetic symptoms of a condition; substantially preventing the appearance of the clinical or aesthetic symptoms of a disease, condition, or disorder; and protecting against harmful or unpleasant symptoms. Treating further refers to achieving one or more of the following: (a) reducing the severity of the disorder; (b) limiting the development of symptoms characteristic of the disorder being treated; (c) limiting the worsening of symptoms characteristic of the disorder being treated; (d) limiting the recurrence of the disorder in patients who previously had the disorder; and (e) limiting the recurrence of symptoms in patients who were previously asymptomatic for the disorder.
[0318] As used herein, the term "ubiquitin C-terminal hydrolase L1" or "UCHL1" refers to a neuron-specific cytoplasmic enzyme that is highly enriched in neurons. It is an indicator of acute injury to brain neurons. It is involved in the degradation of unwanted, misfolded or damaged proteins. Increased CSF and blood concentrations of UCH-L1 are associated with a process of neuronal destruction (loss) and increased permeability of the blood-brain barrier. After TBI, blood UCH-L1 levels correlate with injury severity. [Mondello, S. et al. BMC Neurology (2012) 12: Article 85].
[0319] The term "ULOQ" or "Upper Limit of Quantitation" is used interchangeably to refer to the highest concentration in a calibration curve that can be determined with the required precision and accuracy with a given analytical assay. Values above the ULOQ are ALQ (Above Limit of Quantitation).
[0320] Example
[0321] Composition
[0322] According to one aspect, the present disclosure provides a composition comprising an active ingredient encapsulated in a suspension of particles, the particles comprising a biodegradable polymer containing an effective amount of the active ingredient, wherein the particles are configured to bypass the blood-brain barrier, wherein the active ingredient is synthetic D-beta hydroxybutyrate, and wherein the targeted delivery is delivery to the brain.
[0323] According to some embodiments, the synthetic β-hydroxybutyrate is soluble in water.
[0324] According to some embodiments, the size of the particles is greater than 10nm in diameter, greater than 15nm in diameter, greater than 20nm in diameter, greater than 30nm in diameter, greater than 40nm in diameter, greater than 50nm in diameter, greater than 60nm in diameter, greater than 70nm in diameter, greater than 80nm in diameter, greater than 90nm in diameter, greater than 100nm, greater than 200nm, greater than 300nm, greater than 400nm, greater than 500nm, greater than 600nm, greater than 700nm, greater than 800nm, greater than 900nm, greater than 1000nm, greater than 2000nm, greater than 3000nm, greater than 4000nm, greater than 5000nm, greater than 6000nm, greater than 7000nm, greater than 8000nm, greater than 9000nm, greater than 10,000nm, etc. [See, e.g., Ohta, S. et al. Investigating the optimum size of nanoparticles for their delivery into the brain assisted by focused ultrasound-induced blood brain barrier opening. Scientific Reports (2020) 18220].
[0325] According to some embodiments, the synthetic D-β-hydroxybutyrate is dispersed throughout the particle; or the particle is impregnated with the synthetic D-β-hydroxybutyrate; or the particle comprises a matrix, and the matrix comprises the synthetic D-β-hydroxybutyrate.
[0326] According to some embodiments, a portion of the synthetic D-beta hydroxybutyrate is adsorbed or weakly bound to the surface of the microparticles and facilitates a rapid initial release or burst release.
[0327] According to some embodiments, the particles have any order release kinetics, including zero order release, first order release, second order release, delayed release, sustained release, immediate release, long-term release, or a combination thereof.
[0328] According to some embodiments, release of the synthetic D-beta hydroxybutyrate from the particles is by diffusion, erosion, or both.
[0329] Delivery / Administration Route
[0330] The invention as described contemplates all routes of administration, including intramuscularly, subcutaneously, sublingually, intravenously, intraperitoneally, intranasally, intratracheally, topically, intradermally, intramucosally, intracavernously, intrarectally, into the antrum, gastrointestinal, intraductally, intrathecally, intraventricularly, intrapulmonary, into an abscess, intra-articularly, subpericardially, into the axilla, into the pleural cavity, intradermally, intrabuccally, transmucosally, transdermally, by inhalation, and by subcutaneous injection.
[0331] As used herein, administration includes in vivo administration, as well as direct administration to ex vivo tissues. Typically, the composition can be systemically (i.e., orally, buccally, parenterally or rectally) administered in the form of a single dose unit formulation or multiple dose unit formulations containing non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles (as desired).
[0332] According to some embodiments, the delivery route is by oral administration. The described composition of the present invention can be in a form suitable for oral use, for example as tablets, lozenges, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs. As used herein, the term "oral" or "oral" refers to being introduced into the body by mouth, whereby absorption occurs in one or more of the following areas of the body: mouth, stomach, small intestine, lungs (also specifically referred to as inhalation) and sublingual small blood vessels (also specifically referred to as sublingual). Compositions intended for oral use can be prepared according to any known method, and such compositions can contain one or more medicaments selected from the following groups: sweeteners, flavorings, coloring agents and preservatives, to provide pharmaceutically refined and palatable preparations. Tablets can contain active ingredients mixed with nontoxic pharmaceutically acceptable excipients suitable for preparing tablets. These excipients may be, for example, inert diluents such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating agents and disintegrants such as corn starch or alginic acid; binders such as starch, gelatin or gum arabic; and lubricants such as magnesium stearate, stearic acid or talc. The tablets may be uncoated, or the tablets may be coated by known techniques, for example to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period of time, thereby protecting the composition from oxidation or photodegradation; or for controlled release. For example, a time-delay material such as glyceryl monostearate or glyceryl distearate may be employed.
[0333] The described composition of the invention can also be formulated for oral use in the form of hard gelatin capsules, wherein the active ingredient is mixed with an inert solid diluent (e.g., calcium carbonate, calcium phosphate or kaolin), or in the form of soft gelatin capsules, wherein the active ingredient is mixed with water or an oil medium (e.g., peanut oil, liquid paraffin or olive oil).
[0334] The composition of the present invention described can be formulated as an aqueous suspension, wherein the active ingredient is mixed with an excipient suitable for preparing an aqueous suspension. Such excipients are suspending agents, such as sodium carboxymethylcellulose, methylcellulose, hydroxypropyl methylcellulose, sodium alginate, polyvinyl pyrrolidone, gum tragacanth and gum arabic; dispersants or wetting agents can be naturally occurring phospholipids (e.g., lecithin), or condensation products of olefin oxides and fatty acids (e.g., polyoxyethylene stearate), or condensation products of ethylene oxide and long-chain fatty alcohols (e.g., heptadecaethyleneoxycetanol), or condensation products of ethylene oxide and partial esters derived from fatty acids and hexitol (such as polyoxyethylene sorbitol monooleate) or condensation products of ethylene oxide and partial esters derived from fatty acids and hexitol anhydrides (e.g., polyethylene sorbitan monooleate). The aqueous suspension may also contain one or more coloring agents, one or more flavoring agents, and one or more sweeteners, such as sucrose or saccharin.
[0335] The described compositions of the present invention can be formulated as oily suspensions by suspending the active ingredient in a vegetable oil (e.g., peanut oil, olive oil, sesame oil, or coconut oil) or a mineral oil (e.g., liquid paraffin). The oily suspension can contain a thickening agent, e.g., beeswax, hard paraffin, or cetyl alcohol. Sweeteners, such as those described above, and flavoring agents can be added to provide a palatable oral formulation. These compositions can be preserved by adding an antioxidant (e.g., ascorbic acid).
[0336] The described compositions of the present invention can be formulated in the form of dispersible powders and granules suitable for preparing aqueous suspensions by adding water. The active ingredient in such powders and granules is provided in admixture with a dispersant or wetting agent, a suspending agent and one or more preservatives. Suitable dispersants or wetting agents and suspending agents are illustrated by those already mentioned above. Additional excipients, such as sweeteners, flavoring agents and coloring agents, may also be present.
[0337] The composition of the present invention can also be in the form of an emulsion. An emulsion is a two-phase system prepared by combining two immiscible liquid carriers, one of which is evenly distributed in the other, and consists of globules with a diameter equal to or greater than the diameter of the largest colloidal particle. The globule size is critical and must allow the system to achieve maximum stability. Typically, separation of the two phases will not occur unless a third substance, i.e., an emulsifier, is incorporated. Therefore, an alkaline emulsion contains at least three components, two immiscible liquid carriers and an emulsifier, and an active ingredient.
[0338] Most emulsions incorporate an aqueous phase into a non-aqueous phase (or vice versa).
[0339] However, it is possible to prepare a substantially non-aqueous emulsion, for example, anionic and cationic surfactants of non-aqueous immiscible systems glycerol and olive oil. Therefore, the composition of the present invention can be in the form of an oil-in-water emulsion. The oil phase can be a vegetable oil (for example, olive oil or peanut oil) or a mineral oil (for example, liquid paraffin) or a mixture thereof. Suitable emulsifiers can be naturally occurring gums (for example, gum arabic or tragacanth), naturally occurring phosphatides (for example, soybean, lecithin) and esters or partial esters (for example, sorbitan monooleate) derived from fatty acids and hexitol anhydrides and condensation products of partial esters and ethylene oxide (for example, polyoxyethylene sorbitan monooleate). Emulsions can also contain sweeteners and flavorings.
[0340] The composition of the present invention can also be formulated as syrups and elixirs. Syrups and elixirs can be formulated with sweeteners (e.g., glycerol, propylene glycol, sorbitol or sucrose). Such formulations can also contain demulcents, preservatives, and flavoring agents and coloring agents. Demulcents are protective agents that are mainly used to reduce irritation, especially mucous membranes or abrasions. Many chemical substances have demulcent properties. These substances include alginates, mucus, gums, dextrins, starches, certain sugars and polymer polyols. Other substances include gum arabic, agar, benzoin, carbomer, gelatin, glycerol, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, propylene glycol, sodium alginate, tragacanth gum, hydrogels, etc.
[0341] For buccal administration, the compositions of the invention described may take the form of tablets or lozenges formulated in conventional manner.
[0342] There are three general methods for tablet preparation: wet granulation; dry granulation; and direct compression. The preparation method and added ingredients are selected so that the tablet formulation has the desired physical properties that allow for rapid compression of the tablet. After compression, the tablet must have a number of additional attributes, such as appearance, hardness, disintegration ability, appropriate dissolution characteristics, and uniformity, which are also affected by both the preparation method and the added materials present in the formulation.
[0343] According to some embodiments, the tablet is a compressed tablet (CT). A compressed tablet is a solid dosage form formed under pressure and does not contain a special coating. Typically, the compressed tablet is made of powdered, crystalline or granular materials alone or in combination with a binder, a disintegrant, a controlled release polymer, a lubricant, a diluent and a colorant.
[0344] According to some embodiments, the tablets are sugar-coated tablets. These are compressed tablets containing a sugar coating. Such coatings may be colored and are useful for covering active substances with an unpleasant taste or odor and protecting materials that are sensitive to oxidation.
[0345] According to some embodiments, the tablets are film-coated tablets. These compressed tablets are covered with a thin layer or film of a water-soluble material.
[0346] Many polymeric materials having film-forming properties can be used.
[0347] According to some embodiments, the tablets are enteric-coated tablets. These compressed tablets are coated with a substance that resists solution in gastric fluid but breaks down in the intestines.
[0348] According to some embodiments, the tablet is a multi-compressed tablet. These tablets are made by more than one compression cycle. Layered tablets are prepared by compressing additional tablet granulations on pre-compressed granulations. The operation can be repeated to produce two-layer or three-layer multi-layer tablets. Pressed coated tablets (dry coating) are prepared by feeding pre-compressed tablets into a special tablet press and compressing another granulation layer around the preformed tablet.
[0349] According to some embodiments, the tablet is a controlled release tablet. Compressed tablets can be formulated to slowly release the active substance over an extended period of time. Therefore, these dosage forms are referred to as extended release dosage forms or sustained release dosage forms.
[0350] According to some embodiments, the tablet is a tablet for a solution. These compressed tablets can be used to prepare a solution or to impart a given property to a solution.
[0351] According to some such embodiments, the tablet is an effervescent tablet. In addition to the active substance, these tablets contain sodium bicarbonate and an organic acid (such as tartaric acid or citric acid). In the presence of water, these additives react to release carbon dioxide that acts as a disintegrant and produce effervescence.
[0352] According to some embodiments, the tablet is a compressed suppository or insert.
[0353] According to some embodiments, the tablet is a buccal and / or sublingual tablet. The tablet is a small flat oval tablet intended for buccal administration and which can slowly dissolve or erode by insertion into a cheek pouch.
[0354] According to some embodiments, the tablet is a molded tablet or a triturated tablet.
[0355] In some embodiments, the tablet comprises a compressed core comprising at least one component of the formulation described; and a film-forming composition. Formulations utilizing film-forming compositions are known to those skilled in the art (see, e.g., Remington's Pharmaceutical Sciences, 20th edition, 2000). Such film-forming compositions may comprise, for example, polymers (such as, but not limited to, cellulose esters, cellulose ethers, and cellulose ester-ether polymers), amphiphilic triblock copolymer surfactants (e.g., ethylene oxide-propylene oxide-ethylene oxide), and solvents (e.g., acetone) that form a film on the core. The compressed core may contain a double-layer core comprising an active layer and a push layer.
[0356] According to some embodiments, when delivered orally, the effective amount of exogenous synthetic D-β-hydroxybutyrate can range from at least 500 mg to 100 g (inclusive), i.e., at least 500 mg, at least 500 mg, 600 mg, 700 mg, 800 mg, 900 mg, 1 g, 2 g, 3 g, 4 g, 5 g, 6 g, 7 g, 8 g, 9 g, 10 g, 11 g, 12 g, 13 g, 14 g, 15 g, 16 g, 17 g, 18 g, 19 g, 20 g , 21g, 22g, 23g, 24g, 25g, 26g, 27g, 28g, 29g, 30g, 31g, 32g, 33g, 34g, 35g, 36g, 37g, 38g, 39g, 40g, 41g , 42g, 43g, 44g, 45g, 46g, 47g, 48g, 49g, 50g, 51g, 52g, 53g, 54g, 55g, 56g, 57g, 58g, 59g, 60g, 61g, 62g, 63g, 64g, 65g, 66g, 67g, 68g, 69g, 70g, 71g, 72g, 73g, 74g, 75g, 76g, 77g, 78g, 79g, 80g, 81g, 82g, 83g, 84g, 85g, 86g, 87g, 88g, 89g, 90g, 91g, 92g, 93g, 94g, 95g, 96g, 97g, 98g, 99g or 100g, or can be 10g-50g (including end 48g, 49g, 50g, 51g, 52g, 53g, 54g, 55g, 56g, 57g, 58g, 59g, 60g, 61g, 62g, 63g, 64g, 65g, 66g, 67g, 68g, 69g, 70g, 71g, 72g, 73g, 74g, 75g, 76g, 77g, 78g, 79g, 80g, 81g, 82g, 83g, 84g, 85g, 86g, 87g, 88g, 89g, 90g, 91g, 92g, 93g, 94g, 95g, 96g, 97g, 98g
[0357] Intranasal delivery of dosage forms
[0358] According to some embodiments, delivery is targeted to the brain via intranasal delivery.
[0359] Figure 4 is a cross-sectional illustration showing the internal nasal anatomy. The nasal septum divides the human nasal cavity into two halves, a central partition of bone and cartilage; each symmetrical half opens in the face through the nostrils and connects to the mouth at the nasopharynx. The nasal cavity is subdivided into the nasal vestibule, inferior turbinate, middle turbinate, superior turbinate, olfactory area, frontal sinus, sphenoid sinus, and cribriform plate of the ethmoid bone. [Javia, A. et al., Polymers in nasal drug delivery: an overview. Chapter 11, Polymers in Drug Delivery, 2nd edition, Misra, A. and Shahiwala, A. eds. Elsevier (2021) pp. 306-323].
[0360] The area of the nasal vestibule is about 0.6 cm 2And present in the front part of the nasal cavity, just inside the nostril. Nasal hair (also referred to as nasal hair) is present in this area, and the nasal hair acts as a filter unit for inhaled particles. The nose part is shielded by the stratified squamous epithelium and keratinized epithelium with sebaceous glands [same, citing Marttin, E. et al. Nasal mucociliary clearance as a factor in nasal drug delivery. "Adv. Drug Deliv. Rev. (1998) 29: 13-38; Illum, L. Nasal drug delivery-possibilities, problems and solutions (Nasal drug delivery-possibilities, problems and solutions). "J. Controlled Re. (2003) 87: 187-98]. These properties are necessary for resistance to toxic environmental agents, but also affect the absorption of active substances [Kimbell, JS et al. Correlation of regional formaldehyde flux predictions with the distribution of formaldehyde-induced squamous metaplasia in F344 rat nasal passages. Mutat. Res. Fund. Mol. Mech. Mutagen (1997) 380: 143-54].
[0361] The atrium is located midway between the nasal vestibule and the respiratory zone. Its anterior portion is stratified squamous epithelium, and the posterior region is pseudostratified columnar cells presenting microvilli [ibid., cited in Marttin, E. et al. Nasal mucociliary clearance as a factor in nasal drug delivery. Advanced Drug Delivery Reviews (1998) 29: 13-38].
[0362] In humans, the olfactory area (approximately 15 cm 2) is located on the superior turbinate opposite the septum, just below the cribriform plate of the ethmoid bone, which separates the cranial cavity from the nasal cavity and occupies approximately 5% of the total area of the nasal cavity [ibid., citing Illum, L. Is drug transport from the nose to the brain in humans real? (Is nose-to-brain transport of drugs in man a reality?) (2004) Journal of Pharmacy and Pharmacology (J. Pharm. Pharmacol.) (2004) 56: 3-17], but is of interest in delivering substances to the CNS because it has a highly vascularized epithelial layer, bypasses the BBB, and has connectivity with the cerebrospinal fluid (CSF) and the CNS [ibid., citing Hanson, LR and Frey, WH Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. (2008) BMC Neurosci. 9: S5; Illum, L. Nasal drug delivery—possibilities, problems and solutions. Journal of Controlled Release (2003) 87: 187-98].
[0363] Blood-brain barrier (BBB) is located at the level of brain microvasculature and is essential for maintaining central nervous system (CNS) homeostasis. Although BBB limits potential neurotoxic substances to enter the brain, it is also a major obstacle for therapeutic agents to be delivered to CNS for disease treatment. BBB shows low pinocytosis rate and has tight junctions (TJ), which form a seal between relative endothelial membranes [Lockhead, JJ and Thorne, RG. " Intranasal delivery of biologics to the central nervous system ". " Advanced Drug Delivery Review " (2012) 64: 614-28, citing Reese, TS and Karnovsky, MJ. " Cell Biology Journal (J.CellBiol.) " (1967) 34: 207-17]. Compared to the 3–30 Ω·cm2 transendothelial resistance across most peripheral microvessels, the presence of TJs at the BBB results in a high transendothelial resistance of 1500–2000 Ω·cm2 [ibid., citing Crone, C. and Olesen, SP. Brain Research (1982) 241:49-55; Butt, AM et al. Journal of Physiology (J. Physiol) (1990) 429:47-62]. This high resistance is associated with very low permeability, i.e., the BBB greatly restricts the diffusion of solutes from the blood to the paracellular diffusion in the brain. Generally, only small lipophilic molecules significantly cross the normal healthy BBB by passive diffusion across cells, but some limited transport of certain peptides and peptide analogs has been reported [ibid., citing Banks, WA. Jama Neurology (2009) 9 (Suppl 1): S3]. Essential nutrients such as glucose or iron enter the CNS via specific transporters such as glucose transporter 1 or receptors such as transferrin receptor [ibid., citing Dick, AP et al., Proc. Natl. Acad. Sci. USA (1984) 81:7233-37; Jeffries, WA et al., Nature (1984) 312:162-3]. Receptors and transporters for gut hormones involved in regulating metabolism are expressed at the BBB to relay information between the CNS and the periphery [ibid., citing Banks, WA., Regul. Pept. (20008) 149:11-14]. In addition to its low paracellular permeability and low pinocytosis rate, the BBB also expresses a high number of drug transporters (e.g., P-glycoprotein), which further restrict brain entry of many endogenous and exogenous substances that would otherwise be predicted to cross the BBB based on molecular weight (MW) and lipophilicity considerations. [ibid.].
[0364] The precise pathways and mechanisms by which drugs travel from the nasal epithelium to various regions of the CNS have not been fully elucidated. Substances can cross the olfactory membrane by three mechanisms: transport along the olfactory and trigeminal primary neurons of the olfactory epithelium and transport to the olfactory bulb by intracellular axonal transport; penetration of substances through the olfactory supporting epithelium by transcellular or paracellular mechanisms, followed by uptake into the CNS; and continuous possible distribution to more distant brain tissues by pinocytosis of olfactory neurons [Kimbell, JS et al. Correlation of regional formaldehyde flux predictions in the nasal passages of F344 rats with the distribution of formaldehyde-induced squamous metaplasia. Mutation Research - Basic and Molecular Mechanisms of Mutagenesis (1997) 380: 143-54, citing Illum, L. Is drug transport from the nose to the brain in humans real? (2004) Journal of Pharmacy and Pharmacology (2004) 56: 3-17].
[0365] Olfactory lobe provides access for substances to enter CNS and peripheral circulation. Substances can enter CNS through intraneuronal pathways, which transport active substances through axons, which takes hours to days to make substances reach different areas of the brain. Extraneuronal pathways transport substances through perineural channels, which takes a few minutes for substances to reach parenchyma or CSF [Singh, AK et al. Nasal cavity, a promising, a promising transmucosal platform for drug delivery and research approaches from nasal to brain targeting. "Journal of Drug Delivery Therapy (J.Drug Deliv.Thera.)" (2012) 2]. Therefore, compared with other delivery routes, nasal delivery has many advantages, such as rapid absorption, rapid action and low risk of overdose [ibid., citing Arora, P. et al. Permeability issues in nasal drug delivery. Contemporary Drug Discovery (Drug Discov. Today) (2002) 7: 967-75, Ugwoke, ML et al. The biopharmaceutical aspects of nasal mucoadhesive drug delivery. Journal of Pharmacy and Pharmacology (2001) 53: 3-22; Romeo, V. et al. Effects of physicochemical properties and other factors on systemic nasal drug delivery. Advanced Drug Delivery Review (1998) 29: 89.
[0366] The respiratory epithelium is the primary lining of the human nasal cavity and is essential for cleaning the nasal mucosa by nasal mucociliary clearance (NMCC). The respiratory tract area is approximately 130 cm 2[Same, cited in Pires, A et al. Intranasal drug delivery: how, why and what for? Journal of Pharmacy and Pharmaceutical Sciences (J. Pharm. Pharm. Sci.) (2009) 12: 288-311]. It is composed of five types of cells: ciliated columnar cells, non-ciliated columnar cells, basal cells (about 80%), neurosecretory cells in the basement membrane, and goblet cells (about 20%). These cells help prevent mucosal drying by capturing moisture.
[0367] The nasopharynx is present in the posterior region; the nasopharynx has ciliated cells in the upper part and squamous epithelium in the lower part. Goblet cells and serous mucous glands secrete about 20-40 ml of watery mucus every day [ibid., citing Quraishi, M. et al. Rheology of nasal mucus: a review. Clin. Otolaryngol. Allied Sci. (1998) 23: 403-13]. The nasopharynx consists of nasal-associated lymphoid tissue located directly under the nasal mucosa [ibid., citing Illum, L. Nanoparticulate systems for nasal delivery of drugs: a real improvement over simple systems. J. Pharm. Sci. (2007) 96: 473-83]. [Ibid., citing Stanley, A. et al. Characterization of ovine nasal-associated lymphoid tissue and identification of M cells in the overlying follicle-associated epithelium. J. Comp. Pathol. (2001) 125" 262-70]. Substances administered by the nasal route can be absorbed into the systemic circulation or the brain, or in many cases both. Absorption is controlled by many factors, including the brain influx of chemicals, active metabolizing enzymes in the olfactory mucosa, the olfactory bulbs, and the brain itself.
[0368] Biological barriers in nasal absorption
[0369] Many studies have demonstrated that intranasal (IN) drug delivery can effectively treat animal models of CNS diseases. Most of these studies do not show pharmacokinetic data that clearly demonstrate the brain uptake of compounds administered by the nasal cavity, but present pharmacodynamic data that show a positive effect after IN delivery of substances in animal models. [Lockhead, JJ et al. "Intranasal delivery of biologics to the central nervous system". Advanced Drug Delivery Reviews (2012) 64 7]: 614-28]. This makes it difficult to determine whether the API bypasses the BBB to enter the CNS through a direct nose-to-brain pathway, crosses the BBB to enter the CNS, or may exert its effect by acting on the brain endothelium.
[0370] Mucus. The first step of absorption through the nasal passage is through the mucous membrane. Lipophilic active substances can easily cross biological membranes via the transcellular route because they are able to partition into the lipids (bilayers) of the cell membrane. Therefore, lipophilic active substances can quickly enter both the CSF and the bloodstream after nasal administration; polar active substances can only cross the mucus layer but not the lipid layer. [[Javia, A. et al., Polymers in Nasal Drug Delivery: A Review. Chapter 11, Applications of Polymers in Drug Delivery, 2nd ed. Misra, A. and Shahiwala, A. eds. Elsevier (2021) pp. 306-323, citing Kimbell, JS et al. Prediction of regional formaldehyde flux in the nasal passages of F344 rats and its correlation with the distribution of formaldehyde-induced squamous metaplasia. Mutation Research. Basic and Molecular Mechanisms of Mutagenesis (1997) 380:143-54., citing Sakane, T. et al. The transport of a drug to the cerebrospinal fluid directly from the nasal cavity: the relation to the lipophilicity of the drug. Chem. Pharm. Bull. (1991) 39:2456-58].
[0371] Nasal mucociliary clearance (NMCC). The normal half-life of mucociliary transport in humans is about 12-15 minutes [ibid., citing Marttin, E. et al. Nasal mucociliary clearance as a factor in nasal drug delivery. Advanced Drug Delivery Reviews (1998) 29: 13-38]. The main components involved in nasal mucociliary clearance (NMCC) are the density of cilia, the composition of periciliary fluid and mucus. The rate of NMCC is extremely variable in different regions and under different physiological conditions. Mucociliary activity is regulated by several factors, such as temperature, intracellular calcium and cyclic adenosine monophosphate (cAMP) levels, and by extracellular ATP, age, sex, posture, sleep, exercise, and common environmental pollutants that may affect the frequency of ciliary beats and mucus production, thereby increasing mucociliary clearance. Disease conditions may also affect NMCC [supra, citing Turker, S. et al. Nasal route and drug delivery systems. Pharm World Sci. (2004) 26: 137-42].
[0372] The absorption of substances by the nasal mucosa depends on the time period during which the substance remains in contact with the nasal mucosa. Therefore, interference in NMCC limits active absorption. In order to maximize the transport of active substances to the brain, NMCC needs to be increased to ensure the extended contact time of active substances at the absorption site [ibid., citing Charlton, S. et al. Evaluation of bioadhesive polymers as delivery systems for nose to brain delivery: in vitro characterization studies. Journal of Controlled Release (2007) 118: 225-34]. Efforts to increase the contact / residence time of formulations in the nasal mucosa include polymer properties, such as mucoadhesion, pH sensitivity and thermal gelation. [Ibid., citing Schaefer, ML et al. Trigeminal collaterals in the nasal epithelium and olfactory bulb: a potential route for direct modulation of olfactory information by trigeminal stimulation. J. comp. Neurol. (2002) 444:221-26].
[0373] Enzyme barrier. The enzyme barrier of the nasal mucosa is primarily responsible for reducing the bioavailability of peptides and proteins across the nasal mucosa. This barrier can be overcome by the use of enzyme inhibitors, absorption enhancers (e.g., bile salts, cyclodextrins, glycocholate), and peptide / protease inhibitors.
[0374] P-glycoprotein efflux transporter. P-glycoprotein (P-gp) is a glycosylated membrane protein present in the human nasal respiratory mucosa. [Same, cited in Wioland, MA et al. CFTR, MDR1 and MRP1 immunolocalization in normal human nasal respiratory mucosa. Journal of Histochemistry and Cytochemistry (J. Histochem. Cytochem.) (2000) 48: 1215-22]. Co-administration of P-gp inhibitors as part of nasal formulations increases the permeability of nasally administered active substances [Graff, CL and Pollack, GM. P-glycoprotein attenuates brain uptake of substrates after nasal instillation. Pharmaceutical Research (Pharm. Res.) (2003) 20: 1225-30].
[0375] Physicochemical properties of the active ingredient. The physicochemical properties of the active ingredient, including molecular weight, solubility, dissolution rate, charge, partition coefficient, acid dissociation constant (pKa), particle size, and polymorphism, influence active absorption.
[0376] Substances with a molecular weight of less than 300Da will easily permeate through the aqueous channels of the membrane. For compounds with a molecular weight>300Da, the permeation rate is significantly affected. [Yamamoto, A. et al. Absorption of water-soluble compounds with different molecular weights and [Asu1.7]-eel calcitonin from various mucosal administration sites. Journal of Controlled Release (2001) 76: 363-74].
[0377] The permeability of biological membranes is mainly affected by their lipophilicity [ibid., citing Corbo, DC et al. Characterization of the barrier properties of mucosal membranes. Journal of Pharmaceutical Sciences (J. Pharm. Sci.) (1990) 79: 202-6]. Low molecular weight lipophilic active substances are quite effectively absorbed across the nasal epithelium [ibid., citing Hinchcliffe, M. and Illum, L. Intranasal insulin delivery and therapy. Advanced Drug Delivery Reviews (1999) 35: 199-234].
[0378] Particles of different sizes accumulate in different areas of the respiratory tract, for example, particles >10 μm accumulate in the respiratory tract area through breathing; particles <5 μm are inhaled and reach the lungs; and particles <0.5 μm are exhaled [Sanders, P. et al. Inhalers in healthy subjects and asthmatic patients. STP Pharma Sci. (1997) 7:3000-76].
[0379] Dissolution is another rate-limiting step for nasal absorption, since nasal absorption will only occur after the active substance has dissolved. Therefore, for nasal powder and suspension dosage forms, the dissolution rate is an important parameter. After nasal administration, if dissolution is slow, the particles will be cleared from the airways, followed by a decrease in bioavailability [Romeo, V. et al. Effects of physicochemical properties and other factors on systemic nasal drug delivery. Advanced Drug Delivery Review (1998) 29:39].
[0380] Physicochemical properties of formulations
[0381] pH: Since nasal absorption and penetration of active substances are generally influenced by the pKa value and pH of the formulation, the general rule is that the pH should therefore be selected in the range between 4.5 and 6.5. [Javia, A. et al., Polymers in Nasal Drug Delivery: A Review. Chapter 11, Applications of Polymers in Drug Delivery, 2nd edition, Misra, A. and Shahiwala, A. eds. Elsevier Publishing (2021) pp. 306-323].
[0382] Viscosity: Although increasing the viscosity of a formulation can prolong the contact / residence time of the formulation in the nasal cavity, which can increase penetration, high viscosity formulations can alter the normal function of the nasal cavity, including mucociliary clearance and / or ciliary beat frequency. [Ibid.]
[0383] Osmolarity. More often, isotonic solutions / formulations are applied in the nasal cavity for the purpose of shrinking the nasal epithelium, thereby increasing the penetration of substances due to structural changes. Isotonic solutions also inhibit ciliary activity. {Ibid.}
[0384] Buffer capacity. An acceptable buffer capacity of the formulation may be required to maintain pH. [Ibid.]
[0385] Active concentration, dose and dose volume. The higher the active concentration, the higher the absorption / permeation. The upper limit is 25 mg / dose. The dose volume is ideally in the range of 0.05-0.15 mL / dose (inclusive). [Ibid.]
[0386] Polymers. Polymers (e.g., cellulose derivatives, polyacrylates, starch, gelatin, phospholipids, chitosan, poly-N-alkylacrylamide / poly-N-isopropylacrylamide, cyclodextrins, poloxamers, and methylcellulose) have been shown to be effective in improving the intranasal absorption of therapeutic agents. [Ibid.]
[0387] Starch microspheres. Bioadhesive starch microspheres absorb water from the nasal mucosa and assist in paracellular transport. [Ibid., cited in Illum, L. et al. Bioadhesive starch microspheres and absorption enhancing agents act synergistically to enhance the nasal absorption of polypeptides. International Journal of Pharmacy (Int. J. Pharm.) (2001) 222: 109-19].
[0388] Cyclodextrin. The solubility of active substances can be increased by encapsulating the active substances in carriers such as cyclodextrins. Intranasal delivery along the olfactory pathway to the CNS can be enhanced specifically by using meta-cyclodextrins. [Same, cited in Marttin, E. et al. Efficacy, safety and mechanism of cyclodextrins as absorption enhancers in nasal delivery of peptide and protein drugs. Journal of Drug Target (1998) 6: 17-36; Merkus, F. et al. Cyclodextrins in nasal drug delivery. Advanced Drug Delivery Reviews (1999) 36: 41-57].
[0389] The disadvantages of the dosage form (ie, solution with NMCC) can be overcome by the combination of mucoadhesive and thermoreversible polymers.
[0390] Thermoresponsive polymers. Thermoresponsive polymers have a hydrophobic-hydrophilic balance in their structure, and the thermoresponsive polymers respond to small temperature changes near the critical temperature by chain folding or chain expansion. Examples of thermoreversible polymers include gelatin, carrageenan, methylcellulose, hydroxypropyl methylcellulose (HPMC), xyloglucan, poly (N-isopropylacrylamide-c-acrylic acid), poly (N-isopropylacrylamide) (PNIPAAm) / polyethylene oxide (PEO), poloxamer (Pluronic) and PEO / polylactic acid-co-glycolic acid (PLGA) [same, citing Sharma, N. et al. Mucoadhesive thermoreversible nasal delivery system (Mucoadhesive thermoreversible nasal delivery system). Journal of Pharmaceutical Research (J.Pharm.Res.) (2010) 3: 991-97]. Factors that affect the thermoreversible properties of the formulation are polymer concentration, molecular weight, transition temperature, hydration value, polymer morphology, crystalline state and polymerizability of the polymer, and phase separation of the polymer. [Same, cited Wanka, G. et al. The aggregation behavior of poly-(oxyethylene)-poly-(oxypropylene)-poly-(oxyethylene) block copolymers in aqueous solution. Colloid Polym. Sci. (19990) 268: 101-17]. Methylcellulose and HPMC form gels through hydrophobic interactions between methoxy substitutions. At lower temperatures, there are few polymer-polymer interactions; as the temperature increases, the polymer loses its hydration water and becomes a gel with low viscosity. After the polymer is fully dehydrated, association occurs between polymers and the overall polymer structure appears as an infinite gel network.
[0391] pH sensitive polymers. pH sensitive polymers have low viscosity under normal environmental conditions, but after nasal administration, they gel due to changes in pH in the local nasal mucosa. [Same, citing Shaikh, RP et al. A review of multi-responsive membranous systems for rate-modulated drug delivery. AAPS PharmaSciTech. (2010) 11: 441-59]. This enhances nasal residence time and nasal absorption. These polymers are also described as polyelectrolytes containing ionizable weak acid or weak base parts connected to a hydrophobic backbone in their structure. Polyacid polymers with acidic groups remain unswelled at low pH because the acidic groups of the polymer will be in protonated and unionized form. When the pH of the polymer environment increases, the negatively charged polymer will swell. In contrast, polypolymers swell at lower pH because the basic groups of the polymer will be in ionized form. Examples of pH-sensitive anionic polymers of weak polyacids are polycarboxylic acids such as polyacrylic acid (PAA) or polymethacrylic acid and polysulfonamides [ibid., citing Park, SY and Bae, YH, Novel pH-sensitive polymers containing sulfonamide groups. Macromol. Rapid Commun. (1999) 20: 269-73]. Depending on the electron-withdrawing nature of the substituents on nitrogen, the pKa of weak polyacids varies between 3 and 11. Examples of cationic pH-sensitive polyelectrolytes include poly(N,N-dialkylaminoethyl methacrylate), polylysine, polyethyleneimine and chitosan.
[0392] Mucoadhesive polymers. Nasal absorption of substances can be improved by prolonging the retention of particles in the nasal mucosa. In nasal active delivery, mucoadhesion involves the interaction between mucus secreted by the submucosal glands and mucoadhesive polymers [ibid., citing Salamat-Miller, N. et al. The use of mucoadhesive polymers in buccal drug delivery. Advanced Drug Delivery Reviews (2005) 57: 1666-91]. The sequential steps of mucoadhesion include (1) absorption of water from the mucus layer, resulting in polymer wetting and swelling; (2) as the polymer swells, hydrogen bonds between polymer chains dissociate, resulting in reduced polymer-polymer interactions and increased polymer-water interactions; the free polymer chains then penetrate the mucus [ibid., citing Ugwoke, ML et al. Nasal mucoadhesive drug delivery: background, applications, trends and future perspectives. Advanced Drug Delivery Reviews (2005) 57: 1640-65] and then interact with protein chains present in the nasal mucosa. As a result, the formulation is retained in the nasal cavity, resulting in an increased active concentration gradient across the epithelium. [ibid., citing Jimenez-Castellanos, MR et al. Mucoadhesive drug delivery systems. Drug. Dev. Ind. Pharm. (1993) 19: 143-94]. Exemplary mucoadhesive polymers include chitosan, alginate, and cellulose or derivatives thereof.
[0393] Ion-responsive polymers. In this category, the sol-to-gel transition is due to the presence of monovalent / divalent cations such as Na+, K+, Ca2+, and Mg2+. The most judiciously used polymers in this category are naturally occurring anionic polymers. Gellan gum, carrageenan, pectin, sodium alginate, and xyloglucan possess the property of cation-induced gelation.
[0394] [Same as above]
[0395] According to some embodiments, for intranasal delivery, the maximum amount is about 25 mg / dose administered at a tolerated frequency, for example, every 2, 5, 10, 15, 20, 30, 40, 50, or 60 minutes for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91 , 30 hours, 31 hours, 32 hours, 33 hours, 34 hours, 35 hours, 36 hours, 37 hours, 38 hours, 39 hours, 40 hours, 41 hours, 42 hours, 43 hours, 44 hours, 45 hours, 46 hours, 47 hours, 48 hours, 49 hours, 50 hours, 51 hours, 52 hours, 53 hours, 54 hours, 55 hours, 56 hours, 57 hours, 58 hours, 59 hours, 60 hours, 61 hours, 62 hours, 63 hours, 64 hours, 65 hours, 66 hours, 67 hours, 68 hours, 69 hours, 70 hours, 71 hours, 72 hours, etc.
[0396] According to some embodiments, and based on the HED from the mouse study reported in paragraph
[00635] in the following examples, the minimum daily dose for a 60 kg human (132 pounds) is 250 mg / day. According to some embodiments, the minimum daily dose for a 90 kg human (200 pounds) is 730 mg / day.
[0397] According to some embodiments, the dose time profile is determined such that the dose is administered at a tolerable given frequency (e.g., every 2, 5, 10, 15, 20, 30, 40, 50, or 60 minutes for at least 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, 18 hours, 19 hours, 20 hours, 21 hours, 22 hours, 23 hours, 24 hours, 25 hours, 26 hours, 27 hours, 28 hours, 29 hours, 30 hours, 31 hours, 32 hours, 33 hours, 34 hours, 35 hours, 36 hours, 37 hours, 38 hours, 39 hours, 40 hours, 41 hours, 42 hours, 43 hours, 44 hours, 45 hours, 46 hours, 47 hours, 48 hours, 49 hours, 50 hours, or 51 hours). The desired effective amount is achieved with a maximum of 25 mg / dose delivered intranasally (at least 20 hours, 21 hours, 22 hours, 23 hours or 24 hours for at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 7 days, at least 8 days, at least 9 days, at least 10 days, at least 11 days, at least 12 days, at least 13 days, at least 14 days, at least 15 days, at least 16 days, at least 17 days, at least 18 days, at least 19 days, at least 20 days, at least 21 days).
[0398] According to some embodiments, within 1 minute, within 5 minutes, within 10 minutes, within 15 minutes, within 30 minutes, within 45 minutes, within 1 hour, within 2 hours, within 3 hours, within 4 hours, within 5 hours, within 6 hours, within 7 hours, within 8 hours, within 9 hours, within 10 hours, within 11 hours, within 12 hours, within 13 hours, within 14 hours, within 15 hours, within 16 hours, within 17 hours, within 18 hours, within 19 hours, within 20 hours, within 21 hours, within 22 hours, within 23 hours, within 24 hours, within 1 day, within 2 days, within 3 days, within 4 days, within 5 days, within 6 days, within 7 days before participating in an event for which acquired brain injury is a known risk Intranasal delivery within 1 day, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, etc. and for at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 7 days, at least 8 days, at least 9 days, at least 10 days, at least 11 days, at least 12 days, at least 13 days, at least 14 days, at least 15 days, at least 16 days, at least 17 days, at least 18 days, at least 19 days, at least 20 days, at least 21 days, etc. after participation in an event where acquired brain injury is a known risk is neuroprotective. According to some embodiments, the event is a military operation. According to some embodiments, the event is a sporting event. According to some embodiments, the sporting event is, for example, hockey, football, soccer, baseball, polo, rugby, equestrianism, racing, gymnastics, mountaineering, basketball, mixed martial arts, Brazilian Jiu-Jitsu, Muay Thai, taekwondo, kickboxing, boxing, wrestling, lacrosse, softball, cheerleading, volleyball, beach volleyball, alpine skiing, water skiing, wakeboarding, snowboarding, skateboarding, kayaking, handball, cycling, mountain biking, barrel racing, bull riding, base jumping, skydiving, paragliding, tennis, squash, BMX, motocross, surfing, bobsleigh, luge, skeleton, ball game, plate hockey, camochie, cricket, diving, field hockey, figure skating, speed skating, sailing, ski jumping, ultimate Frisbee, water polo, or windsurfing. Other applications include emergency medicine, such as use by EMTs or emergency rooms in the context of emergencies such as domestic violence, falls, car accidents, etc.
[0399] According to some embodiments, incorporating the D-β-hydroxybutyrate into a polymer carrier can achieve controlled release, including delayed release and sustained release.
[0400] According to some embodiments, the D-beta hydroxybutyrate is bound to HCA2.
[0401] According to some embodiments, the composition can increase brain D-β-hydroxybutyrate levels, e.g., to about 0.1-3 mmol / L or about 0.1-1 mmol / L, for at least 6 hours to at least 48 hours (inclusive), i.e., at least 6 hours, at least 7 hours, at least 8 hours, at least 9 hours, at least 10 hours, at least 11 hours, at least 12 hours, at least 13 hours, at least 14 hours, at least 15 hours, at least 16 hours, at least 17 hours, at least 18 hours, at least 19 hours, at least 20 hours, at least 21 hours, at least 22 hours, at least 23 hours, at least 24 hours, at least 25 hours, at least 26 hours, at least 27 hours, at least 28 hours, at least 29 hours, at least 30 hours, at least 31 hours, at least 32 hours, at least 33 hours, at least 34 hours, at least 35 hours, at least 36 hours, at least 37 hours, at least 38 hours, at least 39 hours, at least 40 hours, at least 41 hours, at least 42 hours, at least 43 hours, at least 44 hours, at least 45 hours, at least 46 hours, at least 47 hours, at least 48 hours, at least 49 hours, at least 50 hours, at least 51 hours, at least 52 hours, at least 53 hours, at least 54 hours, at least 55 hours, at least 56 hours, at least 57 hours, at least 58 hours, at least 59 hours, Hours, at least 22 hours, at least 23 hours, at least 24 hours, at least 25 hours, at least 26 hours, at least 27 hours, at least 28 hours, at least 29 hours, at least 30 hours, at least 31 hours, at least 32 hours, at least 33 hours, at least 34 hours, at least 35 hours, at least 36 hours, at least 37 hours, at least 38 hours, at least 39 hours, at least 40 hours, at least 41 hours, at least 42 hours, at least 43 hours, at least 44 hours, at least 45 hours, at least 46 hours, at least 47 hours, and at least 48 hours.
[0402] According to another aspect, the present disclosure provides a method for promoting brain healing after traumatic brain injury including neuroinflammation, the method comprising: formulating a composition comprising an active ingredient as a suspension of particles, the particles comprising a biodegradable polymer, the biodegradable polymer containing an effective amount of the active ingredient; administering the composition comprising the active ingredient to a subject, wherein the active ingredient is D-β-hydroxybutyrate; and targeting the composition to the brain; wherein healing comprises reducing neuroinflammation.
[0403] According to some embodiments, administration is performed orally or intranasally.
[0404] According to some embodiments, when delivered orally, the effective amount of exogenous synthetic D-β-hydroxybutyrate can range from at least 500 mg to 100 g (inclusive), i.e., at least 500 mg, at least 500 mg, 600 mg, 700 mg, 800 mg, 900 mg, 1 g, 2 g, 3 g, 4 g, 5 g, 6 g, 7 g, 8 g, 9 g, 10 g, 11 g, 12 g, 13 g, 14 g, 15 g, 16 g, 17 g, 18 g, 19 g, 20 g , 21g, 22g, 23g, 24g, 25g, 26g, 27g, 28g, 29g, 30g, 31g, 32g, 33g, 34g, 35g, 36g, 37g, 38g, 39g, 40g, 41g , 42g, 43g, 44g, 45g, 46g, 47g, 48g, 49g, 50g, 51g, 52g, 53g, 54g, 55g, 56g, 57g, 58g, 59g, 60g, 61g, 62g, 63g, 64g, 65g, 66g, 67g, 68g, 69g, 70g, 71g, 72g, 73g, 74g, 75g, 76g, 77g, 78g, 79g, 80g, 81g, 82g, 83g, 84g, 85g, 86g, 87g, 88g, 89g, 90g, 91g, 92g, 93g, 94g, 95g, 96g, 97g, 98g, 99g or 100g, or can be 10g-50g (including end 48g, 49g, 50g, 51g, 52g, 53g, 54g, 55g, 56g, 57g, 58g, 59g, 60g, 61g, 62g, 63g, 64g, 65g, 66g, 67g, 68g, 69g, 70g, 71g, 72g, 73g, 74g, 75g, 76g, 77g, 78g, 79g, 80g, 81g, 82g, 83g, 84g, 85g, 86g, 87g, 88g, 89g, 90g, 91g, 92g, 93g, 94g, 95g, 96g, 97g, 98g
[0405] According to some embodiments, for intranasal delivery, the minimum effective amount is, for example, up to about 25 mg / dose administered at a tolerable frequency every 2 minutes, 5 minutes, 10 minutes, 15 minutes, 20 minutes, 30 minutes, 40 minutes, 50 minutes for 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, 18 hours, 19 hours, 20 hours, 21 hours, 22 hours, 23 hours, 24 hours, 25 hours, 26 hours, 27 hours, 28 hours, 29 hours, 30 hours, 31 hours, 32 hours, 33 hours, 34 hours, 35 hours, Hours, 36 hours, 37 hours, 38 hours, 39 hours, 40 hours, 41 hours, 42 hours, 43 hours, 44 hours, 45 hours, 46 hours, 47 hours, 48 hours, 49 hours, 50 hours, 51 hours, 52 hours, 53 hours, 54 hours, 55 hours, 56 hours, 57 hours, 58 hours, 59 hours, 60 hours, 61 hours, 62 hours, 63 hours, 64 hours, 65 hours, 66 hours, 67 hours, 68 hours, 69 hours, 70 hours, 71 hours, 72 hours, etc. to achieve a minimum daily dose ranging from about 85 mg / day (e.g., for a child weighing about 45 pounds) to about 800 mg / day (e.g., for an adult), inclusive. , i.e. at least about 85 mg / day; about 95 mg / day; about 105 mg / day, about 115 mg / day; about 125 mg / day; about 135 mg / day; about 145 mg / day; about 155 mg / day; about 165 mg / day; about 175 mg / day; about 185 mg / day; about 195 mg / day; about 205 mg / day; about 215 mg / day; about 225 mg / day; about 235 mg / day; about 245 mg / day; about 255 mg / day; about 265 mg / day; about 275 mg / day; about 285 mg / day; about 295 mg / day; about 305 mg / day; about 315 mg / day; about 325 mg / day; about 335 mg / day; about 345 mg / day; about 35 5mg / day; about 365mg / day; about 375mg / day; about 385mg / day; about 395mg / day; about 405mg / day; about 415mg / day; about 425mg / day; about 435mg / day; about 445mg / day; about 455mg / day; about 465mg / day; about 475mg / day; about 485mg / day; about 495mg / day; about 505mg / day; about 515mg / day; about 525mg / day; about 535mg / day; about 545mg / day; about 555mg / day; about 565mg / day; about 575mg / day; about 585mg / day; about 595mg / day; about 605mg / day; about 615mg / day; about 625mg / day;about 635 mg / day; about 645 mg / day; about 655 mg / day; about 665 mg / day; about 675 mg / day; about 685 mg / day; about 695 mg / day; about 705 mg / day; about 715 mg / day; about 725 mg / day; about 735 mg / day; about 745 mg / day; about 755 mg / day; about 765 mg / day; about 775 mg / day; about 785 mg / day; about 795 mg / day; or about 800 mg / day. ;
[0406] According to some embodiments, and based on the human equivalent dose (HED) from the mouse study reported in the following paragraph
[00635] , the minimum daily dose for a 60 kg person (132 pounds) is 250 mg / day. According to some embodiments, the minimum daily dose for a 90 kg person (200 pounds) is 730 mg / day.
[0407] According to some embodiments, the dose-time profile is determined so that the desired effective amount is achieved at a maximum of 25 mg / dose delivered intranasally that can be tolerated at a given frequency (e.g., every 2, 5, 10, 15, 20, 30, 40, 50, or 60 minutes for at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 7 days, at least 8 days, at least 9 days, at least 10 days, at least 11 days, at least 12 days, at least 13 days, at least 14 days, at least 15 days, at least 16 days, at least 17 days, at least 18 days, at least 19 days, at least 20 days, at least 21 days, etc.).
[0408] According to some embodiments, at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 7 days, at least 8 days, at least 9 days, at least 10 days, at least 11 days, at least 12 days, at least 13 days, at least 14 days, at least 15 days, at least 16 days, at least 17 days, at least 18 days, at least 19 days, at least 20 days, at least 21 days, etc. before participation in an event for which acquired brain injury is a known risk and at least 1 day after participation in an event for which acquired brain injury is a known risk , at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 7 days, at least 8 days, at least 9 days, at least 10 days, at least 11 days, at least 12 days, at least 13 days, at least 14 days, at least 15 days, at least 16 days, at least 17 days, at least 18 days, at least 19 days, at least 20 days, at least 21 days, etc. Every 2 minutes, 5 minutes, 10 minutes, 15 minutes, 20 minutes, 30 minutes, 40 minutes, 50 minutes or 60 minutes of intranasal delivery is neuroprotective. According to some embodiments, the event is a military action. According to some embodiments, the event is a sporting event. According to some embodiments, the sporting event is, for example, hockey, football, soccer, baseball, polo, rugby, equestrianism, racing, motorsports, skiing, gymnastics, mountaineering, basketball, mixed martial arts, Brazilian Jiu-Jitsu, Muay Thai, taekwondo, kickboxing, boxing, wrestling, lacrosse, softball, cheerleading, volleyball, beach volleyball, alpine skiing, water skiing, wakeboarding, snowboarding, skateboarding, kayaking, handball, cycling, mountain biking, barrel racing, bull riding, base jumping, skydiving, paragliding, tennis, squash, BMX, motocross, surfing, bobsleigh, luge, skeleton, ball game, lacrosse, camochie, cricket, diving, field hockey, figure skating, speed skating, sailing, ski jumping, ultimate Frisbee, water polo, or windsurfing. Other applications include emergency medicine, such as use by EMTs or emergency rooms in the context of emergencies such as domestic violence, falls, car accidents, etc.
[0409] According to some embodiments, the composition can increase brain D-β-hydroxybutyrate levels, for example to about 0.1-3 mmol / L (inclusive) or about 0.1-1 mmol / L (inclusive) when delivered intranasally, for at least 6 hours to at least 48 hours (inclusive), i.e., at least 6 hours, at least 7 hours, at least 8 hours, at least 9 hours, at least 10 hours, at least 11 hours, at least 12 hours, at least 13 hours, at least 14 hours, at least 15 hours, at least 16 hours, at least 17 hours, at least 18 hours, at least 19 hours, at least 20 hours. Hours, at least 21 hours, at least 22 hours, at least 23 hours, at least 24 hours, at least 25 hours, at least 26 hours, at least 27 hours, at least 28 hours, at least 29 hours, at least 30 hours, at least 31 hours, at least 32 hours, at least 33 hours, at least 34 hours, at least 35 hours, at least 36 hours, at least 37 hours, at least 38 hours, at least 39 hours, at least 40 hours, at least 41 hours, at least 42 hours, at least 43 hours, at least 44 hours, at least 45 hours, at least 46 hours, at least 47 hours, and at least 48 hours.
[0410] According to some embodiments, the β-hydroxybutyrate is soluble in water.
[0411] According to some embodiments, the size of the particle is greater than 10 nm in diameter, greater than 15 nm in diameter, greater than 20 nm in diameter, greater than 30 nm in diameter, greater than 40 nm in diameter, greater than 50 nm in diameter, greater than 60 nm in diameter, greater than 70 nm in diameter, greater than 80 nm in diameter, greater than 90 nm in diameter, greater than 100 nm, greater than 200 nm, greater than 300 nm, greater than 400 nm, greater than 500 nm, greater than 600 nm, greater than 700 nm, greater than 800 nm, greater than 900 nm, greater than 1000 nm, greater than 2000 nm, greater than 3000 nm, greater than 4000 nm, greater than 5000 nm, greater than 6000 nm, greater than 7000 nm, greater than 8000 nm, greater than 9000 nm, greater than 10,000 nm, etc. [See, e.g., Ohta, S. et al. Study on the optimal size of nanoparticle delivery to the brain assisted by focused ultrasound-induced blood-brain barrier opening. Scientific Reports (2020) 18220].
[0412] According to some embodiments, the D-β-hydroxybutyrate is dispersed throughout the particle; or the particle is impregnated with the D-β-hydroxybutyrate; or the particle comprises a matrix, and the matrix comprises the D-β-hydroxybutyrate.
[0413] According to some embodiments, a portion of the D-β hydroxybutyrate is adsorbed or weakly bound to the surface of the microparticles and facilitates a rapid initial release or burst release.
[0414] According to some embodiments, the particles have any order release kinetics, including zero order release, first order release, second order release, delayed release, sustained release, immediate release, long-term release, or a combination thereof.
[0415] According to some embodiments, release of the D-β-hydroxybutyrate from the particles is by diffusion, erosion, or both.
[0416] According to another aspect, the present disclosure provides a method for promoting brain health, comprising formulating a composition comprising a suspension of particles, the particles comprising a biodegradable polymer, the biodegradable polymer comprising an effective amount of a pharmaceutical agent; and administering the composition comprising an active ingredient to a subject, wherein the pharmaceutical agent is synthetic D-β-hydroxybutyrate; and targeting the composition to the brain, wherein burst release and controlled release of the synthetic D-β-hydroxybutyrate f can produce an effective amount of D-β-hydroxybutyrate levels in the brain.
[0417] According to some embodiments, administration is performed orally or intranasally.
[0418] According to some embodiments, when delivered orally, the effective amount of exogenous synthetic D-β-hydroxybutyrate can range from at least 500 mg to 100 g (inclusive), i.e., at least 500 mg, at least 500 mg, 600 mg, 700 mg, 800 mg, 900 mg, 1 g, 2 g, 3 g, 4 g, 5 g, 6 g, 7 g, 8 g, 9 g, 10 g, 11 g, 12 g, 13 g, 14 g, 15 g, 16 g, 17 g, 18 g, 19 g, 20 g , 21g, 22g, 23g, 24g, 25g, 26g, 27g, 28g, 29g, 30g, 31g, 32g, 33g, 34g, 35g, 36g, 37g, 38g, 39g, 40g, 41g , 42g, 43g, 44g, 45g, 46g, 47g, 48g, 49g, 50g, 51g, 52g, 53g, 54g, 55g, 56g, 57g, 58g, 59g, 60g, 61g, 62g, 63g, 64g, 65g, 66g, 67g, 68g, 69g, 70g, 71g, 72g, 73g, 74g, 75g, 76g, 77g, 78g, 79g, 80g, 81g, 82g, 83g, 84g, 85g, 86g, 87g, 88g, 89g, 90g, 91g, 92g, 93g, 94g, 95g, 96g, 97g, 98g, 99g or 100g, or can be 10g-50g (including end 47g, 48g, 49g, 50g, 51g, 52g, 53g, 54g, 55g, 56g, 57g, 58g, 59g, 60g, 61g, 62g, 63g, 64g, 65g, 66g, 67g, 68g, 69g, 70g, 71g, 72g, 73g, 74g, 75g, 76g, 77g, 78g, 79g, 80g, 81g, 82g, 83g, 84g, 85g, 86g, 87g, 88g, 89g, 90g, 91g, 92g, 93g, 94g,
[0419] According to some embodiments, when delivered intranasally, a maximum dose of 25 mg / dose is administered at a tolerated frequency, for example, every 2, 5, 10, 15, 20, 30, 40, or 50 minutes for at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91 , 37 hours, 38 hours, 39 hours, 40 hours, 41 hours, 42 hours, 43 hours, 44 hours, 45 hours, 46 hours, 47 hours, 48 hours, 49 hours, 50 hours, 51 hours, 52 hours, 53 hours, 54 hours, 55 hours, 56 hours, 57 hours, 58 hours, 59 hours, 60 hours, 61 hours, 62 hours, 63 hours, 64 hours, 65 hours, 66 hours, 67 hours, 68 hours, 69 hours, 70 hours, 71 hours, 72 hours, etc., to achieve a minimum daily dose ranging from about 85 mg / day (e.g., for a child weighing about 45 pounds) to about 800 mg / day (e.g., for an adult), inclusive, i.e., at least about 8 5mg / day; about 95mg / day; about 105mg / day, about 115mg / day; about 125mg / day; about 135mg / day; about 145mg / day; about 155mg / day; about 165mg / day; about 175mg / day; about 185mg / day; about 195mg / day; about 205mg / day; about 215mg / day; about 225mg / day; about 235mg / day; about 245mg / day; about 255mg / day; about 265mg / day; about 275mg / day; about 285mg / day; about 295mg / day; about 305mg / day; about 315mg / day; about 325mg / day; about 335mg / day; about 345mg / day; about 355mg / day; about 3 65 mg / day; about 375 mg / day; about 385 mg / day; about 395 mg / day; about 405 mg / day; about 415 mg / day; about 425 mg / day; about 435 mg / day; about 445 mg / day; about 455 mg / day; about 465 mg / day; about 475 mg / day; about 485 mg / day; about 495 mg / day; about 505 mg / day; about 515 mg / day; about 525 mg / day; about 535 mg / day; about 545 mg / day; about 555 mg / day; about 565 mg / day; about 575 mg / day; about 585 mg / day; about 595 mg / day; about 605 mg / day; about 615 mg / day; about 625 mg / day; about 635 mg / day;about 645 mg / day; about 655 mg / day; about 665 mg / day; about 675 mg / day; about 685 mg / day; about 695 mg / day; about 705 mg / day; about 715 mg / day; about 725 mg / day; about 735 mg / day; about 745 mg / day; about 755 mg / day; about 765 mg / day; about 775 mg / day; about 785 mg / day; about 795 mg / day; or about 800 mg / day. ;
[0420] According to some embodiments, and based on the HED from the mouse study reported in the following paragraph
[00635] , the minimum daily dose for a 60 kg human (132 pounds) is 250 mg / day. According to some embodiments, the minimum daily dose for a 90 kg human (200 pounds) is 730 mg / day.
[0421] According to some embodiments, the dose-time profile is determined so that the desired effective amount is achieved at a maximum of 25 mg / dose delivered intranasally that can be tolerated at a given frequency (e.g., every 2, 5, 10, 15, 20, 30, 40, 50, or 60 minutes for at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 7 days, at least 8 days, at least 9 days, at least 10 days, at least 11 days, at least 12 days, at least 13 days, at least 14 days, at least 15 days, at least 16 days, at least 17 days, at least 18 days, at least 19 days, at least 20 days, at least 21 days, etc.).
[0422] According to some embodiments, within 1 minute, within 5 minutes, within 10 minutes, within 15 minutes, within 30 minutes, within 45 minutes, within 1 hour, within 2 hours, within 3 hours, within 4 hours, within 5 hours, within 6 hours, within 7 hours, within 8 hours, within 9 hours, within 10 hours, within 11 hours, within 12 hours, within 13 hours, within 14 hours, within 15 hours, within 16 hours, within 17 hours, within 18 hours, within 19 hours, within 20 hours, within 21 hours, within 22 hours, within 23 hours, within 24 hours, within 1 day, within 2 days, within 3 days, within 4 days, within 5 days, within 6 days, within 7 days before participating in an event for which acquired brain injury is a known risk Intranasal delivery within 1 day, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, etc. and for at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 7 days, at least 8 days, at least 9 days, at least 10 days, at least 11 days, at least 12 days, at least 13 days, at least 14 days, at least 15 days, at least 16 days, at least 17 days, at least 18 days, at least 19 days, at least 20 days, at least 21 days, etc. after participation in an event where acquired brain injury is a known risk is neuroprotective. According to some embodiments, the event is a military operation. According to some embodiments, the event is a sporting event. According to some embodiments, the sporting event is, for example, hockey, football, soccer, baseball, polo, rugby, equestrianism, racing, motorsports, skiing, gymnastics, mountaineering, basketball, mixed martial arts, Brazilian Jiu-Jitsu, Muay Thai, taekwondo, kickboxing, boxing, wrestling, lacrosse, softball, cheerleading, volleyball, beach volleyball, alpine skiing, water skiing, wakeboarding, snowboarding, skateboarding, kayaking, handball, cycling, mountain biking, barrel racing, bull riding, base jumping, skydiving, paragliding, tennis, squash, BMX, motocross, surfing, bobsleigh, luge, skeleton, ball game, lacrosse, camochie, cricket, diving, field hockey, figure skating, speed skating, sailing, ski jumping, ultimate Frisbee, water polo, or windsurfing. Other applications include emergency medicine, such as use by EMTs or emergency rooms in the context of emergencies such as domestic violence, falls, car accidents, etc.
[0423] According to some embodiments, the composition can increase brain D-β-hydroxybutyrate levels, for example to about 0.1-3 mmol / L (inclusive) or about 0.1-1 mmol / L (inclusive) when delivered intranasally, for at least 6 hours to at least 48 hours (inclusive), i.e., at least 6 hours, at least 7 hours, at least 8 hours, at least 9 hours, at least 10 hours, at least 11 hours, at least 12 hours, at least 13 hours, at least 14 hours, at least 15 hours, at least 16 hours, at least 17 hours, at least 18 hours, at least 19 hours, at least 20 hours. Hours, at least 21 hours, at least 22 hours, at least 23 hours, at least 24 hours, at least 25 hours, at least 26 hours, at least 27 hours, at least 28 hours, at least 29 hours, at least 30 hours, at least 31 hours, at least 32 hours, at least 33 hours, at least 34 hours, at least 35 hours, at least 36 hours, at least 37 hours, at least 38 hours, at least 39 hours, at least 40 hours, at least 41 hours, at least 42 hours, at least 43 hours, at least 44 hours, at least 45 hours, at least 46 hours, at least 47 hours, and at least 48 hours.
[0424] According to some embodiments, the size of the particle is greater than 10 nm in diameter, greater than 15 nm in diameter, greater than 20 nm in diameter, greater than 30 nm in diameter, greater than 40 nm in diameter, greater than 50 nm in diameter, greater than 60 nm in diameter, greater than 70 nm in diameter, greater than 80 nm in diameter, greater than 90 nm in diameter, greater than 100 nm, greater than 200 nm, greater than 300 nm, greater than 400 nm, greater than 500 nm, greater than 600 nm, greater than 700 nm, greater than 800 nm, greater than 900 nm, greater than 1000 nm, greater than 2000 nm, greater than 3000 nm, greater than 4000 nm, greater than 5000 nm, greater than 6000 nm, greater than 7000 nm, greater than 8000 nm, greater than 9000 nm, greater than 10,000 nm, or the like. [See, e.g., Ohta, S. et al. Study on the optimal size of nanoparticle delivery to the brain assisted by focused ultrasound-induced blood-brain barrier opening. Scientific Reports (2020) 18220].
[0425] According to some embodiments, the D-β-hydroxybutyrate is dispersed throughout the particle; or the particle is impregnated with the D-β-hydroxybutyrate; or the particle comprises a matrix, and the matrix comprises the D-β-hydroxybutyrate.
[0426] According to some embodiments, a portion of the D-β hydroxybutyrate is adsorbed or weakly bound to the surface of the microparticles and facilitates a rapid initial release or burst release.
[0427] According to some embodiments, the particles have any order release kinetics, including zero order release, first order release, second order release, delayed release, sustained release, immediate release, long-term release, or a combination thereof.
[0428] According to some embodiments, release of the D-β-hydroxybutyrate from the particles is by diffusion, erosion, or both.
[0429] Pharmaceutical composition
[0430] According to another aspect, the present disclosure provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutic amount of an API, wherein the API is synthetic D-β-hydroxybutyrate (BHB), wherein the targeted delivery is to the olfactory region of the nasal cavity, and wherein the targeted delivery achieves a therapeutically effective amount of the API in the brain.
[0431] According to some embodiments, the pharmaceutical composition comprises an active substance formulated as a solution, a suspension, or a dispersion. According to some embodiments, the API is formulated as a solution. According to some embodiments, the API is formulated as a suspension. According to some embodiments, the API is formulated as a suspension, wherein the suspension comprises a particle size distribution of a population of particles comprising the API. According to some embodiments, the API is formulated as a dispersion. According to some embodiments, the API is formulated as a dispersion, wherein the dispersion comprises a particle size distribution of a population of particles comprising the API.
[0432] According to some embodiments, the pharmaceutical composition comprises a liquid spray formulation or a dry powder formulation.
[0433] According to some embodiments, the pharmaceutical composition comprises a liquid spray formulation of the API. According to some embodiments, the pharmaceutical composition is delivered as a liquid spray comprising a droplet size distribution comprising droplets comprising the API.
[0434] According to some embodiments, the pharmaceutical composition comprises a dry powder formulation. According to some embodiments, the dry powder formulation, when aerosolized, comprises a cloud of very fine particles comprising the API.
[0435] According to some embodiments, the formulation is formulated with an excipient. According to some embodiments, the excipient maximizes the solubility of the API. According to some embodiments, the excipient enhances the adhesion of the API to the nasal mucosa in the olfactory region. According to some embodiments, the enhanced adhesion enhances the absorption of the API in the nasal mucosa.
[0436] According to some embodiments, the nasal aerosol comprises a formulation, a container, a valve, an actuator, a dust cap, associated accessories and protective packaging, which together constitute the drug product. For insufflation administration, for example, the pharmaceutical composition according to the invention as described can be conveniently delivered from a pressurized package in the form of an aerosol spray presentation using a suitable propellant (e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas). In the case of a pressurized aerosol, the dosage unit can be determined by providing a valve for delivering a metered amount. Capsules and cartridges (e.g., gelatin) for insufflators can be formulated to contain a powder mix of the active compound and a suitable powder base (such as lactose or starch).
[0437] According to some embodiments, the formulation is filled in a unit dose device. According to some devices, the formulation is filled in a multi-dose device. According to some embodiments, exemplary devices include a spray pump and a metered dose inhaler. According to some embodiments, the liquid formulation is filled in a spray pump (an exemplary device for delivering intranasal formulations). According to some embodiments, the dry powder formulation is filled in a dry powder device, which includes a formulation of an active agent and a container closure system.
[0438] For example, a typical nasal spray formulation consists of an active agent suspended or dissolved in an aqueous medium that is filled into a bottle with a metered spray pump. Pump actuation by the subject delivers drug-laden droplets into the nasal cavity. The role of the pump, which is an integral part of the overall assembly, is to atomize and deliver an accurate dose of the drug.
[0439] Most nasal spray pumps produce droplets containing therapeutic amounts of API in the range of about 20 μm to about 120 μm, inclusive (i.e., about 20 μm, about 25 μm, about 30 μm, about 35 μm, about 40 μm, about 45 μm, about 50 μm, 55 μm, about 60 μm, about 65 μm, about 70 μm, about 75 μm, about 80 μm, about 85 μm, about 90 μm, about 95 μm, about 100 μm, about 105 μm, about 110 μm, about 115 μm, or about 120 μm) [Yu, G. et al. Fluid flow and particle diffusion in the human upper respiratory system. Aerosol Science and Technology. Technol.) (1998) 28: 146-58], so that the droplet size allows the droplets to be deposited in the olfactory area of the nasal cavity to deliver the API to the brain. If the droplet size is too fine (<10 μm), there is a possibility that the droplets will pass through the nasal passages and deposit in the lungs. If the droplet size is too large, the spray may be trapped in the nostrils. Laser diffraction techniques can measure the size of the droplets by measuring the intensity of light scattered by the particles as a function of angle to determine the droplet size for a given device and formulation.
[0440] In evaluating the performance of a pump, the characteristics of the spray plume ejected are considered important. According to some embodiments, the pump performance is characterized by the spray pattern and plume geometry of the plume ejected by the delivery device. During the very early life of an aqueous nasal spray plume, the formulation may exit the actuator orifice in the form of a narrow stream, which then forms a relatively stable, fully expanded conical plume before separating from the orifice. The term "plume geometry" describes a side view of an aerosol cloud parallel to the axis of the plume. According to some embodiments, the measurement of the plume geometry includes an image taken from the side of the plume perpendicular to a laser sheet aligned with the expected central plume axis. According to some embodiments, the measurement of the plume geometry is performed by flash illumination of the plume with photographic image capture. According to some embodiments, the plume geometry is characterized by the spray angle and the plume width.
[0441] According to some embodiments, the pharmaceutical composition includes a formulation comprising a distribution of particles containing an API. According to some embodiments, the diameter of the majority of the particle distribution ranges from about 25 μm to about -40 μm (including the end value), i.e., about 25 μm, about 26 μm, about 27 μm, about 28 μm, about 29 μm, about 30 μm, about 31 μm, about 32 μm, about 333, about 34 μm, about 35 μm, about 36 μm, about 37 μm, about 38 μm, about 39 μm or about 40 μm. According to some embodiments, the particle distribution is depleted of smaller particles that would otherwise enter the lungs.
[0442] According to some embodiments, a viscosity enhancer / mucoadhesive polymer (e.g., microcrystalline cellulose, sodium carboxymethylcellulose, hydroxypropyl methylcellulose, or a combination thereof) may be added to the formulation in an amount of 0.1%, 0.2%, 0.3%, 1%, or 2% by weight or by volume of the formulation to increase the absorption of the API in the nasal mucosa of the olfactory region of the nasal cavity. According to some embodiments, the viscosity of each nasal spray formulation will be measured. According to some embodiments, the spray pattern and plume geometry of each nasal spray formulation will be measured. According to some embodiments, the droplet size distribution of each nasal spray is determined to determine the median (Dv50), 10th percentile (Dv10), and 90th percentile (Dv90) of the cumulative distribution of the undersize.
[0443] According to some embodiments, for intranasal delivery, up to about 25 mg / dose is administered at a tolerable frequency, for example, every 2, 5, 10, 15, 20, 30, 40, 50, or 60 minutes for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91 Hours, 37 hours, 38 hours, 39 hours, 40 hours, 41 hours, 42 hours, 43 hours, 44 hours, 45 hours, 46 hours, 47 hours, 48 hours, 49 hours, 50 hours, 51 hours, 52 hours, 53 hours, 54 hours, 55 hours, 56 hours, 57 hours, 58 hours, 59 hours, 60 hours, 61 hours, 62 hours, 63 hours, 64 hours, 65 hours, 66 hours, 67 hours, 68 hours, 69 hours, 70 hours, 71 hours, 72 hours, etc., to achieve a minimum daily dose ranging from about 85 mg / day (e.g., for a child weighing about 45 pounds) to about 800 mg / day (e.g., for an adult), inclusive, i.e., at least about 85mg / day; about 95mg / day; about 105mg / day, about 115mg / day; about 125mg / day; about 135mg / day; about 145mg / day; about 155mg / day; about 165mg / day; about 175mg / day; about 185mg / day; about 195mg / day; about 205mg / day; about 215mg / day; about 225mg / day; about 235mg / day; about 245mg / day; about 255mg / day; about 265mg / day; about 275mg / day; about 285mg / day; about 295mg / day; about 305mg / day; about 315mg / day; about 325mg / day; about 335mg / day; about 345mg / day; about 355mg / day; about 365 mg / day; about 375 mg / day; about 385 mg / day; about 395 mg / day; about 405 mg / day; about 415 mg / day; about 425 mg / day; about 435 mg / day; about 445 mg / day; about 455 mg / day; about 465 mg / day; about 475 mg / day; about 485 mg / day; about 495 mg / day; about 505 mg / day; about 515 mg / day; about 525 mg / day; about 535 mg / day; about 545 mg / day; about 555 mg / day; about 565 mg / day; about 575 mg / day; about 585 mg / day; about 595 mg / day; about 605 mg / day; about 615 mg / day; about 625 mg / day; about 635 mg / day;about 645 mg / day; about 655 mg / day; about 665 mg / day; about 675 mg / day; about 685 mg / day; about 695 mg / day; about 705 mg / day; about 715 mg / day; about 725 mg / day; about 735 mg / day; about 745 mg / day; about 755 mg / day; about 765 mg / day; about 775 mg / day; about 785 mg / day; about 795 mg / day; or about 800 mg / day. ;
[0444] According to some embodiments, and based on the human equivalent dose (HED) from the mouse study reported in the following paragraph
[00635] , the minimum daily dose for a 60 kg person (132 pounds) is 250 mg / day. According to some embodiments, the minimum daily dose for a 90 kg person (200 pounds) is 730 mg / day.
[0445] According to some embodiments, the dose-time profile is determined so that the desired effective amount is achieved at a maximum of 25 mg / dose delivered intranasally that can be tolerated at a given frequency (e.g., every 2, 5, 10, 15, 20, 30, 40, 50, or 60 minutes for at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 7 days, at least 8 days, at least 9 days, at least 10 days, at least 11 days, at least 12 days, at least 13 days, at least 14 days, at least 15 days, at least 16 days, at least 17 days, at least 18 days, at least 19 days, at least 20 days, at least 21 days, etc.).
[0446] According to some embodiments, within 1 minute, within 5 minutes, within 10 minutes, within 15 minutes, within 30 minutes, within 45 minutes, within 1 hour, within 2 hours, within 3 hours, within 4 hours, within 5 hours, within 6 hours, within 7 hours, within 8 hours, within 9 hours, within 10 hours, within 11 hours, within 12 hours, within 13 hours, within 14 hours, within 15 hours, within 16 hours, within 17 hours, within 18 hours, within 19 hours, within 20 hours, within 21 hours, within 22 hours, within 23 hours, within 24 hours, within 1 day, within 2 days, within 3 days, within 4 days, within 5 days, within 6 days, within 7 days before participating in an event for which acquired brain injury is a known risk Intranasal delivery within 1 day, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, etc. and for at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 7 days, at least 8 days, at least 9 days, at least 10 days, at least 11 days, at least 12 days, at least 13 days, at least 14 days, at least 15 days, at least 16 days, at least 17 days, at least 18 days, at least 19 days, at least 20 days, at least 21 days, etc. after participation in an event where acquired brain injury is a known risk is neuroprotective. According to some embodiments, the event is a military operation. According to some embodiments, the event is a sporting event. According to some embodiments, the sporting event is, for example, hockey, football, soccer, baseball, polo, rugby, equestrianism, racing, motorsports, skiing, gymnastics, mountaineering, basketball, mixed martial arts, Brazilian Jiu-Jitsu, Muay Thai, taekwondo, kickboxing, boxing, wrestling, lacrosse, softball, cheerleading, volleyball, beach volleyball, alpine skiing, water skiing, wakeboarding, snowboarding, skateboarding, kayaking, handball, cycling, mountain biking, barrel racing, bull riding, base jumping, skydiving, paragliding, tennis, squash, BMX, motocross, surfing, bobsleigh, luge, skeleton, ball game, lacrosse, camochie, cricket, diving, field hockey, figure skating, speed skating, sailing, ski jumping, ultimate Frisbee, water polo, or windsurfing. Other applications include emergency medicine, such as use by EMTs or emergency rooms in the context of emergencies such as domestic violence, falls, car accidents, etc.
[0447] According to some embodiments, incorporating the D-β-hydroxybutyrate into a polymer carrier can achieve controlled release, including delayed release and sustained release.
[0448] According to some embodiments, the D-beta hydroxybutyrate is bound to HCA2.
[0449] According to some embodiments, the composition can increase brain D-β-hydroxybutyrate levels, e.g., to about 0.1-3 mmol / L or about 0.1-1 mmol / L, for at least 6 hours to at least 48 hours (inclusive), i.e., at least 6 hours, at least 7 hours, at least 8 hours, at least 9 hours, at least 10 hours, at least 11 hours, at least 12 hours, at least 13 hours, at least 14 hours, at least 15 hours, at least 16 hours, at least 17 hours, at least 18 hours, at least 19 hours, at least 20 hours, at least 21 hours, at least 22 hours, at least 23 hours, at least 24 hours, at least 25 hours, at least 26 hours, at least 27 hours, at least 28 hours, at least 29 hours, at least 30 hours, at least 31 hours, at least 32 hours, at least 33 hours, at least 34 hours, at least 35 hours, at least 36 hours, at least 37 hours, at least 38 hours, at least 39 hours, at least 40 hours, at least 41 hours, at least 42 hours, at least 43 hours, at least 44 hours, at least 45 hours, at least 46 hours, at least 47 hours, at least 48 hours, at least 49 hours, at least 50 hours, at least 51 hours, at least 52 hours, at least 53 hours, at least 54 hours, at least 55 hours, at least 56 hours, at least 57 hours, at least 58 hours, at least 59 hours, 4 hours, at least 41 hours, at least 42 hours, at least 43 hours, at least 44 hours, at least 45 hours, at least 46 hours, at least 47 hours, or at least 48 hours.
[0450] method.
[0451] (1) Before injury
[0452] According to another aspect, the present disclosure provides a method for reducing the risk of brain damage caused by acquired brain injury in a subject susceptible to or otherwise at risk of developing the acquired brain injury, the method comprising administering a pharmaceutical composition comprising a pharmaceutically acceptable carrier and formulation, the formulation comprising a therapeutic amount of an API, wherein the API is synthetic D-beta hydroxybutyrate,
[0453] wherein said administration is performed intranasally (IN),
[0454] wherein said administering comprises targeted delivery to the olfactory region of the nasal cavity of said subject;
[0455] wherein the targeted delivery achieves a therapeutically effective amount of the API in the brain, and
[0456] The effective amount of the pharmaceutical composition (i) eliminates or reduces the risk of the acquired brain injury, or (ii) reduces the severity of the acquired brain injury, or (iii) delays the onset of the acquired brain injury; or (iv) a combination thereof.
[0457] According to some embodiments, the acquired brain injury is a traumatic brain injury. According to some embodiments, the traumatic brain injury comprises a concussion. According to some embodiments, the subject's risk of developing the acquired brain injury is increased by participation in an event for which the acquired brain injury is a known risk. According to some embodiments, the event is a military operation. According to some embodiments, the event is a sporting event. According to some embodiments, the sporting event is, for example, hockey, football, soccer, baseball, polo, rugby, equestrian, racing, motorsports, skiing, gymnastics, mountaineering, basketball, mixed martial arts, Brazilian Jiu-Jitsu, Muay Thai, taekwondo, kickboxing, boxing, wrestling, lacrosse, softball, cheerleading, volleyball, beach volleyball, alpine skiing, water skiing, wakeboarding, snowboarding, skateboarding, kayaking, handball, cycling, mountain biking, barrel racing, bull riding, base jumping, skydiving, paragliding, tennis, squash, BMX, motocross, surfing, bobsleigh, luge, skeleton, ball game, lacrosse, camochie, cricket, diving, field hockey, figure skating, speed skating, sailing, ski jumping, ultimate Frisbee, water polo, or windsurfing. Or (iv) a combination thereof. Other applications include emergency medicine, such as use by EMTs or emergency rooms in the context of emergencies such as domestic violence, falls, car accidents, etc.
[0458] According to some embodiments, administration within 1 minute, within 5 minutes, within 10 minutes, within 15 minutes, within 30 minutes, within 45 minutes, within 1 hour, within 2 hours, within 3 hours, within 4 hours, within 5 hours, within 6 hours, within 7 hours, within 8 hours, within 9 hours, within 10 hours, within 11 hours, within 12 hours, within 13 hours, within 14 hours, within 15 hours, within 16 hours, within 17 hours, within 18 hours, within 19 hours, within 20 hours, within 21 hours, within 22 hours, within 23 hours, within 24 hours, within 1 day, within 2 days, within 3 days, within 4 days, within 5 days, within 6 days, within 7 days, within 8 days, within 9 days, within 10 days, within 11 days, within 12 days, within 13 days, within 14 days, within 15 days, within 16 days, within 17 days, within 18 days, within 19 days, within 20 days, within 21 days, etc. prior to an event for which acquired brain injury is a known risk is neuroprotective.
[0459] According to some embodiments, the pharmaceutical composition comprises an active substance formulated as a solution, suspension or dispersion. According to some embodiments, the API is formulated as a solution. According to some embodiments, the API is formulated as a suspension. According to some embodiments, the API is formulated as a suspension, wherein the suspension comprises a particle size distribution of a population of particles comprising the API n. According to some embodiments, the API is formulated as a dispersion. According to some embodiments, the API is formulated as a dispersion, wherein the dispersion comprises a particle size distribution of a population of particles comprising the API.
[0460] According to some embodiments, the pharmaceutical composition comprises a liquid spray formulation or a dry powder formulation.
[0461] According to some embodiments, the pharmaceutical composition comprises a liquid spray formulation of the API. According to some embodiments, the pharmaceutical composition is delivered as a liquid spray comprising a droplet size distribution comprising droplets comprising the API.
[0462] According to some embodiments, the pharmaceutical composition comprises a dry powder formulation. According to some embodiments, the aerosolized dry powder formulation comprises a cloud of very fine particles comprising the API.
[0463] According to some embodiments, the formulation is formulated with an excipient. According to some embodiments, the excipient maximizes the solubility of the API. According to some embodiments, the excipient enhances the adhesion of the API to the nasal mucosa in the sense of smell. According to some embodiments, the enhanced adhesion enhances the absorption of the API in the nasal mucosa.
[0464] According to some embodiments, the nasal aerosol comprises a formulation, a container, a valve, an actuator, a dust cap, associated accessories and protective packaging, which together constitute the drug product. For insufflation administration, for example, the pharmaceutical composition according to the invention as described can be conveniently delivered from a pressurized package in the form of an aerosol spray presentation using a suitable propellant (e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas). In the case of a pressurized aerosol, the dosage unit can be determined by providing a valve for delivering a metered amount. Capsules and cartridges (e.g., gelatin) for insufflators can be formulated to contain a powder mix of the active compound and a suitable powder base (such as lactose or starch).
[0465] According to some embodiments, the formulation is filled in a unit dose device. According to some devices, the formulation is filled in a multi-dose device. According to some embodiments, exemplary devices include a spray pump and a metered dose inhaler. According to some embodiments, the liquid formulation is filled in a spray pump (an exemplary device for delivering intranasal formulations). According to some embodiments, the dry powder formulation is filled in a dry powder device, which includes a formulation of an active agent and a container closure system.
[0466] For example, a typical nasal spray formulation consists of an active agent suspended or dissolved in an aqueous medium that is filled into a bottle with a metered spray pump. Pump actuation by the subject delivers drug-laden droplets into the nasal cavity. The role of the pump, which is an integral part of the overall assembly, is to atomize and deliver an accurate dose of the drug.
[0467] Most nasal spray pumps produce droplets containing therapeutic amounts of API in the range of about 20 μm to about 120 μm (i.e., about 20 μm, about 25 μm, about 30 μm, about 35 μm, about 40 μm, about 45 μm, about 50 μm, 55 μm, about 60 μm, about 65 μm, about 70 μm, about 75 μm, about 80 μm, about 85 μm, about 90 μm, about 95 μm, about 100 μm, about 105 μm, about 110 μm, about 115 μm, or about 120 μm) [Yu, G. et al. Fluid Flow and Particle Diffusion in the Human Upper Respiratory System. Aerosol Science and Technology (1998) 28: 146-58], so that the droplet size allows the droplets to be deposited in the olfactory region of the nasal cavity for delivery of the API to the brain. If the droplet size is too fine (<10 μm), there is a possibility that the droplets will pass through the nasal passages and deposit in the lungs. If the droplet size is too large, the spray may be trapped in the nostrils. Laser diffraction techniques can measure the size of the droplets by measuring the intensity of light scattered by the particles as a function of angle to determine the droplet size for a given device and formulation.
[0468] In evaluating the performance of a pump, the characteristics of the spray plume ejected are considered important. According to some embodiments, the pump performance is characterized by the spray pattern and plume geometry of the plume ejected by the delivery device. During the very early life of an aqueous nasal spray plume, the formulation may exit the actuator orifice in the form of a narrow stream, which then forms a relatively stable, fully expanded conical plume before separating from the orifice. The term "plume geometry" describes a side view of an aerosol cloud parallel to the axis of the plume. According to some embodiments, the measurement of the plume geometry includes an image taken from the side of the plume perpendicular to a laser sheet aligned with the expected central plume axis. According to some embodiments, the measurement of the plume geometry is performed by flash illumination of the plume with photographic image capture. According to some embodiments, the plume geometry is characterized by the spray angle and the plume width.
[0469] According to some embodiments, the pharmaceutical composition comprises a formulation comprising a distribution of particles comprising an API. According to some embodiments, a majority of the particle distribution has a diameter ranging from about 25 μm to about -40 μm, i.e., about 25 μm, about 26 μm, about 27 μm, about 28 μm, about 29 μm, about 30 μm, about 31 μm, about 32 μm, about 333, about 34 μm, about 35 μm, about 36 μm, about 37 μm, about 38 μm, about 39 μm, or about 40 μm. According to some embodiments, the particle distribution is depleted of smaller particles that would otherwise enter the lungs.
[0470] According to some embodiments, a viscosity enhancer / mucoadhesive polymer (e.g., microcrystalline cellulose, sodium carboxymethylcellulose, or hydroxypropyl methylcellulose, or a combination thereof) may be added to the formulation in an amount of 0.1%, 0.2%, 0.3%, 1%, or 2% by weight or by volume of the formulation to increase the absorption of the API in the nasal mucosa of the olfactory region of the nasal cavity. According to some embodiments, the viscosity of each nasal spray formulation will be measured. According to some embodiments, the spray pattern and plume geometry of each nasal spray formulation will be measured. According to some embodiments, the droplet size distribution of each nasal spray is determined to determine the median (Dv50), 10th percentile (Dv10), and 90th percentile (Dv90) of the cumulative distribution of the undersize.
[0471] According to some embodiments, for intranasal delivery, up to about 25 mg / dose is administered at a tolerable frequency, for example, every 2, 5, 10, 15, 20, 30, 40, 50, or 60 minutes for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91 Hours, 37 hours, 38 hours, 39 hours, 40 hours, 41 hours, 42 hours, 43 hours, 44 hours, 45 hours, 46 hours, 47 hours, 48 hours, 49 hours, 50 hours, 51 hours, 52 hours, 53 hours, 54 hours, 55 hours, 56 hours, 57 hours, 58 hours, 59 hours, 60 hours, 61 hours, 62 hours, 63 hours, 64 hours, 65 hours, 66 hours, 67 hours, 68 hours, 69 hours, 70 hours, 71 hours, 72 hours, etc., to achieve a minimum daily dose ranging from about 85 mg / day (e.g., for a child weighing about 45 pounds) to about 800 mg / day (e.g., for an adult), inclusive, i.e., at least about 85mg / day; about 95mg / day; about 105mg / day, about 115mg / day; about 125mg / day; about 135mg / day; about 145mg / day; about 155mg / day; about 165mg / day; about 175mg / day; about 185mg / day; about 195mg / day; about 205mg / day; about 215mg / day; about 225mg / day; about 235mg / day; about 245mg / day; about 255mg / day; about 265mg / day; about 275mg / day; about 285mg / day; about 295mg / day; about 305mg / day; about 315mg / day; about 325mg / day; about 335mg / day; about 345mg / day; about 355mg / day; about 365 mg / day; about 375 mg / day; about 385 mg / day; about 395 mg / day; about 405 mg / day; about 415 mg / day; about 425 mg / day; about 435 mg / day; about 445 mg / day; about 455 mg / day; about 465 mg / day; about 475 mg / day; about 485 mg / day; about 495 mg / day; about 505 mg / day; about 515 mg / day; about 525 mg / day; about 535 mg / day; about 545 mg / day; about 555 mg / day; about 565 mg / day; about 575 mg / day; about 585 mg / day; about 595 mg / day; about 605 mg / day; about 615 mg / day; about 625 mg / day; about 635 mg / day;about 645 mg / day; about 655 mg / day; about 665 mg / day; about 675 mg / day; about 685 mg / day; about 695 mg / day; about 705 mg / day; about 715 mg / day; about 725 mg / day; about 735 mg / day; about 745 mg / day; about 755 mg / day; about 765 mg / day; about 775 mg / day; about 785 mg / day; about 795 mg / day; or about 800 mg / day. ;
[0472] According to some embodiments, and based on the HED from the mouse study reported in the following paragraph
[00635] , the minimum daily dose for a 60 kg human (132 pounds) is 250 mg / day. According to some embodiments, the minimum daily dose for a 90 kg human (200 pounds) is 730 mg / day.
[0473] According to some embodiments, the dose-time profile is determined so that the desired effective amount is achieved at a maximum of 25 mg / dose delivered intranasally that can be tolerated at a given frequency (e.g., every 2, 5, 10, 15, 20, 30, 40, 50, or 60 minutes for at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 7 days, at least 8 days, at least 9 days, at least 10 days, at least 11 days, at least 12 days, at least 13 days, at least 14 days, at least 15 days, at least 16 days, at least 17 days, at least 18 days, at least 19 days, at least 20 days, at least 21 days, etc.).
[0474] According to some embodiments, intranasal delivery within 1 minute, within 5 minutes, within 10 minutes, within 15 minutes, within 30 minutes, within 45 minutes, within 1 hour, within 2 hours, within 3 hours, within 4 hours, within 5 hours, within 6 hours, within 7 hours, within 8 hours, within 9 hours, within 10 hours, within 11 hours, within 12 hours, within 13 hours, within 14 hours, within 15 hours, within 16 hours, within 17 hours, within 18 hours, within 19 hours, within 20 hours, within 21 hours, within 22 hours, within 23 hours, within 24 hours, within 1 day, within 2 days, within 3 days, within 4 days, within 5 days, within 6 days, within 7 days, within 8 days, within 9 days, within 10 days, within 11 days, within 12 days, within 13 days, within 14 days, within 15 days, within 16 days, within 17 days, within 18 days, within 19 days, within 20 days, within 21 days, etc. prior to an event for which acquired brain injury is a known risk is neuroprotective.
[0475] According to some embodiments, the event is a military action. According to some embodiments, the event is a sporting event. According to some embodiments, the sporting event is, for example, hockey, football, soccer, baseball, polo, rugby, equestrianism, racing, motorsports, skiing, gymnastics, mountaineering, basketball, mixed martial arts, Brazilian Jiu-Jitsu, Muay Thai, taekwondo, kickboxing, boxing, wrestling, lacrosse, softball, cheerleading, volleyball, beach volleyball, alpine skiing, water skiing, wakeboarding, snowboarding, skateboarding, kayaking, handball, cycling, mountain biking, barrel racing, bull riding, base jumping, parachuting, paragliding, tennis, squash, BMX, motocross, surfing, bobsleigh, luge, skeleton, ball game, lacrosse, camochie, cricket, diving, field hockey, figure skating, speed skating, sailing, ski jumping, ultimate Frisbee, water polo, or windsurfing. Other applications include emergency medicine, such as use by EMTs or emergency rooms in the context of emergencies such as domestic violence, falls, car accidents, etc.
[0476] According to some embodiments, incorporating the D-β-hydroxybutyrate into a polymer carrier can achieve controlled release, including delayed release and sustained release.
[0477] According to some embodiments, the D-beta hydroxybutyrate is bound to HCA2.
[0478] According to some embodiments, the composition can increase brain D-β-hydroxybutyrate levels, e.g., to about 0.1-3 mmol / L or about 0.1-1 mmol / L, for at least 6 hours to at least 48 hours (inclusive), i.e., at least 6 hours, at least 7 hours, at least 8 hours, at least 9 hours, at least 10 hours, at least 11 hours, at least 12 hours, at least 13 hours, at least 14 hours, at least 15 hours, at least 16 hours, at least 17 hours, at least 18 hours, at least 19 hours, at least 20 hours, at least 21 hours, at least 22 hours, at least 23 hours, at least 24 hours, at least 25 hours, at least 26 hours, at least 27 hours, at least 28 hours, at least 29 hours, at least 30 hours, at least 31 hours, at least 32 hours, at least 33 hours, at least 34 hours, at least 35 hours, at least 36 hours, at least 37 hours, at least 38 hours, at least 39 hours, at least 40 hours, at least 41 hours, at least 42 hours, at least 43 hours, at least 44 hours, at least 45 hours, at least 46 hours, at least 47 hours, at least 48 hours, at least 49 hours, at least 50 hours, at least 51 hours, at least 52 hours, at least 53 hours, at least 54 hours, at least 55 hours, at least 56 hours, at least 57 hours, at least 58 hours, at least 59 hours, 4 hours, at least 41 hours, at least 42 hours, at least 43 hours, at least 44 hours, at least 45 hours, at least 46 hours, at least 47 hours, or at least 48 hours.
[0479] (2) After injury
[0480] According to another aspect, the present disclosure provides a method for treating symptoms of brain damage in a subject, the brain damage comprising neuroinflammation, the method comprising administering a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a formulation comprising a therapeutic amount of an API, wherein the API is synthetic D-beta hydroxybutyrate,
[0481] wherein the administration is performed intranasally (IN);
[0482] wherein said administering comprises targeted delivery to the olfactory region of the nasal cavity of said subject,
[0483] wherein said targeted delivery achieves a therapeutically effective amount of said API in the brain,
[0484] The effective amount of the pharmaceutical composition achieves one or more therapeutic effects, and the one or more therapeutic effects include:
[0485] (a) reducing the severity of the acquired brain injury;
[0486] (b) limiting the development of symptoms characteristic of the acquired brain injury being treated;
[0487] (c) limiting the progression of symptoms characteristic of the acquired brain injury being treated;
[0488] (d) limiting the recurrence of said acquired brain injury in a subject who has previously suffered from said acquired brain injury; or
[0489] (e) limiting the recurrence of symptoms in a subject who was previously asymptomatic for said acquired brain injury.
[0490] According to some embodiments, the acquired brain injury is a traumatic brain injury. According to some embodiments, the traumatic brain injury comprises a concussion. According to some embodiments, the subject's risk of developing an acquired brain injury is increased by the subject's participation in an event for which the acquired brain injury is a known risk. According to some embodiments, the event is a military operation. According to some embodiments, the event is a sporting event. According to some embodiments, the sporting event is, for example, hockey, football, soccer, baseball, polo, rugby, equestrianism, racing, motorsports, skiing, mountaineering, gymnastics, basketball, mixed martial arts, Brazilian Jiu-Jitsu, Muay Thai, taekwondo, kickboxing, boxing, wrestling, lacrosse, softball, cheerleading, volleyball, beach volleyball, alpine skiing, water skiing, wakeboarding, snowboarding, skateboarding, kayaking, handball, cycling, mountain biking, barrel racing, bull riding, base jumping, skydiving, paragliding, tennis, squash, BMX, motocross, surfing, bobsleigh, luge, skeleton, ball game, lacrosse, camochie, cricket, diving, field hockey, figure skating, speed skating, sailing, ski jumping, ultimate Frisbee, water polo, or windsurfing. Other applications include emergency medicine, such as use by EMTs or emergency rooms in the context of emergencies such as domestic violence, falls, car accidents, etc.
[0491] According to some embodiments, administration is performed within at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 7 days, at least 8 days, at least 9 days, at least 10 days, at least 11 days, at least 12 days, at least 13 days, at least 14 days, at least 15 days, at least 16 days, at least 17 days, at least 18 days, at least 19 days, at least 20 days, at least 21 days, etc. after the event, for example every 2 minutes, 5 minutes, 10 minutes, 15 minutes, 20 minutes, 30 minutes, 40 minutes, 50 minutes, or 60 minutes, at a tolerated frequency of 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, 18 hours, 19 hours, 20 hours, 21 hours, 22 hours, 23 hours, 24 hours.
[0492] According to some embodiments, the pharmaceutical composition comprises a liquid spray formulation or a dry powder formulation. According to some embodiments, the pharmaceutical composition comprises a liquid spray formulation. According to some embodiments, the pharmaceutical composition comprises a dry powder formulation. According to some embodiments, the formulation is formulated with an excipient. According to some embodiments, the excipient maximizes the solubility of the API. According to some embodiments, the excipient enhances the adhesion of the API to the nasal mucosa. According to some embodiments, the enhanced adhesion enhances the absorption of the API in the nasal mucosa.
[0493] According to some embodiments, the pharmaceutical composition comprises an active substance formulated as a solution, suspension or dispersion. According to some embodiments, the API is formulated as a solution. According to some embodiments, the API is formulated as a suspension. According to some embodiments, the API is formulated as a suspension, wherein the suspension comprises a particle size distribution of a population of particles comprising the API n. According to some embodiments, the API is formulated as a dispersion. According to some embodiments, the API is formulated as a dispersion, wherein the dispersion comprises a particle size distribution of a population of particles comprising the API.
[0494] According to some embodiments, the pharmaceutical composition comprises a liquid spray formulation or a dry powder formulation.
[0495] According to some embodiments, the pharmaceutical composition comprises a liquid spray formulation of the API. According to some embodiments, the pharmaceutical composition is delivered as a liquid spray comprising a droplet size distribution comprising droplets comprising the API.
[0496] According to some embodiments, the pharmaceutical composition comprises a dry powder formulation. According to some embodiments, the aerosolized dry powder formulation comprises a cloud of very fine particles comprising the API.
[0497] According to some embodiments, the formulation is formulated with an excipient. According to some embodiments, the excipient maximizes the solubility of the API. According to some embodiments, the excipient enhances the adhesion of the API to the nasal mucosa in the sense of smell. According to some embodiments, the enhanced adhesion enhances the absorption of the API in the nasal mucosa.
[0498] According to some embodiments, the nasal aerosol comprises a formulation, a container, a valve, an actuator, a dust cap, associated accessories and protective packaging, which together constitute the drug product. For insufflation administration, for example, the pharmaceutical composition according to the invention as described can be conveniently delivered from a pressurized package in the form of an aerosol spray presentation using a suitable propellant (e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas). In the case of a pressurized aerosol, the dosage unit can be determined by providing a valve for delivering a metered amount. Capsules and cartridges (e.g., gelatin) for insufflators can be formulated to contain a powder mix of the active compound and a suitable powder base (such as lactose or starch).
[0499] According to some embodiments, the formulation is filled in a unit dose device. According to some embodiments, the formulation is filled in a multi-dose device. According to some embodiments, exemplary devices include a spray pump and a metered dose inhaler. According to some embodiments, the liquid formulation is filled in a spray pump (an exemplary device for delivering intranasal formulations). According to some embodiments, the dry powder formulation is filled in a dry powder device, which includes a formulation of an active agent and a container closure system.
[0500] For example, a typical nasal spray formulation consists of an active agent suspended or dissolved in an aqueous medium that is filled into a bottle with a metered spray pump. Pump actuation by the subject delivers drug-laden droplets into the nasal cavity. The role of the pump, which is an integral part of the overall assembly, is to atomize and deliver an accurate dose of the drug.
[0501] Most nasal spray pumps produce droplets containing therapeutic amounts of API in the range of about 20 μm to about 120 μm (i.e., about 20 μm, about 25 μm, about 30 μm, about 35 μm, about 40 μm, about 45 μm, about 50 μm, 55 μm, about 60 μm, about 65 μm, about 70 μm, about 75 μm, about 80 μm, about 85 μm, about 90 μm, about 95 μm, about 100 μm, about 105 μm, about 110 μm, about 115 μm, or about 120 μm) [Yu, G. et al. Fluid Flow and Particle Diffusion in the Human Upper Respiratory System. Aerosol Science and Technology (1998) 28: 146-58], so that the droplet size allows the droplets to be deposited in the olfactory region of the nasal cavity for delivery of the API to the brain. If the droplet size is too fine (<10 μm), there is a possibility that the droplets will pass through the nasal passages and deposit in the lungs. If the droplet size is too large, the spray may be trapped in the nostrils. Laser diffraction techniques can measure the size of the droplets by measuring the intensity of light scattered by the particles as a function of angle to determine the droplet size for a given device and formulation.
[0502] In evaluating the performance of a pump, the characteristics of the spray plume ejected are considered important. According to some embodiments, the pump performance is characterized by the spray pattern and plume geometry of the plume ejected by the delivery device. During the very early life of an aqueous nasal spray plume, the formulation may exit the actuator orifice in the form of a narrow stream, which then forms a relatively stable, fully expanded conical plume before separating from the orifice. The term "plume geometry" describes a side view of an aerosol cloud parallel to the axis of the plume. According to some embodiments, the measurement of the plume geometry includes an image taken from the side of the plume perpendicular to a laser sheet aligned with the expected central plume axis. According to some embodiments, the measurement of the plume geometry is performed by flash illumination of the plume with photographic image capture. According to some embodiments, the plume geometry is characterized by the spray angle and the plume width.
[0503] According to some embodiments, the pharmaceutical composition comprises a formulation comprising a distribution of particles comprising an API. According to some embodiments, a majority of the particle distribution has a diameter ranging from about 25 μm to about -40 μm, i.e., about 25 μm, about 26 μm, about 27 μm, about 28 μm, about 29 μm, about 30 μm, about 31 μm, about 32 μm, about 333, about 34 μm, about 35 μm, about 36 μm, about 37 μm, about 38 μm, about 39 μm, or about 40 μm. According to some embodiments, the particle distribution is depleted of smaller particles that would otherwise enter the lungs.
[0504] According to some embodiments, a viscosity enhancer / mucoadhesive polymer (e.g., microcrystalline cellulose, sodium carboxymethylcellulose, hydroxypropyl methylcellulose, or a combination thereof) may be added to the formulation in an amount of 0.1%, 0.2%, 0.3%, 1%, or 2% by weight or by volume of the formulation to increase the absorption of the API in the nasal mucosa of the olfactory region of the nasal cavity. According to some embodiments, the viscosity of each nasal spray formulation will be measured. According to some embodiments, the spray pattern and plume geometry of each nasal spray formulation will be measured. According to some embodiments, the droplet size distribut...
Claims
1. A composition comprising an active ingredient encapsulated in a suspension of particles, the particles comprising a biodegradable polymer containing an effective amount of an active agent, wherein the particles are configured to bypass the blood-brain barrier, wherein the active ingredient is synthetic D-beta hydroxybutyrate, and wherein the targeted delivery is delivery to the brain.
2. The composition according to claim 1, a. wherein the size of the particles is greater than 10 nm in diameter, greater than 15 nm in diameter, greater than 20 nm in diameter, greater than 30 nm in diameter, greater than 40 nm in diameter, greater than 50 nm in diameter, greater than 60 nm in diameter, greater than 70 nm in diameter, greater than 80 nm in diameter, greater than 90 nm in diameter, greater than 100 nm in diameter, greater than 200 nm in diameter, greater than 300 nm in diameter, greater than 400 nm in diameter, greater than 500 nm in diameter, greater than 600 nm in diameter, greater than 700 nm in diameter, greater than 800 nm in diameter, greater than 900 nm in diameter, greater than 1000 nm in diameter, greater than 2000 nm in diameter, greater than 3000 nm in diameter, greater than 4000 nm in diameter, greater than 5000 nm in diameter, greater than 6000 nm in diameter, greater than 7000 nm in diameter, greater than 8000 nm in diameter, greater than 9000 nm in diameter, or greater than 10,000 nm in diameter; or b. wherein the synthetic D-β-hydroxybutyrate is dispersed throughout the particles; or the particles are impregnated with the D-β-hydroxybutyrate; or the particles include a matrix, and the matrix includes the D-β-hydroxybutyrate; or c. wherein the synthetic D-β-hydroxybutyrate is integrated into a polymer carrier to achieve controlled release, including delayed release and sustained release; or d. wherein the polymer comprises a mucoadhesive polymer, a thermoresponsive polymer, or both; or e. wherein a portion of the synthetic D-β-hydroxybutyrate is adsorbed or weakly bound to the surface of the particles and contributes to a rapid initial release or burst release; or f. wherein the particles have any order release kinetics, including zero order release, first order release, second order release, delayed release, sustained release, immediate release, long term release or a combination thereof; or g. wherein the release of the synthetic D-β-hydroxybutyrate from the particles is by diffusion, erosion, or both; or h. wherein the composition is formulated for intranasal delivery.
3. The composition of claim 2, wherein the mucoadhesive polymer comprises chitosan, alginate and cellulose or a derivative thereof.
4. The composition of claim 3, wherein the thermoreversible polymer comprises gelatin, carrageenan, methylcellulose, hydroxypropylmethylcellulose (HPMC), xyloglucan, poly(N-isopropylacrylamide-c-acrylic acid), poly(N-isopropylacrylamide) (PNIPAAm) / polyethylene oxide (PEO), poloxamer (Pluronic) or PEO / polylactic-co-glycolic acid (PLGA).
5. The composition according to claim 3, wherein the polymer is selected from cellulose derivatives, polyacrylates, starch, gelatin, phospholipids, chitosan, poly-N-alkylacrylamide / poly-N-isopropylacrylamide, cyclodextrin, poloxamer and methylcellulose.
6. The composition of claim 2, wherein when formulated for intranasal delivery, a maximum amount of about 25 mg / dose is administered to achieve a minimum daily dose ranging from about 85 mg / day to about 800 mg / day, inclusive.
7. A method for promoting brain health, the method comprising (a) formulating a composition comprising an active ingredient as a suspension of particles, the particles comprising a biodegradable polymer, the biodegradable polymer containing an effective amount of the active ingredient; (b) administering the composition comprising the active ingredient to a subject, wherein the active ingredient is D-β-hydroxybutyrate; and (c) targeting the composition to the brain, wherein burst release and controlled release of the D-β-hydroxybutyrate can produce effective D-β-hydroxybutyrate levels in the brain.
8. The method according to claim 7, a. wherein the size of the particles is greater than 10 nm in diameter, greater than 15 nm in diameter, greater than 20 nm in diameter, greater than 30 nm in diameter, greater than 40 nm in diameter, greater than 50 nm in diameter, greater than 60 nm in diameter, greater than 70 nm in diameter, greater than 80 nm in diameter, greater than 90 nm in diameter, greater than 100 nm in diameter, greater than 200 nm in diameter, greater than 300 nm in diameter, greater than 400 nm in diameter, greater than 500 nm in diameter, greater than 600 nm in diameter, greater than 700 nm in diameter, greater than 800 nm in diameter, greater than 900 nm in diameter, greater than 1000 nm in diameter, greater than 2000 nm in diameter, greater than 3000 nm in diameter, greater than 4000 nm in diameter, greater than 5000 nm in diameter, greater than 6000 nm in diameter, greater than 7000 nm in diameter, greater than 8000 nm in diameter, greater than 9000 nm in diameter, or greater than 10,000 nm in diameter; or b. wherein the synthetic D-β-hydroxybutyrate is dispersed throughout the particles; or the particles are impregnated with the D-β-hydroxybutyrate; or the particles include a matrix, and the matrix includes the D-β-hydroxybutyrate; or c. wherein the synthetic D-β-hydroxybutyrate is integrated into a polymer carrier to achieve controlled release, including delayed release and sustained release; or d. wherein the polymer comprises a mucoadhesive polymer, a thermoresponsive polymer, or both; or e. wherein a portion of the synthetic D-β-hydroxybutyrate is adsorbed or weakly bound to the surface of the particles and contributes to a rapid initial release or burst release; or f. wherein the particles have any order release kinetics, including zero order release, first order release, second order release, delayed release, sustained release, immediate release, long term release or a combination thereof; or g. wherein the release of the synthetic D-β-hydroxybutyrate from the particles is by diffusion, erosion, or both; or h. wherein the composition is formulated for oral delivery or intranasal delivery.
9. The method of claim 8, wherein the mucoadhesive polymer comprises chitosan, alginate and cellulose or derivatives thereof.
10. The method of claim 9, wherein the thermoreversible polymer comprises gelatin, carrageenan, methylcellulose, hydroxypropylmethylcellulose (HPMC), xyloglucan, poly(N-isopropylacrylamide-c-acrylic acid), poly(N-isopropylacrylamide) (PNIPAAm) / polyethylene oxide (PEO), poloxamer (Pluronic), or PEO / polylactic-co-glycolic acid (PLGA).
11. The method of claim 9, wherein the polymer is selected from the group consisting of cellulose derivatives, polyacrylates, starch, gelatin, phospholipids, chitosan, poly-N-alkylacrylamide / poly-N-isopropylacrylamide, cyclodextrin, poloxamer and methylcellulose.
12. The method of claim 8, wherein when formulated for intranasal delivery, a maximum amount of about 25 mg / dose is administered to achieve a minimum daily dose ranging from about 85 mg / day to about 800 mg / day, inclusive.
13. A method for reducing the risk of brain damage caused by acquired brain injury in a subject susceptible to or otherwise at risk of developing said acquired brain injury, the method comprising administering a pharmaceutical composition comprising a pharmaceutically acceptable carrier and formulation, the formulation comprising a therapeutic amount of an API, wherein the API is synthetic D-beta hydroxybutyrate, wherein said administration is performed intranasally (IN), wherein said administering comprises targeted delivery to the olfactory region of the nasal cavity of said subject; wherein the targeted delivery achieves an effective amount of the API in the brain, and The effective amount of the pharmaceutical composition (i) eliminate or reduce the risk of such acquired brain damage, or (ii) reduce the severity of the acquired brain injury, or (iii) delaying the onset of said acquired brain damage; or (iv) combinations thereof.
14. The method according to claim 13, (a) wherein the acquired brain injury is a traumatic brain injury; or (b) wherein said administration is neuroprotective; or (c) wherein the subject's risk of developing the acquired brain injury is increased by participation in an event for which the acquired brain injury is a known risk; or (d) wherein said administration is within 1 minute, within 5 minutes, within 10 minutes, within 15 minutes, within 30 minutes, within 45 minutes, within 1 hour, within 2 hours, within 3 hours, within 4 hours, within 5 hours, within 6 hours, within 7 hours, within 8 hours, within 9 hours, within 10 hours, within 11 hours, within 12 hours, within 13 hours, within 14 hours, within 15 hours, within 16 hours, within 17 hours, within 18 hours, within 19 hours, within 20 hours, within 21 hours, within 22 hours, within 23 hours, within 24 hours, within 1 day, within 2 days, within 3 days, within 4 days, within 5 days, within 6 days, within 7 days, within 8 days, within 9 days, within 10 days, within 11 days, within 12 days, within 13 days, within 14 days, within 15 days, within 16 days, within 17 days, within 18 days, within 19 days, within 20 days, within 21 days, etc., a maximum amount of 25 mg / dose; or (e) wherein the pharmaceutical composition comprises a liquid spray formulation or a dry powder formulation; or (f) wherein the pharmaceutical composition comprises an active substance formulated as a solution, suspension or dispersion; or (g) wherein the minimum daily dose of the pharmaceutical composition contains from about 85 mg / day to about 800 mg / day, inclusive, of the API.
15. The method of claim 14, wherein the traumatic brain injury comprises a concussion.
16. The method of claim 14, wherein the event is a military action or a sporting event.
17. The method of claim 16, wherein the sporting event is hockey, football, soccer, baseball, polo, rugby, equestrian, auto racing, gymnastics, mountain climbing, basketball, mixed martial arts, Brazilian Jiu-Jitsu, Muay Thai, taekwondo, kickboxing, boxing, wrestling, lacrosse, softball, cheerleading, volleyball, beach volleyball, alpine skiing, water skiing, wakeboarding, snowboarding, skateboarding, kayaking, handball, cycling, mountain biking, barrel racing, bull riding, base jumping, skydiving, paragliding, tennis, squash, BMX, motocross, surfing, bobsleigh, luge, skeleton, ball game, lacrosse, camogie, cricket, diving, field hockey, figure skating, speed skating, sailing, ski jumping, ultimate Frisbee, water polo, or windsurfing.
18. The method according to claim 14, wherein (1) The pharmaceutical composition is delivered as a liquid spray, the liquid spray comprising a droplet size distribution, the droplet size distribution comprising droplets containing the API; or (2) The dry powder formulation, when aerosolized, comprises a cloud of very fine particles comprising the API; or (3) The formulation is formulated with excipients.
19. The method of claim 18, wherein the droplet size distribution of the liquid spray containing a therapeutic amount of the API ranges from about 20 μm to about 120 μm, inclusive.
20. The method of claim 18, wherein the particle distribution is depleted of smaller particles that would otherwise enter the lungs.
21. A method for treating symptoms of brain damage in a subject, the brain damage comprising neuroinflammation, the method comprising administering a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a formulation comprising a therapeutic amount of an API, wherein the API is synthetic D-beta hydroxybutyrate, wherein the administration is performed intranasally (IN); wherein said administering comprises targeted delivery to the olfactory region of the nasal cavity of said subject, wherein said targeted delivery achieves an effective amount of said API in the brain, The effective amount of the pharmaceutical composition achieves one or more therapeutic effects, and the one or more therapeutic effects include: (i) reducing the severity of the acquired brain injury; or (ii) limiting the development of symptoms characteristic of the acquired brain injury being treated; or (iii) limiting the progression of symptoms characteristic of the acquired brain injury being treated; or (iv) limiting the recurrence of said acquired brain injury in a subject who has previously suffered from said acquired brain injury; or (v) limiting the recurrence of symptoms in a subject who was previously asymptomatic for said acquired brain injury; or (vi) any combination thereof.
22. The method according to claim 21, (a) wherein the acquired brain injury is a traumatic brain injury; or (b) wherein said administration is neuroprotective; or (c) wherein the subject's risk of developing the acquired brain injury is increased by participation in an event for which the acquired brain injury is a known risk; or (d) wherein said administration is within 1 minute, within 5 minutes, within 10 minutes, within 15 minutes, within 30 minutes, within 45 minutes, within 1 hour, within 2 hours, within 3 hours, within 4 hours, within 5 hours, within 6 hours, within 7 hours, within 8 hours, within 9 hours, within 10 hours, within 11 hours, within 12 hours, within 13 hours, within 14 hours, within 15 hours, within 16 hours, within 17 hours, within 18 hours, within 19 hours, within 20 hours, within 21 hours, within 22 hours, within 23 hours, within 24 hours, within 1 day, within 2 days, within 3 days, within 4 days, within 5 days, within 6 days, within 7 days, within 8 days, within 9 days, within 10 days, within 11 days, within 12 days, within 13 days, within 14 days, within 15 days, within 16 days of said brain injury , a maximum of 25 mg / dose within 17 days, within 18 days, within 19 days, within 20 days, within 21 days, for at least 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, 18 hours, 19 hours, 20 hours, 21 hours, 22 hours, 23 hours, at least 24 hours, at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 7 days, at least 8 days, at least 9 days, at least 10 days, at least 11 days, at least 12 days, at least 13 days, at least 14 days, at least 15 days, at least 16 days, at least 17 days, at least 18 days, at least 19 days, at least 20 days, at least 21 days, etc.; or (e) wherein the pharmaceutical composition comprises a liquid spray formulation or a dry powder formulation; or (f) wherein the pharmaceutical composition comprises an active substance formulated as a solution, suspension or dispersion; or (g) wherein the minimum daily dose of the pharmaceutical composition contains from about 85 mg / day to about 800 mg / day, inclusive, of the API.
23. The method of claim 22, wherein the traumatic brain injury comprises a concussion.
24. The method of claim 22, wherein the event is a military action or a sporting event.
25. The method of claim 24, wherein the sporting event is hockey, football, soccer, baseball, polo, rugby, equestrian, auto racing, gymnastics, mountain climbing, basketball, mixed martial arts, Brazilian Jiu-Jitsu, Muay Thai, taekwondo, kickboxing, boxing, wrestling, lacrosse, softball, cheerleading, volleyball, beach volleyball, alpine skiing, water skiing, wakeboarding, snowboarding, skateboarding, kayaking, handball, cycling, mountain biking, barrel racing, bull riding, base jumping, skydiving, paragliding, tennis, squash, BMX, motocross, surfing, bobsleigh, luge, skeleton, ball game, racquetball, camochie, cricket, diving, field hockey, figure skating, speed skating, sailing, ski jumping, ultimate Frisbee, water polo, or windsurfing.
26. The method of claim 22, wherein (1) The pharmaceutical composition is delivered as a liquid spray, the liquid spray comprising a droplet size distribution, the droplet size distribution comprising droplets containing the API; or (2) The dry powder formulation, when aerosolized, comprises a cloud of very fine particles comprising the API; or (3) The formulation is formulated with excipients.
27. The method of claim 26, wherein the droplet size distribution of the liquid spray containing a therapeutic amount of the API ranges from about 20 μm to about 120 μm, inclusive.
28. A method for reducing the risk of acquired brain injury in a subject susceptible to or otherwise at risk of developing said acquired brain injury and for treating symptoms of said brain injury after said subject has acquired said acquired brain injury, wherein said subject's risk of developing said acquired brain injury is increased by participation in an event for which acquired brain injury is a known risk; said method comprising (a) administering a pharmaceutical composition prior to the event, the pharmaceutical composition comprising a pharmaceutically acceptable carrier and a formulation comprising a therapeutic amount of an API, wherein the API is synthetic D-beta hydroxybutyrate, wherein the administration is intranasal (IN) and is neuroprotective, wherein said administering comprises targeted delivery to the olfactory region of the nasal cavity of said subject; wherein the targeted delivery achieves an effective amount of the API in the brain, and The effective amount of the pharmaceutical composition (i) eliminate or reduce the risk of such acquired brain damage, or (ii) reduce the severity of the acquired brain injury, or (iii) delaying the onset of said acquired brain damage; or (iv) any combination thereof; as well as (b) continuing said intranasal (IN) administration after said brain injury is obtained in said event, Wherein the effective amount of the pharmaceutical composition achieves one or more therapeutic effects, and the one or more therapeutic effects include: (i') reducing the severity of the acquired brain injury; (ii') limiting the development of symptoms characteristic of the acquired brain injury being treated; (iii') limiting the progression of symptoms characteristic of the acquired brain injury being treated; (iv') limiting the recurrence of said acquired brain injury in a subject who has previously suffered from said acquired brain injury; or (v') limiting the recurrence of symptoms in a subject who was previously asymptomatic for said acquired brain injury; (vi') or a combination thereof.
29. The method according to claim 28, (a) wherein the acquired brain injury is a traumatic brain injury; or (b) wherein the pharmaceutical composition comprises a liquid spray formulation or a dry powder formulation; or (c) wherein the pharmaceutical composition comprises the API formulated as a solution, suspension or dispersion; or (d) wherein the minimum daily dose of the pharmaceutical composition contains from about 85 mg / day to about 800 mg / day, inclusive, of the API.
30. The method of claim 29, wherein the traumatic brain injury comprises a concussion.
31. The method of claim 29, wherein the event is a military action or a sporting event.
32. The method of claim 31, wherein the sporting event is hockey, football, soccer, baseball, polo, rugby, equestrian, auto racing, gymnastics, mountain climbing, basketball, mixed martial arts, Brazilian Jiu-Jitsu, Muay Thai, taekwondo, kickboxing, boxing, wrestling, lacrosse, softball, cheerleading, volleyball, beach volleyball, alpine skiing, water skiing, wakeboarding, snowboarding, skateboarding, kayaking, handball, cycling, mountain biking, barrel racing, bull riding, base jumping, skydiving, paragliding, tennis, squash, BMX, motocross, surfing, bobsleigh, luge, skeleton, ball game, racquetball, camochie, cricket, diving, field hockey, figure skating, speed skating, sailing, ski jumping, ultimate Frisbee, water polo, or windsurfing.
33. The method according to claim 29, wherein said administering is performed every 2 minutes, 5 minutes, 10 minutes, 20 minutes, 30 minutes, 40 minutes, 50 minutes, or 60 minutes for at least 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, 18 hours, 19 hours, 20 hours, 21 hours, 22 hours, 23 hours, 24 hours prior to said event at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 7 days, at least 8 days, at least 9 days, at least 10 days, at least 11 days, at least 12 days, at least 13 days, at least 14 days, at least 15 days, at least 16 days, at least 17 days, at least 18 days, at least 19 days, at least 20 days, at least 21 hours prior to said event at a maximum amount of 25 mg / dose; Every 2 minutes, 5 minutes, 10 minutes, 20 minutes, 30 minutes, 40 minutes, 50 minutes or 60 minutes for at least 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, 18 hours, 19 hours, 20 hours, 21 hours, 22 hours, 23 hours, or at least 24 hours, at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 7 days, at least 8 days, at least 9 days, at least 10 days, at least 11 days, at least 12 days, at least 13 days, at least 14 days, at least 15 days, at least 16 days, at least 17 days, at least 18 days, at least 19 days, at least 20 days, at least 21 days after the brain injury is obtained.
34. The method of claim 29, wherein (1) the pharmaceutical composition is delivered as a liquid spray, the liquid spray comprising a droplet size distribution, the droplet size distribution comprising droplets containing the API; or (2) The dry powder formulation comprises a cloud when aerosolized, wherein the cloud comprises a distribution of fine particles comprising the API; or (3) The formulation is formulated with excipients.
35. The method of claim 34, wherein the droplet size distribution of the liquid spray containing a therapeutic amount of the API ranges from about 20 μm to about 120 μm, inclusive.
36. The method of claim 34, wherein the particle distribution is depleted of smaller particles that would otherwise enter the lungs.
37. A pharmaceutical composition for reducing the risk of brain damage caused by acquired brain injury in a subject susceptible to or otherwise at risk of developing said acquired brain injury, the composition comprising a pharmaceutically acceptable carrier and a formulation comprising a therapeutic amount of an API, wherein the API is synthetic D-β-hydroxybutyrate, wherein treatment comprises (a) before the subject participates in an event for which acquired brain injury is a known risk; (b) after the subject participates in the event; or both, targeting delivery of a maximum amount of 25 mg / dose to the olfactory region of the nasal cavity of the subject, which is used to treat symptoms of the acquired brain injury including neuroinflammation in the subject.
38. The pharmaceutical composition for use according to claim 37, wherein the targeted delivery achieves an effective amount of the API in the brain of the subject; and The effective amount of the pharmaceutical composition (i) limiting the development of symptoms characteristic of the acquired brain injury; and / or (ii) limiting the progression of symptoms characteristic of the acquired brain injury; and / or (iii) limiting the recurrence of said acquired brain injury in a subject who has previously suffered from said acquired brain injury; and / or (v) limiting the recurrence of symptoms in a subject who was previously asymptomatic for said acquired brain injury.
39. The pharmaceutical composition for use according to claim 37, (a) wherein the acquired brain injury is a traumatic brain injury; and / or (b) wherein the brain damage comprises neuroinflammation; and / or (b) the event is a sporting event; and / or (c) the incident is a military operation; and / or (d) wherein said administration is neuroprotective; and / or (e) wherein the pharmaceutical composition comprises the API formulated as a solution, suspension or dispersion; and / or (f) wherein the minimum daily dose of the pharmaceutical composition contains from about 85 mg / day to about 800 mg / day, inclusive, of the API.
40. The pharmaceutical composition for use of claim 39, wherein the traumatic brain injury comprises a concussion.
41. The pharmaceutical composition for use of claim 39, wherein the sporting event is hockey, football, soccer, baseball, polo, rugby, equestrianism, auto racing, motorsports, skiing, gymnastics, mountaineering, basketball, mixed martial arts, Brazilian Jiu-Jitsu, Muay Thai, taekwondo, kickboxing, boxing, wrestling, lacrosse, softball, cheerleading, volleyball, beach volleyball, alpine skiing, water skiing, wakeboarding, snowboarding, skateboarding, kayaking, handball, cycling, mountain biking, barrel racing, bull riding, base jumping, skydiving, paragliding, tennis, squash, BMX, motocross, surfing, bobsleigh, luge, skeleton, ball game, lacrosse, camochie, cricket, diving, field hockey, figure skating, speed skating, sailing, ski jumping, ultimate Frisbee, water polo, or windsurfing.
